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Abstract 
Complex II of the respiratory chain (RC) recently emerged as a prominent regulator of cell 
death. In both cancer as well as neurodegenerative diseases, mutations in its subunits have been 
found along with other genetic alterations indirectly affecting this complex. Moreover, anticancer 
compounds were developed that target complex II and cause cell death in a tumour-specific way. 
I found evidence that this protein assembly is specifically activated for cell death via the 
dissociation of its SDHA and SDHB subunits from the membrane-anchoring proteins through 
mitochondrial Ca2+ influx. 
The relationship between Ca2+ and cell death activation has been under intense investigation, 
but not much has been identified on the associated mechanisms. Ca2+ influx into mitochondria 
plays a significant role in cell death induction, but it was unknown how the observed massive Ca2 
accumulation activates the organelle for cell destruction. The disintegration of complex II 
subunits is prevented in vitro when cardiolipin is substituted with a lipid devoid of Ca2+ binding. 
Cardiolipin is known to associate with complex II, but coalesces into tight homotypic clusters 
upon Ca2+ binding. When complex II is deprived of this lipid, it disintegrates for ROS formation 
and cell death induction. My results reveal Ca2+ binding to cardiolipin and subsequent complex II 
disintegration as a crucial step for oxidative stress and cell death induction. Ultimately, it 
emphasizes the important role that Ca2+ plays in ROS-induced cell death via the respiratory chain, 
which can be used for many translational investigations. For instance, future studies on Ca2+ and 
its binding to cardiolipin for cell death induction will further elucidate complex II as a target for 
cancer treatment as well as neurodegenerative diseases and reveal its role as a nexus for many 
diverse stimuli in cell death signalling. 
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HEK  :  Human Embryonic Kidney  
HEPES  :  4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid  
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Hip  :  Huntingtin-Interacting Protein  
Hippi  :  Hip-Interacting Protein  
HK  :  Hexokinase  
HR domain  :  Heptad Repeat Domain  
HRP  :  Horse Raddish Peroxidase  
Htra2  :  High Temperature Requirement Protein 2  
IAP  :  Inhibitor of Apoptosis Protein  
IBM  :  IAP Binding Motif  
iCAD  :  Inhibitor of Caspase-Activating DNase  
ICE  :  Interleukin-1β Converting Enzyme  
IKK  :  IκB Kinase  
IMM  :  Inner Mitochondrial Membrane  
IMS  :  Inter-Mitochondrial Membrane Space  
IP  :  Immunoprecipitation  
IP3R  :  Inositol 1,4,5-trisphosphate Receptor  
IRE  :  Inositol Requirement  
JC-1  :  5,5',6,6'-tetrachloro-1,1',3,3'-
tetraethylbenzimidazolylcarbocyanine iodide  
JNK  :  c-Jun N-terminal Kinase  
Kd  :  Dissociation Constant  
Ku70  :  Ku Autoantigen 70kDa  
LB-broth  :  Luria-Bertani broth  
LRR  :  Leucine-Rich Domain  
Mdivi-1  :  Mitochondrial Division Inhibitor 1  
Mfn  :  Mitofusin  
MHC  :  Major Histocompatibility Complex  
MISC1  :  Mitochondrial Morphology and Cristae 
Structure  
MitoPLD  :  Mitochondrial Phospholipase  
MLD  :  Myosin-like Domain  
MOMP  :  Mitochondrial Outer Membrane 
Permeabilisation  
mRNA  :  Messenger RNA  
NACHT :  Neuronal Apoptosis Inhibitory Protein, 
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  MHC class II Transcription Activator, 
Incompatibility Locus Protein from 
Podospora anserina, and Telomerase-
Associated Protein  
NAD  :  Nicotinamide Adenine Dinucleotide  
NAIP  :  Neuronal Apoptosis Inhibitory Protein  
NB domain  :  Nucleotide-Binding Domain  
NB-ARC  :  Nucleotide-Binding Apaf-1, R-gene, and 
Ced-4  
NDUS1  :  NADH Dehydrogenase Ubiquinone Fe-S 
protein 1  
NFκB  :  Nuclear Factor-κB  
NLS  :  Nuclear Localisation Signal  
NMR  :  Nuclear Magnetic Resonance  
NT  :  Non-Treated  
Nur77  :  Neural Orphan Nuclear Receptor  
OMM  :  Outer Mitochondrial Membrane  
Opa1  :  Optic Atrophy 1  
PAGE  :  Polyacrylamide Gel Electrophoresis  
PAK2  :  p20-Activated Kinase 2  
PARP  :  Poly ADP-Ribose Polymerase  
PBR  :  Peripheral Benzodiazepine Receptor  
PBS  :  Phosphate Buffered Saline  
PBS-T  :  PBS with 0.1% Tween  
PCR  :  Polymerase Chain Reaction  
PERK  :  PRKR-Like Endoplasmic Reticulum Kinase  
PI  :  Propidium Iodide  
PIDD  :  p53-induced Protein with a Death Domain  
PKB  
PML 
:  Protein Kinase B  
Promyelocytic Leukemia Tumor Suppressor 
Pol  
PS 
: 
:  
Reverse Transcriptase 
Phosphatidylserine  
PT  :  Permeability Transition  
PTP  :  Permeability Transition Pore  
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PVDF  :  Polyvinylidene Fluoride  
RAIDD  :  RIP-Associated ICH-1/CED-3 Homologous 
Protein with Death Domain  
Rev  :  Reverse Transcriptase  
RING  :  Really Interesting New Gene  
RIP  :  Receptor Interaction Protein  
RNA  :  Ribonucleic Acid  
ROCK1  :  Rho-Associated Coiled-Coil Containing 
Protein Kinase 1  
ROS  :  Reactive Oxygen Species  
RT  :  Room Temperature  
RyR  :  Ryanodine Receptor  
S.D.  :  Standard Deviation  
SC  :  Scramble  
SDS  :  Sodium Dodecyl Sulfate  
SERCA  :  Sarcoplasmic/Endooplasmic Reticulum 
Calcium ATPase  
shRNA  :  Short Hairpin RNA  
siRNA  :  Short Interfering RNA  
Smac  :  Second Mitochondria Derived Activator of 
Caspase  
SNARE  :  Soluble NSF Attachment Protein Receptors  
SODD  :  Silencer of DD  
STS  :  Staurosporine  
TAE buffer  :  Tris-acetate-EDTA buffer  
tBid  :  Truncated Bid  
TBS  :  Tris Buffered Saline  
TBSS 
TCA  
:  
: 
TBS with 0.02% w/v saponine  
Tricarboxylic acid cycle 
TE buffer  :  Tris-EDTA buffer  
TEMED  :  Tetramethylethylenediamine  
Tg  :  Thapsigargin  
TM  :  Transmembrane  
TMRE  :  tetramethylrhodamine ethyl ester  
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TNF  :  Tumour Necrosis Factor  
TNF-R  :  TNF Receptor  
TPR  :  Tetratricopeptide Repeat  
TR3  :  Thyroid Hormone Receptor 3  
TRADD  :  TNF-R1-associated Death Domain Protein  
TRAF2  :  TNF Receptor-associated Factor 2  
TRAIL-R  :  TNF-related Apoptosis Inducing Ligand 
Receptor  
UPR  :  Unfolded Protein Response  
UV  :  Ultraviolet  
VDAC  :  Voltage-Dependent Anion Channel  
vDED  :  Variant of DED  
vMIA  :  Viral Mitochondria-Localized Inhibitor of 
Apoptosis  
VSVG  :  Vesicular Stomatitis Virus Glycoprotein  
WD repeats  :  Tryptophan-Aspartic Acid Dipeptide 
Repeats  
WT  :  Wild Type  
XBP  :  X-Box Protein  
YC  :  Yellow Cameleon  
YFP  :  Yellow Fluorescent Protein  
β-gal  :  β-galactosidase  
ΔΨm  :  Mitochondrial Electrochemical Protein 
Gradient  
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Introduction 
 
1.   Cell Death: Apoptosis and Necrosis 
 
Cell death is vital in controlling cellular homeostasis to maintain tissue integrity in multicellular 
organisms. Two major, yet fundamentally different forms of cell death are known: necrosis and 
apoptosis. 
 
1.1   Necrosis 
 
The word necrosis originates in the ancient Greek “nekus”, whose literal translation is “a dead 
body.” This form of cell death is an accidental, passive process resulting in an early disruption of 
the plasma membrane and the progressive breakdown of cellular organelles accompanied by 
organelle swelling (oncosis) leading to the lysis of the cell and the leakage of cellular contents into 
the extracellular space, which provokes an inflammatory response (Fig. 1 A (Leist & Jaattela, 
2001)). Neighbouring cells can then also undergo necrosis upon lysis of a single cell thus necrotic 
cell death often affects a group of cells. Cellular necrosis is caused by several external causes such 
as violent perturbation of the environment (extreme high or low temperatures for example), 
mechanical trauma, infections and poisons. Clinically, hypoxic cells or tissues that underwent 
ischaemic injury often present necrotic cell deaths. Additionally, venoms produced by certain 
animals or the infections by particular bacteria can cause rapid and severe necrosis such as Group 
A streptococcus causing necrotizing fasciitis. 
 
1.2   Apoptosis 
 
Apoptosis or programmed cell death (Lockshin & Williams, 1965), in contrast to necrosis, 
requires the evolutionarily conserved, securely regulated activation of an energy-requiring 
intracellular machinery. The word apoptosis was coined by Currie and colleagues in 1972 (Kerr, 
Wyllie, & Currie, 1972). The name also originates from the ancient Greek; the prefix apo- means 
“off, from, away” and -ptosis means “falling”. Apoptosis was first described as a series of 
morphological changes and these changes are still important hallmarks of apoptotic cell deaths 
(see below for details). Unlike necrotic cells, apoptosis can occur in a single cell without inciting 
an inflammatory response, due mainly to its rapid phagocytosis by macrophages and the 
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suppression of inflammatory cytokines via the induced production of anti-inflammatory factors, 
including TGF-β and prostaglandin E2, that this process triggers (Henson & Bratton, 2013). 
Characteristics of apoptotic cells include cell shrinkage and organelle condensation (Fig. 1 B,C). 
The cellular contents of dying cells are packaged into membrane-enclosed vesicles at a later stage 
during apoptosis termed “apoptotic bodies”, which are then recognised by neighbouring cells or 
macrophages and cleared by phagocytosis (Fig. 1 C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Apoptosis is an essential part of life for multicellular organisms that play important roles in 
development and tissue homeostasis (Prindull, 1995). Many cells are produced in excess during 
development, which eventually undergo apoptosis and thereby contribute to a successful 
organogenesis and tissue formation (Meier, Finch, & Evan, 2000; Scavo, Ertsey, Chapin, Allen, & 
Kitterman, 1998; Schittny, Djonov, Fine, & Burri, 1998). Failure to undergo programmed cell 
death during development can cause birth defects, for example syndactyly in humans. Apoptosis 
is not only important during development but plays a critical role in adult organisms as well. It 
maintains the homeostasis of adult organs and tissues, and this regulation is especially important 
for a multicellular long-lived organism. Additionally, apoptotic cell death eliminates cells that are 
Figure 1. Necrotic and apoptotic cell death. (A) Necrotic cell undergoing cell lysis with the contents of the 
intracellular organelles being released into the extracellular environment. (B) Late stage apoptotic cell forming 
several membrane enclosed vesicles as depicted by the presence of small vacuolar structures in the cytosol. (C) 
Apoptotic cell is engulfed for clearing. Figure was taken from thesis of Dr. A-L Mahul Mellier (University of Grenoble) 
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a threat to the organism, such as virally infected cells or cells with damaged DNA, thus 
supporting the host immune system (Green & Martin, 1995; Liebermann, Hoffman, & Steinman, 
1995; Shibata, Kyuwa, Lee, Toyoda, & Goto, 1994). Deregulation of this homeostasis will lead to 
various diseases(Thompson, 1995) and has been observed in numerous pathological and 
therapeutic settings (Reed, 2002; Thompson, 1995). Suppression of apoptosis is linked to cancer, 
atherosclerosis and autoimmune disorders. Other diseases are characterised by an excess of 
apoptosis such as viral infection (eg AIDS), neurodegenerative disorders (eg Alzheimer’s disease 
or Parkinson’s disease), autoimmune disorders (eg multiple sclerosis), haematological disorders 
(eg myelodysplastic syndromes), and toxin-induced diseases (eg alcohol-induced hepatitis). 
Apoptotic cells are defined both by morphological and biochemical changes (Table 1). 
Characteristic morphological features of apoptotic cells include cell shrinkage, chromatin 
condensation, membrane blebbing, cell detachment (if adherent), production of apoptotic bodies, 
and finally engulfment by macrophages or neighbouring cells (fig. 2) ((Kerr et al., 1972; Savill & 
Fadok, 2000). In addition to these visible features, apoptotic cells undergo a series of biochemical 
changes (Table 1). It is often detected that the free cytoplasmic calcium concentration is 
increased during apoptosis (fig. 3 A,B), which will activate certain apoptotic pathways. The 
mitochondrial membrane potential is often lost, which inhibits the production of ATP, and the 
rupture of the outer mitochondrial membrane induces the release of pro-apoptotic factors from 
the mitochondrial inter-membrane space. Most importantly, a family of cysteine-dependent 
aspartate-specific proteases, also known as caspases, are activated (fig. 1 A,C). This family of 
proteases target hundreds of cellular substrates (S. J. Martin & Green, 1995) and the substrate 
cleavage creates many of the morphological features of apoptotic cells as well as several 
biochemical changes, such as DNA degradation or nuclear karyorrhexis(Cohen et al., 1994). 
 
Morphological Features Biochemical Features 
Cell shrinkage Free [Ca2+]c rise 
Chromatin condensation DNA degradation 
Nuclear fragmentation Caspase activation 
Membrane blebbing Loss of mitochondrial membrane 
potential 
Cell detachment Phosphatidylserine externalisation 
Production of apoptotic bodies  
Phagocytosis of cell corpses  
Table 1. Characteristics of apoptotic cells 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. The morphological features of apoptosis. The formation of apoptotic bodies consists of marked 
condensation of both the nucleus and cytoplasm, nuclear fragmentation, and the separation of cell surface 
proteins to produce membrane-bounded, compressed, but well-preserved cell remnants of various sizes. Figure 
was taken from J. F. R. Kerr et al 1972. 
 
24 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
B C 
Figure 3. Time Lapse Images of Cells Undergoing Apoptosis: Biochemical Features. HeLa cells were transfected 
with the cytosolic calcium indicator YC3.6. Cells were subsequently treated with doxorubicin (2 µM) and CaspaTag 
Caspase-3/7 sulforhodamine (a dye that only binds to activated caspase-3 or -7 and emits red fluorescence upon binding). 
(A) The top six panels show the time course of cytosolic calcium increase (as indicated by the increased green fluorescence) 
and the activation of caspase-3 or/and -7 (as indicated by the red fluorescence). (B, C) The bottom two figures show the 
cytosolic calcium elevation and the Caspase-3 or/and -7 activation of a representative cell. Figure was taken from thesis of Dr. 
Ryota Iwasawa (Imperial College London) 
 
25 
 
2.   Caspases: Initiators of Apoptosis 
 
A family of cysteine-dependent aspartate-specific proteases (Caspases) are the main 
initiators and executioners of apoptosis (Alnemri et al., 1996; S. J. Martin & Green, 
1995). Their activation is one of the major hallmarks of apoptotic cell death. Caspases 
use a cysteine residue as the nucleophilic group for substrate binding and cleave a peptide 
bond C-terminal to an aspartate residue (Stennicke & Salvesen, 1998). The study of 
caspases originated from the discovery of the cell death-inducing gene ced-3 in C. 
elegans, whose mammalian homologue is interleukin-1β converting enzyme (ICE or 
caspase-1 (Xue, Shaham, & Horvitz, 1996),(Yuan, Shaham, Ledoux, Ellis, & Horvitz, 
1993)), which has 28% sequence identity with a complete conservation of the active 
pentapeptide sequence to Ced-3. ICE (caspase-1) was initially studied based on its 
involvement in the 31kDa cytokine pro-interleukin-1β cleavage to produce the 17kDa 
mature interleukin-1β (Cerretti et al 1992, Thornberry et al 1992) that mediates an 
inflammatory response. This protein eventually led to the discovery of other caspases 
involved directly in the processes of cell death (Stennicke & Salvesen, 2000; Yuan et al., 
1993). 
 
2.1   Classification of Caspases 
 
Numerous caspases have been identified in mammals and can be classified depending 
on their sequence similarities, function, structure, and substrate preference. The 
phylogenetic tree of the fourteen mammalian caspases is shown (fig. 4). Although the 
family of these protease function as central initiators and executioners of apoptosis, some 
of them (Caspase-1, -4, -5, -13, -14 and murine caspase-11, -12) are involved in the 
procession of pro-inflammatory cytokines and in mediating inflammatory responses. The 
remaining caspases (Caspase-2, -3, -6, -7, -8, -9 and -10) are involved in the processes of 
cell death (fig. 4). Those caspases can be further subdivided into two groups: initiator 
caspases (Caspase-2, -8, -9 and -10) and effector caspases (Caspase-3, -6 and -7). The 
initiator caspases first receive death signals and get activated in a caspase-activating 
signalling complex. Activation of effector caspases is dependent on activated initiator 
caspases and it is the effector caspases that execute apoptosis. 
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Structurally all caspases contain a highly homologous protease domain (fig. 4), which 
consists of a ~18kDa large subunit (p18) and a ~10kDa small subunit (p10). In addition 
to the protease domain, some caspases also possess large prodomains (fig. 4). For 
effector caspases, this prodomain is a short stretch of amino acids (~30 amino acids). On 
the contrary, initiator caspases and some cytokine-activating caspases feature long 
prodomains (>100 amino acids) containing either two “Death Effector Domain (DED)“ 
(Caspase-8 and -10) or one “Caspase Recruiting Domain (CARD)” (Caspase-2 and -9 
((Boldin, Goncharov, Goltsev, & Wallach, 1996; Fernandes-Alnemri et al., 1996; Muzio 
et al., 1996)), which mediate homotypic interactions between upstream adaptor molecules 
that also contain either DED or CARD domains (Ashkenazi & Dixit, 1998; Hofmann, 
Bucher, & Tschopp, 1997). 
Since the proteolytic cleavage mediated by caspases generally occurs at the C-terminal 
of an aspartate residue, the presence of this amino acid is crucial and its mutation greatly 
reduces or abrogates the caspase recognition (Howard et al., 1991; Sleath, Hendrickson, 
Kronheim, March, & Black, 1990). However, it was also found that at least three amino 
acids positioned N-terminal to this aspartate residue are important for substrate cleavage 
(Cohen, 1997; Humke, Ni, & Dixit, 1998; Mittl et al., 1997; Rotonda et al., 1996; 
Thornberry et al., 1997; Van de Craen et al., 1997; Walker et al., 1994; Wilson et al., 
1994). The various caspases, regardless of their structure or function, have a high 
preference for those three amino acids (fig. 4). One of the preferred sequences is DEVD 
(aspartic acid-glutamic acid-valine-aspartic acid), which is preferentially used by Caspase-
3 and -7; VEHD (valine-glutamic acid-histidine-aspartic acid) targeted by Caspase-6, -8 
and -10; DEHD (aspartic acid-glutamic acid-histidine-aspartic acid) is used by Caspase-2; 
and W/LEHD (tryptophan/leucine-glutamic acid-histidine-aspartic acid) recognized by 
Caspase-1, -4, -5 and -9 (Thornberry et al., 1997). 
 
 
 
 
 
 
Figure 4. Classification of Caspases. Caspases 
can be classified by their i) sequence homology, ii) 
function, iii) structure, or iv) substrate preference. 
The phylogenetic tree of 14 representative 
mammalian caspases is shown on the left 
(mcaspase-11 and -12 are murine caspases). The 
caspases involved in apoptosis can be further 
subdivided into effector and initiator caspases. All 
caspases contain a protease domain, which 
consists of large and small subunit. Initiator 
caspases and some cytokine-activating caspases 
possess long prodomains of either DED or 
CARD. Caspases also have different preferences 
for the tri-amino acids N-terminal to the aspartic 
acid residue. Figure was adapted from Thornberry et al 
1997. 
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Caspases are not produced as an active enzyme from mRNA but are rather 
synthesised as an inactive pro-enzyme (zymogen). Therefore they require to be activated. 
The methods of activation for initiator and the effector caspases are different but the 
basic processes of activation follows similar steps and are outlined below (fig. 5). A 
procaspase contains a prodomain and two subunits of the protease domain (the large p18 
and small p10 subunits) as described above. Within a large subunit, there is a conserved 
pentapeptide activation motif (QACXG where X is R, Q or G) that contains the active 
cysteine residue, which is required for caspase binding. During the first stage of 
activation, the aspartate residue that flanks a large and small subunit is cleaved to 
produce two fragments: prodomain with the large subunit and the small subunit 
(Thornberry et al., 1997). Following the first cleavage, the bond after the aspartate 
residue that separates the prodomain and the large subunit is cleaved. Then, the 
separated large and small subunits interact to form a pro-active heterodimerized enzyme 
bearing one active site. This heterodimer subsequently homodimerizes to form a fully 
mature active caspase. Thus, an active caspase is a heterotetramer containing two active 
sites (Wolf & Green, 1999). The active initiator caspases (caspase-2, -8, -9 and -10) then 
cleave and thereby trans-activate effector caspases-3, -6 and -7 (Fernandes-Alnemri et al., 
1996; Muzio, Salvesen, & Dixit, 1997; Orth, O'Rourke, Salvesen, & Dixit, 1996; 
Stennicke et al., 1998; Stennicke & Salvesen, 1998; X. Yang, Stennicke, et al., 1998). 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Mechanism of Caspase 
Activation. Caspases are produced as 
an inactive zymogen. The first 
cleavage separates the small sub-unit 
of protease domain from the pro-
domain and the large sub-unit 
resulting in the production of three 
fragments. Small and large sub-units 
from the protease domain associate 
to form a pro-active heterodimer. 
This heterodimer then dimerizes to 
form a mature active caspase, which 
is a heterotetramer containing two 
active sites. Figure was taken from thesis 
of Dr. A-L Mahul Mellier (University of 
Grenoble) 
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The activation of initiator caspases were previously thought to occur by 
autoproteolytic activation by caspases. Two caspases that come into close proximity 
activate each other by self-cleavage (known as “induced proximity model” (Ashkenazi & 
Dixit, 1998; D. A. Martin, Siegel, Zheng, & Lenardo, 1998; Muzio, Stockwell, Stennicke, 
Salvesen, & Dixit, 1998; X. Yang, Chang, & Baltimore, 1998a). However, recently this 
model was refined to the “proximity-induced dimerization model” as explained in figure 
5. In this model, initiator caspases are recruited to a protein complex which serves as a 
platform for the caspase activation that harbours either a “death effector domain 
(DED)” or another homotypic protein interaction module called “caspase recruiting 
domain (CARD)” (refer to section 3 for more detail) (Thornberry & Lazebnik, 1998). 
The initiator procaspase-8 or -10 are mainly activated at the plasma membrane within a 
complex known as death inducing signalling complex (DISC) (Varfolomeev et al., 1998). 
The FADD adaptor protein in this complex contains the DED domain. The initiator 
procaspase-9, on the other hand, cannot be activated at this complex as procaspase-9 
does not possess any DED. Instead, procaspase-9 is activated within a platform known 
as apoptosome, which is a protein complex of cytochrome c, CARD containing Apaf-1 
and procaspase-9 (Hakem et al., 1998; Kuida et al., 1998). Effector caspases (procaspase-
3, -6 and -7) are primarily activated by initiator caspases thereby establishing a cascade of 
caspase-dependent caspase activation. 
 
2.2   Substrates of Caspases 
 
Caspases execute apoptotic signalling pathways by cleaving cellular proteins. There are 
over two hundreds caspase substrates identified to date and those include cell cycle-
related proteins (such as the retinoblastoma protein), DNA repair proteins (such as poly 
ADP-ribose polymerase (Nicholson et al., 1995; Tewari et al., 1995)), structural proteins 
(such as nuclear lamins) and apoptotic proteins (Degterev, Boyce, & Yuan, 2003). One of 
the most prominent substrates of caspase are caspase themselves. Effector caspases are 
activated by the cleavage mediated by the initiator caspases (see section 2.2). The most 
important effector caspase is caspase-3 and the morphological characteristics of 
apoptotic cells including DNA degradation, mitochondrial dysfunctioning, membrane 
blebbing and cell detachment are manifested mainly by caspase-3 cleavage of cellular 
protein substrates. However, caspase-6 and -7 share some substrates with caspase-3 and 
therefore the loss of caspase-3 can in part be compensated (Zheng et al., 2000). 
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One of the most well-characterized substrates is poly-ADP-ribose polymerase 
(PARP). It functions as one of the key DNA repair enzymes. The cleavage of PARP 
produces a 89kDa catalytic domain and a 24kDa DNA-binding domain (Kaufmann, 
Desnoyers, Ottaviano, Davidson, & Poirier, 1993). The conservation of the 89kDa 
catalytic domain allows cells to utilise ATP during the execution phase of apoptosis 
(Takahashi & Earnshaw, 1996). However, the cleavage has been shown to interfere with 
the functionality of PARP as a DNA repair enzyme. Thus, the cleavage of PARP 
maintains its function to produce energy but loses its function as a DNA repair enzyme. 
The procession of PARP is a direct indicator of apoptosis and the activation of caspase-
3. 
Almost all apoptotic cells undergo DNA degradation and this feature is manifested by 
caspase-3. Caspase-activated DNase (CAD) and 40kDa DNA fragmentation factor 
(DFF) is complexed with inhibitor of CAD (iCAD) and 45kDa DFF (DFF45) in healthy, 
non-apoptotic cells. However, iCAD/DFF45 inhibition of CAD/DFF40 is abrogated by 
the cleavage of iCAD induced by caspase-3, which allows the exposure of the catalytic 
domain of this DNase, which then cleaves A/T-rich regions of DNA to produce 50-
200kbp DNA fragments (Enari et al., 1998; X. Liu, Zou, Slaughter, & Wang, 1997; 
Sakahira, Enari, & Nagata, 1998). 
A 75kDa mitochondrial respiratory complex I protein, NADH dehydrogenase 
ubiquinone Fe-S protein 1 (NDUS1), is another important substrate of caspases. Caspase 
cleavage of NDUS1 is related to the dysfunctioning of mitochondria including outer 
mitochondrial membrane permeabilisation, disruption of the electron transport chain for 
ATP production and the production of reactive oxygen species (Ricci et al., 2004). 
A number of pro-apoptotic kinases are substrates of caspases. A Rho-associated 
coiled-coil containing protein kinase 1 (ROCK1) was reported to be a substrate of 
caspases and its cleavage was observed in response to tumour necrosis factor (TNF) 
treatment. The cleaved ROCK1 was shown to be both necessary and sufficient to induce 
membrane blebbing of a cell (Coleman et al., 2001). Another kinase, p21-activated kinase 
2 (PAK2), is also cleaved by caspase-3 and reported to contribute to the formation of 
apoptotic bodies (N. Lee et al., 1997; Rudel & Bokoch, 1997). 
As well as apoptotic signalling proteins, cleavage of structural proteins contributes to 
the morphological characteristics of apoptotic cells. Cleavage of fodrin and gelsolin, for 
example, lead to a disruption of actin filament networks, which results in the loss of cell 
shape and detachment from the matrix (Kothakota et al., 1997; S. J. Martin et al., 1995). 
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Some adherent junction proteins, β-catenin and plakoglobin γ-catenin, that connect 
neighbouring cells are cleaved by caspases, too. Their cleavage disrupts the cell-cell 
communication thereby leading to cell detachment in the tissues (Schmeiser, Hammond, 
Roberts, & Grand, 1998). The cleavage of nuclear lamin A and C is reported to be 
involved in nuclear condensation observed during apoptosis (Lazebnik et al., 1995; Rao, 
Perez, & White, 1996; Takahashi et al., 1996)  
 
3.   Apoptosis Pathways: Extrinsic and Intrinsic 
 
Apoptotic pathways involve many proteins that are required to orchestrate complex signalling 
pathways. Two major pathways that lead to the activation of caspases and the induction of cell 
death are known: the extrinsic and intrinsic pathway. These two pathways share a basic signalling 
cascade: the initiation phase, the integration/decision phase and the execution phase. The initial 
reception of the apoptotic signal is highly heterogeneous and depends on the nature of the death-
inducing signals. In the extrinsic pathway, it is the ligand ligation to a death receptor and in the 
case of the intrinsic pathway, it is damage inflicted on a cellular organelle (nucleus, endoplasmic 
reticulum, lysosomes, Golgi apparatus or mitochondria). The integration/decision phase involves 
the formation of a caspase-activation complex and caspase activation. Cells then pass the point of 
no return and are destined to die. In the last phase, morphological and biochemical changes 
occur due to the cleavage of cellular proteins by caspases. The biggest difference between the two 
pathways is the initial reception of the death signals. The extrinsic pathway receives its first 
apoptotic signal at plasma membrane receptors, whereas mitochondria are the central regulators 
of signals in the intrinsic pathway. 
 
3.1 Extrinsic Pathway 
 
The extrinsic pathway or the death receptor-dependent pathway of apoptosis first 
receives its signal from plasma membrane receptors (Ashkenazi & Dixit, 1998). These 
receptors belong to the tumour necrosis factor (TNF) receptor superfamily and are 
characterized by the presence of two to five copies of cysteine-rich extracellular repeats. 
This superfamily includes Fas (also known as Apo-1 or CD95), TNF-receptor-1 (TNF-
R1), death receptor-3, TNF-related apoptosis inducing ligand receptor-1 (TRAIL-R1), 
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TRAIL-R2 and death receptor 6. The TNF-R1 mediated and the Fas receptor mediated 
pathways are most intensively studied. 
The tumour necrosis factor (TNF) is a multifunctional pro-inflammatory cytokine 
mainly produced by macrophages. TNF is involved in the progression of many diseases 
such as rheumatoid arthritis and Crohn’s disease and inhibitors of TNF is used for 
therapeutic purposes. 
On the plasma membrane, TNF-R1 forms, upon binding its ligand, a homotrimer and 
each protein contains a death domain (DD) facing the cytosol. This DD is used to recruit 
several adaptor proteins to form a death-inducing signalling complex (DISC) leading to 
the activation of initiator caspases upon binding of TNF to the TNF-R1. However, in 
the absence of TNF, the receptor is bound to Silencer of DD (SODD), which inhibits 
the recruitment of the adaptor proteins for caspase activation thus acting as a negative 
regulator of apoptosis (fig. 7, TNF receptor mediated pathway (Y. Jiang, Woronicz, Liu, 
& Goeddel, 1999)). In the presence and upon binding of TNF to its receptor, SODD 
dissociates from the TNF-R1 complex allowing the exposure of the DD and the 
recruitment of another DD-containing protein, “TNF-R1-associated death domain 
protein” (TRADD) (fig. 7 (H. Hsu, Xiong, & Goeddel, 1995)). Following the binding of 
TRADD to TNF-R1 complex, there are two possible consequences. 
One scenario is that the DD of TRADD recruits “receptor interaction protein (RIP)” 
and “TNF receptor-associated factor-2” (TRAF2 (G. Chen & Goeddel, 2002; H. Hsu, 
Shu, Pan, & Goeddel, 1996)). This tetra-protein complex consisted of TNF-R1, 
TRADD, RIP and TRAF2 is known as complex I (fig. 7, TNF receptor mediated 
pathway, left). This complex can lead to one of three different outcomes (fig. 7). In one 
scenario “nuclear factor-κB (NFκB)” is activated and promotes survival of the cells (Y. 
Lin, Devin, Rodriguez, & Liu, 1999). This is triggered and regulated by the 
phosphorylation of IκB. The initiation begins with the recruitment of the heterodimer of 
IκB kinases (IKKα and IKKβ) and the regulatory protein NEMO (also known as IKKγ) 
to the TNF-R1 signalling complex I by TRAF2 (Devin, Lin, & Liu, 2003). RIP seems to 
stabilise the IKK complex. In a non-induced state, NF-κB is retained in the cytosol by 
the interaction with IκB. However, upon recruitment of IKK complex to the TNF-R1 
signalling complex I, IκB is targeted and phosphorylated for proteolytic degradation by 
the proteasomes. The degradation of IκB releases the heterodimer of NF-κB (p55 and 
p65) and they translocate to the nucleus where they promote the transcription of survival 
genes such as Bcl-2 and c-IAPs. In the second scenario, c-Jun N-terminal kinase (JNK) is 
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activated through complex I. Upon activation of JNK, it translocates to the nucleus and 
activates transcription factors, for example, c-Jun and ATF-2, by phosphorylation. These 
transcription factors control the regulation of several genes including genes involved in 
apoptosis regulation, c-IAP and c-FLIP (Hu, Vincenz, Ni, Gentz, & Dixit, 1997; 
Srinivasula et al., 1997) for example, thereby preventing the induction of apoptosis. In 
the last scenario, “RIP-associated ICH-1/CED-3 homologous protein with death 
domain” (RAIDD) or synonymously known as “caspase and RIP adapter with death 
domain” (CRADD) associates with RIP (Ahmad et al., 1997; Duan & Dixit, 1997). A 
domain similar to the caspase recruitment domain (CARD) of RAIDD is able to activate 
initiator procaspase-2 to a mature caspase-2 for the induction of cell death (Duan & 
Dixit, 1997).  
The second, fundamentally different scenario of TNF-R1 mediated apoptosis involves 
a different set of proteins that are recruited to the receptor. The TRADD associates with 
TNF-R1 complex through its DD and the DD of TRADD recruits “Fas-associated 
death domain” (FADD). In addition to a DD, FADD also contains death effector 
domain (DED) for the recruitment of DED-containing initiator caspases (procaspase-8 
and -10). A complex of TNF-R1, TRADD, FADD and procaspases-8 or -10 is known as 
complex II (fig. 7, TNF receptor mediated pathway, right). This recruitment of 
procaspases results in a temporal elevation of caspase concentration around the TNF-R1, 
which leads to caspase activation (J. W. Kim, Choi, & Joe, 2000) by the proximity-
induced dimerization model. The activated caspase-8 or -10 then activate effector 
caspases such as procaspase-3 or -7 for the execution of cell death (fig. 7). 
The TNF-R1 mediated apoptosis does not induce cell death spontaneously as it can 
both result in a pro-survival pathway or in a pro-apoptotic pathway. The NF-κB pathway 
and the JNK pathway lead to an expression of pro-survival proteins (Stehlik et al., 1998; 
Wajant, Pfizenmaier, & Scheurich, 2003). The cytotoxic effects of TNF is only 
manifested when NF-κB activation is blocked either by the inhibition of NF-κB protein 
synthesis or by the expression of dominant negative IκB (Wang, Mayo, & Baldwin, 1996), 
which usually does not happen in vitro. A study in mice indicated that the loss-of-
function of proteins involved in the NF-κB activation pathway are either embryonic 
lethal or results in neonatal fatality (Beg, Sha, Bronson, Ghosh, & Baltimore, 1995). This 
indicates that the ability of TNF to induce apoptosis is concurrently suppressed in vitro 
by a constitutive activation of NF-κB. 
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Fas is a heavily glycosylated 40-45kDa protein involved in cytotoxic T-cell mediated 
killing. The Fas receptor homotrimerizes at the plasma membrane similar to the TNF-R1 
(Ashkenazi & Dixit, 1998; Pitti et al., 1996; Smith, Farrah, & Goodwin, 1994). Ligation of 
Fas ligand to the Fas receptor forms a platform for the caspase activation known as 
“death inducing signalling complex (DISC)” via the DD of the Fas receptor (fig. 7, Fas 
receptor mediated pathway (Boldin et al., 1995; Chinnaiyan, O'Rourke, Tewari, & Dixit, 
1995; Kischkel et al., 1995; Nagata, 1997). The adaptor protein FADD is first recruited to 
the Fas-receptor, and the DED of the FADD allows the association of procaspases-8 or 
-10 (Chinnaiyan et al., 1995; Medema et al., 1997). The formation of DISC quickly 
increases the local concentration of procaspases, which in turn become mature, active 
caspases (Boatright et al., 2003; Donepudi, Mac Sweeney, Briand, & Grutter, 2003; 
Walczak & Krammer, 2000). Activated caspase-8 or -10 then activate downstream 
effector procaspases such as procaspases-3 or -7 (Stennicke et al., 1998), and the 
activated caspase-3 or -7 execute apoptosis by substrate cleavage (fig. 7). 
Another protein cFLIP (cellular FADD-like ICE inhibitory protein) negatively 
regulates death-receptor mediated apoptosis (fig. 6, (Hu et al., 1997; Irmler et al., 1997; 
Srinivasula et al., 1997)). Two isoforms of cFLIP, cFLIP1 and cFLIP2, have been 
identified (Inohara, Koseki, Hu, Chen, & Nunez, 1997; Irmler et al., 1997). Both 
isoforms contain tandem repeats of death effector domains that are highly homologous 
to that of procaspases-8. In addition to the tandem repeats of DED, cFLIP2 possesses 
inactive (due to mutations in the catalytic domain) protease-like domain similar to that of 
procaspases-8. The presence of this domain allows cFLIPs to be also recruited to the 
DISC (Krueger, Schmitz, Baumann, Krammer, & Kirchhoff, 2001). However, since both 
isoforms of FLIPs do not have any protease activity, they act as a competitive antagonist 
of procaspases-8 at the DISC to inhibit the activation of procaspases-8 for cell death 
induction. 
 
3.2 Intrinsic Pathway 
 
The intrinsic apoptotic pathway is characterized by the permeabilisation of the 
mitochondria and cytochrome c release into the cytoplasm. This pathway is usually 
initiated by stress stimuli such as cytotoxic drugs, ionizing radiation, heat shock, DNA 
damage, reactive oxygen species, nutrient deprivation, and cytokines. These stimuli 
eventually lead to apoptosis when the balance between the activities of pro-apoptotic and 
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anti-apoptotic members of the B-cell lymphoma-2 (Bcl-2) proteins superfamily is 
disturbed. Bcl-2 was first identified as a proto-oncogene by a common translocation in 
human follicular B-cell lymphoma (Bakhshi et al., 1985; Cleary, Smith, & Sklar, 1986; 
Tsujimoto, Gorham, Cossman, Jaffe, & Croce, 1985) and the overexpression of Bcl-2 in 
transgenic animal models mimicked the human disease (McDonnell et al., 1989; 
McDonnell & Korsmeyer, 1991). Unlike other proto-oncogenes that promote cell 
proliferation to produce cancer, Bcl-2 was found to promote cell growth by inhibiting 
cell death induced by multiple physiological and pathological stimuli (Hockenbery, 
Nunez, Milliman, Schreiber, & Korsmeyer, 1990; Kinloch, Treherne, Furness, & 
Hajimohamadreza, 1999; Vaux, Cory, & Adams, 1988). There are over twenty Bcl-2 
family members identified and examples are shown in Table 2. Ced-9 is the homolog of 
Bcl-2 in C. elegans (Hengartner, Ellis, & Horvitz, 1992; Hengartner & Horvitz, 1994) and 
viral homologues of Bcl-2 have been also identified in Epstein-Barr virus (BHRF1 
(Cleary et al., 1986)), adenovirus (E1B 19K (Boyd et al., 1994; Chiou, Tseng, Rao, & 
White, 1994; Rao et al., 1992; E. White et al., 1992)) and African swine fever virus 
(LMW5-HL (Neilan et al., 1993)). The sequence alignment of Bcl-2 family members 
revealed that they share at least one of the four conserved Bcl-2 homology domains (BH 
domain) and often contain transmembrane domain (TM) at the C-terminus for 
membrane anchorage (fig. 6). The Bcl-2 family members can be divided into three 
groups: anti-apoptotic, pro-apoptotic and BH3-only pro-apoptotic (Table 2 and fig. 6). 
The anti-apoptotic members, such as Bcl-2 and Bcl-XL (Boise et al 1993), contain all 
four BH domains (BH1, BH2, BH3 and BH4 domains, fig. 6). The pro-apoptotic 
members, Bax (Oltvai, Milliman, & Korsmeyer, 1993) and Bak (Chittenden et al., 1995; 
Farrow et al., 1995; Kiefer et al., 1995) for example, contain only three BH domains 
(BH1, BH2 and BH3 domains, fig. 6). Lastly, BH3-only members, such as Bim and Bid, 
possess only one BH domain (BH3 domain, fig. 6) and act as pro-apoptotic factors either 
by suppressing the activity of anti-apoptotic Bcl-2 family members or by 
activating/promoting the activity of pro-apoptotic members of Bcl-2 family members. 
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Table 4. Bcl-2 Family Members 
Figure 6. Bcl-2 Family Members. Bcl-2 family members can be divided into three functional groups: anti-
apoptotic, pro-apoptotic, and pro-apoptotic BH3-only. Their functions vary but at least one of the Bcl-2 
homology domains (BH domain) is present in all members. Anti-apoptotic members contain all four BH 
domains (BH1, 2, 3 and 4) whereas pro-apoptotic members possess only three BH domains (BH1, 2 and 3). 
Many family members also contain a transmembrane domain for membrane anchorage. Figure was taken from 
thesis of Dr. Ryota Iwasawa (Imperial College London). 
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Bcl-2 is a 26 kDa protein localized to mitochondria (Hockenbery et al., 1990), the 
endoplasmic reticulum (ER) and other perinuclear membranes (Korsmeyer, 1995). It is 
involved in the maintenance of mitochondrial membranes, balances the interaction 
between other members of Bcl-2 family members such as Bax, and calcium homeostasis 
in the ER. Together with other anti-apoptotic Bcl-2 family members, Bcl-2 works to 
prevent the release of cytochrome c from mitochondria, and thereby promotes cell 
survival. Detailed three dimensional studies of monomeric Bcl-XL have proven that the 
BH1, BH2 and BH3 domains are in close proximity to form a hydrophobic groove 
(Fesik, 2000; Hengartner, 2000; Muchmore et al., 1996; Sattler et al., 1997) that can 
accommodate the BH3 domain of the pro-apoptotic Bcl-2 family members thus 
inhibiting their activation (Kluck, Bossy-Wetzel, Green, & Newmeyer, 1997; J. Yang et 
al., 1997). 
On the contrary, pro-apoptotic members promote the release of cytochrome c from 
mitochondria, and this decision is regulated by the ratio between anti-apoptotic and pro-
apoptotic Bcl-2 members present in the cell (Danial & Korsmeyer, 2004). Bax was the 
first pro-apoptotic member of Bcl-2 family to have identified through its interaction with 
Bcl-2 (Oltvai et al., 1993). In accordance with its pro-apoptotic function, knock-out 
mouse model showed a selective expansion of cell population leading to a lymphoid 
hyperplasia (Knudson, Tung, Tourtellotte, Brown, & Korsmeyer, 1995). In the inactive 
state, Bax is localized largely in the cytosol as a monomer although some are loosely 
attached to the outer mitochondrial membrane. Upon reception of apoptosis signals, 
however, Bax undergoes an allosteric conformational change and gets inserted to the 
outer mitochondrial membrane (OMM (Desagher et al., 1999)). The activated Bax then 
undergoes homooligomerization (Gross, Jockel, Wei, & Korsmeyer, 1998) or 
heterooligomerization with Bak, another pro-apoptotic Bcl-2 member. This 
oligomerization has been postulated to form a pore to allow the release of inner 
mitochondrial space proteins (discussed later in detail). The double knock-out of Bax and 
Bak makes cells resistant to almost all the death-stimuli for the intrinsic pathway of 
apoptosis (Lindsten et al., 2000; Wei et al., 2001), and in fact, these proteins together 
constitute a required gateway for the intrinsic pathway operative in mitochondria (Wei et 
al., 2001) and in the ER (Scorrano et al., 2003). BH-3 only members trigger apoptosis in 
response to various stimuli by acting as upstream sentinels, which selectively respond to 
specific signals by first receiving the death signals and transmitting them to other 
members of Bcl-2 family proteins (Cheng et al., 2001). BH3-only members alone, 
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however, are insufficient to induce apoptosis (Cheng et al., 2001; Zong, Lindsten, Ross, 
MacGregor, & Thompson, 2001). 
The intrinsic pathway or the mitochondria-dependent pathway of apoptosis is 
initiated by various stimuli such as growth factor deprivation, calcium flux, UV 
irradiation or treatment with chemotherapeutic drugs but all these signals converge on 
mitochondria (fig. 7, fig. 8 (Green, Knight, Melino, Finazzi-Agro, & Orrenius, 2004)) for 
the induction of mitochondrial outer membrane permeabilisation (MOMP (Green & 
Kroemer, 2004)). Details of the induction of MOMP will be discussed in later sections, 
but the activation of Bax seems to be fundamentally required for the MOMP and the 
signalling cues for the activation of the intrinsic pathway promote such activation by 
either directly enhancing Bax activation or by modulating/inhibiting the activity of anti-
apoptotic Bcl-2 family members, such as Bcl-2 or Bcl-XL (fig. 7, fig. 8). 
The withdrawal of growth factors or the deprivation of cytokine activities, for 
example, inactivates PKB/AKT (protein kinase B/Rac-alpha serine/threonine-protein 
kinase (Datta et al., 1997)). The inactivation of these kinases de-phosphorylates inactive 
Bad and activates it (Zha, Harada, Yang, Jockel, & Korsmeyer, 1996). It is then able to 
inhibit the anti-apoptotic Bcl-2 and Bcl-XL, as well as promote Bax activation. Similarly, 
chemotherapeutic drugs signal and act on the transcription factor p53 to promote the 
expression of Bax and two BH3-only proteins, Noxa and Puma (Nakano & Vousden, 
2001; Oda et al., 2000; Yu, Zhang, Hwang, Kinzler, & Vogelstein, 2001). Noxa and 
Puma, too, are capable of inhibiting anti-apoptotic Bcl-2 members and promoting the 
Bax activation. Other apoptosis mediators such as calcium flux and UV irradiation 
activate the BH3-only protein Bim (Puthalakath, Huang, O'Reilly, King, & Strasser, 1999) 
and Bmf, respectively, and they inhibit anti-apoptotic Bcl-2 members to enhance Bax 
activation.  
Following the activation of Bax and the induction of MOMP, several pro-apoptotic 
proteins are released from mitochondria into the cytosol (fig. 7, fig. 8), such as 
endonuclease G (End. G), apoptosis inducing factor (AIF), Smac/Diablo, Omi/Htra2, 
and, most importantly, cytochrome c (Cyt.c (X. Liu, Kim, Yang, Jemmerson, & Wang, 
1996)). Cytosolic Cyt.c associates with the caspase recruiting domain- (CARD) containing 
adaptor protein “apoptotic peptidase activating factor 1 (Apaf-1).” The CARD domain 
of Apaf-1 then recruits procaspases-9 to form a heptamer of Cyt. c, Apaf-1 and 
procaspases-9 known as Apoptosome (Acehan et al., 2002; P. Li et al., 1997; Rodriguez 
et al., 1999; Srinivasula, Ahmad, Fernandes-Alnemri, & Alnemri, 1998; Stennicke et al., 
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1999; X. Yang, Chang, & Baltimore, 1998b; Zou, Li, Liu, & Wang, 1999) in a ATP-
dependent manner (Zou, Henzel, Liu, Lutschg, & Wang, 1997; Zou et al., 1999). This 
protein aggregate activates procaspase-9, which then activates procaspases-3, -7 and -6 
for apoptosis execution (fig. 7 (P. Li et al., 1997; Shi, 2002a, 2002b; Zou et al., 1997)). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Overview of Extrinsic and Intrinsic Apoptosis Pathways. For the Receptor Mediated Extrinsic Pathway:  
Upon TNF binding to the TNF-R1, SODD dissociates and the receptor either forms complex I or complex II. Complex I 
consists of TNF-R1, TRADD, TRAF2 and RIP. It can either activate NF-κB, recruit RAIDD to activate procaspases-2, 
or activate the JNK pathway. Complex II is constituted of TNF-R1, TRADD, FADD and either procaspases-8 or -10. 
These caspases are activated at this complex. The ligation of Fas to the Fas-R results in a homotrimerization of Fas-R and 
recruits FADD and procaspases-8 or -10 to form a death-inducing signalling complex. Procaspase-8 or -10 are activated at 
the DISC complex and activate down-stream caspases. For the Mitochondria Mediated Intrinsic Pathway: Cellular stresses 
such as growth factor deprivation, calcium influx, UV irradiation or chemotherapeutic drugs signal to BH3-only members 
of Bcl-2 family. They either suppress anti-apoptotic members of Bcl-2 family proteins or promote the activation of Bax to 
induce the permeabilisation of the outer mitochondrial membrane. Such permeabilisation results in a release of 
proapoptotic proteins from mitochondria including cytochrome c, AIF, endonuclease G or Smac/Diablo. Released 
cytochrome c forms a complex with Apaf-1 and procaspases-9 to form the apoptosome where procaspase-9 is activated. 
Figure was adapted from thesis of Dr. Ryota Iwasawa (Imperial College London). 
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Figure 8. Illustration of the apoptotic cell death pathways. The extrinsic pathway is triggered by ligands binding 
to receptors on the cell surface (TNFR1, CD95, TRAIL), resulting in their oligomerization, formation of DISC and 
caspase-8 activation. In Type I cells caspase-8 activates caspase-3, which results in the cleavage of a host of target 
proteins and apoptosis. In Type II cells, caspase-8 cleaves Bid, resulting in the engagement of the mitochondrial 
pathway. The latter involves the release of pro-apoptotic 
proteins (cytochrome c, Smac, Omi, AIF and EndoG) from the mitochondrial intermembrane space into the cytosol 
via Bax/Bak-mediated pores in the outer membrane. Here, cytochrome c, Smac and Omi participate in the activation 
of the caspase cascade, while AIF and EndoG are further translocated to the nucleus, where they participate in 
chromatin condensation and large-scale DNA fragmentation. XIAP is a cytosolic inhibitor of apoptosis protein, 
whose activity is blocked by Smac and Omi. Figure was taken from (Zhivotovsky & Orrenius, 2011).  
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4.   Calcium and Cell Death 
 
Research studies throughout the past several years have shown that the Ca2+ ion plays 
an important role in cell signalling and in most aspects of cell physiology, including gene 
transcription, cell cycle regulation and cell proliferation. Furthermore, its crucial function 
during cell death regulation has been emphasized. Necrotic cell death was early 
associated with intracellular Ca2+ overload, and multiple functions in the apoptotic 
process have subsequently been found to be governed by Ca2+ signalling. More recently, 
other modes of cell death, notably anoikis and autophagic cell death, have been 
demonstrated to also be modulated by Ca2+ transients (fig. 9 (Zhivotovsky & Orrenius, 
2011)). 
 
  
 
 
 
 
 
 
 
 
 
 
4.1 Calcium and phagocytosis 
The apoptotic cell death process is terminated by the phagocytosis of the dying cell 
via macrophages or neighbouring cells. Phosphatidylserine on the apoptotic cell surface 
is the most prominent phagocytic signal, mediated by a number of bridging molecules 
(Hanayama et al., 2004). In healthy cells, phospholipids are distributed unevenly across 
the plasma membrane with a majority of the phosphatidylethanolamine, and all of the 
PS, being present in the inner leaflet of the plasma membrane; while in apoptotic cells, 
the PS pool is moved to the cell surface with distribution of other major phospholipids 
being unaffected. The exposure of PS leads to phagocytic activity and its distribution is 
Figure 9. Calcium involvement in 
various cell death modalities. Ca2+ 
signalling has been known for some time 
to be involved in both the initiation and 
effectuation of cell death. Key events in 
the apoptotic process are known to be 
triggered by Ca2+ signals. Some forms of 
autophagic cell death and anoikis have 
also been shown to be Ca2+- dependent. 
Figure was taken from (Zhivotovsky & 
Orrenius, 2011).  
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controlled by Ca2+-dependent scramblase that catalyzes the non-specific randomization 
of phospholipids across the bilayer along with an ATP-dependent 
aminophospholipidtranslocase that mediates movement of aminophospholipids from the 
outer to the inner leaflet (Zhivotovsky & Orrenius, 2011). Phospholipid scrambling is 
stimulated by Ca2+ and there are suggestions that transmembrane protein 16F is the 
responsible in apoptotic cells for PS exposure (Suzuki, Umeda, Sims, & Nagata, 2010). 
 
4.2 Calcium and the endoplasmic reticulum 
In mammalian cells, the ER is responsible for Ca2+ signalling as well as storage and the 
modifications of newly manufactured proteins. Disruptions in these functions can result 
in ER stress, which ultimately leads to apoptosis induction via the activation of pro-
caspase-12 (Nakagawa et al., 2000). A variety of drugs, particularly tunicamycin, can 
induce apoptosis via this effect. The activation of this enzyme, which is localized in the 
ER membrane, occurs when calpain is activated by the mobilization of intracellular Ca2+ 
stores during ER stress. Pro-caspase-12 may also be activated via its recruitment into 
TNF receptor-associated factor-2, formed as part of the unfolded protein response 
pathway (Yoneda et al., 2001). It has been shown that ER stress induced by Ca2+ 
depletion or changes in the transport systems are linked directly to caspase activation. 
Upon activation, caspase-12 acts on effector caspases to elicit apoptosis. 
Extranuclear PML (promyelocytic leukemia tumor suppressor), a pharmacological 
target for the modulation in Ca2+ signalling via the ER, was shown to be specifically 
enriched in mitochondria-associated membranes as well as the ER itself (Giorgi et al., 
2010). PML’s signalling domain is involved in Ca2+ transport from the ER to 
mitochondria and apoptosis induction. Found within a complex with the IP3 receptor 
(IP3R), protein kinase Akt, and protein phosphatase 2a (PP2a), PML acts as an Akt- and 
PP2a-dependent modulator of IP3R phosphorylation and IP3R-mediated Ca2+ release, 
with the effect being specific for Ca2+-dependent apoptosis. Consecutive Ca2+ release 
from the ER is regulated by IP3R, with some being taken up by the mitochondria and 
used for optimal cellular respiration and ATP production. Cleavage of the IP3R has been 
shown to promote Ca2+ accumulation via the mitochondria and apoptosis (Berridge, 
Bootman, & Roderick, 2003). Another link between the ER and the mitochondria 
involves cytochrome c release. It has been demonstrated that cytochrome c released from 
the mitochondria can bind to IP3R in addition to Apaf-1, thus blocking the inhibition of 
its function via an increased cytosolic Ca2+ level (Boehning et al., 2003). This results in 
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continual Ca2+ rise, leading to amplified cytochrome c release and increase of the 
apoptotic signal. 
 
4.3 A cell death signal 
Ca2+ signals direct a multitude of essential cell functions necessary for cell survival. 
However, it is also well-known that an excess amount of Ca2+ may lead to cytotoxicity, 
resulting in either apoptotic, necrotic, or autophagic forms of cell death. Therefore, cell 
death can be triggered by a decrease in Ca2+ homeostatic control, but also caused by 
more subdued changes in Ca2+ dispersal within intracellular regions. Historically, the role 
of the Ca2+ ion as an inducer of cell death began back during Fleckenstein’s observation 
that excess Ca2+ entry into cardiomyocytes might be the mechanism that triggers cardiac 
pathology following ischemia (Fleckenstein, Janke, Doring, & Leder, 1974). Successive 
studies have stressed the importance of this observation, as both receptor 
overstimulation (Leonard & Salpeter, 1979) and cytotoxic agents (Trump & Berezesky, 
1995) were found to cause lethal Ca2+ influx into cells. An earlier link between Ca2+ and 
apoptosis was the discovery that Ca2+ induced a typically apoptotic DNA fragmentation 
pattern in isolated thymocyte nuclei via the activation of Ca2+- and Mg2+- dependent 
endonuclease (Wyllie, 1980). More recent studies have shown that non-disruptive 
changes in Ca2+ signalling could also have detrimental effects, consisting of apoptotic 
induction (Berridge et al., 2003). In addition, Ca2+- dependent processes are responsible 
for the processing of AIF, leading to its mobilization from the mitochondria and 
cytosolic release (Norberg et al., 2008). 
 
4.3.1 The role of mitochondria in calcium signalling 
It has been well established that the mitochondria actively participates in intracellular 
Ca2+ compartmentalization (Carafoli, 2002). Ca2+ is taken up electrophoretically from the 
cytosol via a uniport transporter and can be released via various routes. The uniporter’s 
affinity for Ca2+ is low, and the size of the mitochondrial Ca2+ pool is small under 
physiological conditions. Under pathological conditions, much larger amounts of Ca2+ 
can accumulate in the mitochondria, when cytosolic Ca2+ concentrations begin to 
increase (Thor, Hartzell, & Orrenius, 1984). Mitochondrial Ca2+ uptake has long been 
thought of as a security mechanism during cases of temporary cytosolic Ca2+ overload. 
This view has changed following the development of novel indicators, which can sense 
intracellular Ca2+ fluctuations in specific compartments (Rizzuto, Simpson, Brini, & 
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Pozzan, 1992). Implementing this technology, it has become evident that mitochondrial 
Ca2+ fluxes are assimilated parts of intracellular Ca2+ signalling. The low affinity of the 
mitochondrial Ca2+ import system is relieved by the proximity of the mitochondria to the 
ER and by the formation of Ca2+ “hotspots” at the mouth of ER release channels, where 
the local Ca2+ concentration may reach very high levels (Hajnoczky, Robb-Gaspers, Seitz, 
& Thomas, 1995). Successive uptake of Ca2+ by the mitochondria stimulates the Ca2+- 
sensitive matrix dehydrogenases, key sources of NADH for the respiratory chain and 
thus for mitochondrial ATP production. The significance of this mechanism for normal 
cellular energy metabolism has been demonstrated convincingly by a group from the 
University of Pennsylvania through the identification of an unexpected and essential role 
for constitutive InsP3R-mediated Ca
2+ release in maintaining cellular bioenergetics; 
constitutive InsP3R Ca
2+ signalling is required for macroautophagy suppression in cells 
with nutrient-replete media and in its absence, cells become metabolically compromised 
due to diminished mitochondrial Ca2+ uptake (Cardenas et al., 2010).  
The recruitment of the mitochondrial pathway of apoptosis signalling results in the 
permeabilization of the OMM and the release of a multitude of mitochondrial proteins, 
some of which induce distinct apoptotic events in other subcellular compartments. 
Permeabilization of the OMM is achieved by several different mechanisms. This may 
consist of pore formation by pro-apoptotic Bcl-2 family proteins such as Bax and Bak, 
and membrane rupture as a result of mitochondrial swelling. Besides for the activation of 
Bad by calcineurin-catalyzed dephosphorylation, there is no established role for Ca2+ in 
the activation of the Bcl-2 family proteins during apoptosis (Zhivotovsky & Orrenius, 
2011). Ca2+ triggers another mechanism of OMM permeabilization involving the opening 
of a PTP, which consists of a large protein-based complex. The pore has been localised 
to contact sites between the inner and outer mitochondrial membranes and functions like 
a voltage-operated channel with the pore opening being activated by a high level of Ca2+ 
in the matrix and further stimulated by oxidative stress, pyridine nucleotide and thiol 
oxidation, alkalinisation, as well as low transmembrane potential. Prolonged opening of 
the pore allows Ca2+ as well as other matrix components that are low in molecular weight 
to escape from the mitochondria, while the influx of water and solutes from the cytosol 
results in mitochondrial swelling and rupturing of the membrane. 
The mitochondrial PTP has been widely studied, but little is known concerning its 
structure. Initial experiments done by Szabó and Zoratti have suggested that the PTP 
may consist of Voltage Dependent Anion Channel (VDAC) molecules, but this 
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hypothesis was proven incorrect when VDAC-/- mitochondria were still capable of 
undergoing activation of the PTP (Baines, Kaiser, Sheiko, Craigen, & Molkentin, 2007; 
Szabo & Zoratti, 1993). Further investigations convincingly suggested that the 
mitochondrial permeability transition was formed by the inner membrane Adenine 
Nucleotide Translocase (ANT), but the removal of this protein still led to activation 
(Kokoszka et al., 2004; Varanyuwatana & Halestrap, 2012). So far, the only components 
of the mitochondrial PTP that has been identified are the translocator protein (TSPO), 
previously known as the peripheral benzodiazepine receptor, located in the 
mitochondrial outer membrane, and cyclophilin-D in the mitochondrial matrix (Baines et 
al., 2005; Sileikyte et al., 2011). Hence, the mechanism by which Ca2+ activates 
mitochondria for cell death is largely unknown and remains to be investigated.     
 
4.4 Cell death via mitochondrial permeabilization 
Although opening of the PTP has been linked to necrotic cell death, there are a 
number of agents that have been shown to induce apoptosis via Ca2+-mediated 
mitochondrial permeability transition. These treatments include Ca2+ ionophores and 
thapsigargin, neurotoxins, chemotherapeutics, and pro-oxidants such as arachidonic acid 
and peroxynitrite. In some instances, cell death could be prevented by inhibitors of 
mitochondrial Ca2+ uptake or PTP formation; these include ruthenium red and 
cyclosporine A (Zhivotovsky & Orrenius, 2011). PTP formation usually results in the 
release from the mitochondria of cytochrome c, AIF, as well as other pro-apoptotic 
proteins. Apoptotic stimuli has been observed, particularly ceramide, to induce a switch 
in mitochondrial Ca2+ signalling at the start of the apoptotic process via the facilitation of 
Ca2+- induced opening of the PTP (Szalai, Krishnamurthy, & Hajnoczky, 1999). 
Accordingly, one observation was made that the resistance of leukemic cells to 2-
chlorodeoxyadenosin (CDA) is linked with an augmented ability of their mitochondria to 
sequester Ca2+ without associated induction of the PTP (Chandra et al., 2002). The CDA-
resistant cells were selectively cross-resistant to Ca2+-mediated apoptosis, particularly 
thapsigargin, but not to CD95-mediated apoptosis, including staurosporine. 
The uncoupling of mitochondria as a result of pore opening would lead to active 
hydrolysis of cytosolic ATP or uncoupling-stimulated ATPase activity. This would cause 
a drop in ATP content and an agitation of cytosolic Ca2+ homeostasis and activation of 
various catabolic enzymes such as proteases, phospholipases, etc. This model of OMM 
permeabilization can be used to best represent conditions associated with localized 
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mitochondrial Ca2+ overload (Al-Nasser & Crompton, 1986). Transient pore opening 
might also occur when a small percentage of mitochondria would have open pores at a 
given time (Rizzuto, Brini, Murgia, & Pozzan, 1993). In this scenario, mitochondrial 
protein release would occur without amplitude swelling or a drop in mitochondrial 
membrane potential of the entire organelle population. This situation occurs under 
normal physiological circumstances as well, when mitochondria are located in close 
proximity to calcium microdomains, where the local concentration of ionized calcium 
exceeds the average concentration measured in the cytosol (Y. Li, Johnson, Capano, 
Edwards, & Crompton, 2004). The frequency of impulsive pore opening and closure may 
increase due to apoptotic stimuli, resulting in mitochondrial intermembrane space 
proteins being translocated into the cytosol. 
Current studies are being made regarding the important role of the PTP for the 
release of cytochrome c from the mitochondria under apoptotic scenarios. One way of 
accomplishing this is via overexpression of CypD, a crucial component of the pore 
complex. This overexpression has led to opposite effects on apoptosis and necrosis, 
promoting NO-induced necrosis, whilst inhibiting NO- and staurosporine-induced 
apoptosis. CypD- deficient cells however, were resistant to necrotic cell death induced by 
ROS and Ca2+ overload, but died normally in response to apoptotic stimuli (Baines et al., 
2005). Furthermore, CypD- deficient mice have shown resistance to 
ischemia/reperfusion- induced cardiac injury, suggesting that the CypD- dependent PTP 
regulates, to some extent, forms of necrotic, but not apoptotic cell death (Nakagawa et 
al., 2005). 
 
 
 
           
             
 
 
 
 
 
 
Figure 10. Illustration of the intracellular 
targets in Ca2+-mediated cytotoxicity. The 
presence of calcium in different intracellular 
compartments induces the activation of 
various molecules involved in the regulation 
of cell death. The disruption of Ca2+ signalling 
may lead to the activation of multiple 
cytotoxic mechanism such as the 
mitochondrial permeability transition and 
disruption of cytoskeletal organization. Ca2+ 
activation of NO synthases, calcineurin, 
transglutaminase, calpain, phospholipases or 
endonucleases has been shown to take part in 
various forms of apoptotic cell death. Figure 
was adapted from (Zhivotovsky & Orrenius, 2011).  
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4.5 Calcium-activated effector mechanisms 
There are many targets for Ca2+ in cell death signalling, including protein kinases and 
phosphates, NO synthases, endonucleases, transglutaminases, phospholipases, and 
proteases (fig. 9). Recently, there has been compelling evidence regarding proteases, 
including members of the calpain family of Ca2+- activated cysteine proteases, being 
involved in apoptosis. Inhibitor studies suggest that the association of calpain with 
apoptosis is more prominent in certain cell types such as thymocytes, monocytes, 
cardiomyocytes, and neurons (Vanags, Porn-Ares, Coppola, Burgess, & Orrenius, 1996). 
Calpain has been further reported to cleave the endogenous calcineurin inhibitor 
cain/cabin 1, leading to the activation of calcineurin and the promotion of cell death (M. 
J. Kim et al., 2002). Data indicate that the cross-talk between calpain and caspases is 
crucial for regulation of the apoptotic process. A variety of cellular proteins can be 
cleaved by both calpain and caspases during apoptosis. 
 
4.5.1 AIF processing triggered by calcium 
Recent studies have shown that a novel function of Ca2+ and calpain is present in 
apoptosis signalling, particularly during the processing of mitochondrial AIF (Norberg et 
al., 2008). AIF, reportedly being the first protein to mediate caspase-independent, 
apoptotic cell death, is a 62 kDA flavoprotein anchored to the mitochondrial inner 
membrane, near complex I (Susin et al., 1996). It is anchored by part of its peptide chain 
and requires cleavage before a 57 kDa pro-apoptotic fragment can be released into the 
cytosol for translocation into the nucleus, promoting large-scale DNA fragmentation and 
chromatin condensation via a mechanism not yet defined. A calpain localized to the 
intermembrane space of the mitochondria is responsible for AIF cleavage. It is activated 
by a sustained elevation of intracellular Ca2+ levels. The oxidative modification of AIF by 
ROS produced in the mitochondria, further stimulates AIF proteolysis, leading to 
carbonylation of the protein and increased predisposition to calpain cleavage (Norberg, 
Gogvadze, Vakifahmetoglu, Orrenius, & Zhivotovsky, 2010). In lung cancer cells of 
neuroendocrine origin and in cortical neurons that have been treated with protein kinase 
C inhibitors, such as staurosporine or PKC 412, the activating Ca2+ signal then originates 
from the import of extracellular Ca2+ through a hyperpolarization-activated cyclic 
nucleotide-gated (HCN2) ion channel in the plasma membrane (Norberg, Karlsson, et 
al., 2010). Down-regulating this channel in neurons and tumour cells blocks the influx of 
Ca2+ as well as AIF processing and apoptosis. 
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4.5.2 Calcium-mediated nuclear changes 
Nuclear Ca2+ signalling remains a controversial topic. Recently, it has been shown that 
nicotinic acid adenine dinucleotide phosphate (NAADP) can release Ca2+ from the 
nuclear envelope, which consists of an ER-type Ca2+ store (Gerasimenko, Maruyama, 
Tepikin, Petersen, & Gerasimenko, 2003). Similar to IP3, NAADP reduces the Ca2+ 
concentration within the nuclear envelope, which is associated with a momentary rise in 
the nucleoplasmic Ca2+ concentration. Furthermore, Ca2+ overload, along with calpain 
activation, results in a perturbation of macromolecular partitioning across the nuclear 
membrane with increased leakage of the nuclear barrier, affecting nucleocytoplasmic 
transport (Bano et al., 2010). Ca2+ fluctuations in the intranuclear region can also 
influence chromatin organization, induce gene expression, and affect several enzyme 
activities, including protein kinases, endonucleases, and proteases. This affect is due to 
different mechanisms and it has been shown that nuclear Ca2+ sequestration is associated 
with chromatin unfolding (Nicotera, Zhivotovsky, & Orrenius, 1994). The facilitation of 
histone HI redistribution or topoisomerase II activation may be initiated by ion changes 
in the nuclear matrix via chromatin unfolding. This process could produce changes in the 
supercoiling of a particular chromatin domain. The resulting torsional stress could distort 
the chromatin structure and impose DNase sensitivity on a portion of the domain. The 
chromatin structure may be influenced, and the interaction of histone proteins with the 
nucleosomes may change further. The activation of specific genes within the unfolded 
region incorporates the activation and binding of a specific transcription factor protein, 
which would not occur without the initial chromatin unfolding. Apoptosis has been 
shown to be delayed by agents that increase chromatin compaction (Dypbukt et al., 
1994). 
Ca2+ regulates directly as well as indirectly several genes involved in cell death 
signalling. Some of these genes include calmodulin, c-fos, and growth-arrest genes such as 
gadd 153, as well as numerous others. Calmodulin and Ca2+ are well-established regulators 
of the cell cycle. The expression of an integral form of Ca2+/calmodulin-stimulated 
protein kinase II can lead to cell cycle arrest in the G2 phase. Changes in the cell cycle 
may lead to apoptosis. In many cells, the expression of early response genes, such as c-fos, 
precedes apoptosis, and are regulated by Ca2+. These genes are components of signal 
transduction systems and their products may be required to promote subsequent events 
leading to apoptosis.  
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The longstanding exposure of human macrophages to TNF leads to sustained 
activation of early response genes, such as c-jun and NFкB, resulting in signalling events 
that culminate in the induction and activation of Ca2+- dependent transcription factor 
(NFAT), priming macrophages to terminal differentiation and cell death (Yarilina, Xu, 
Chen, & Ivashkiv, 2011). It has recently been shown that Ca2+ is required for nuclear 
accumulation of clusterin, a heterodimeric glycoprotein produced ubiquitously in 
mammalian tissues. This accretion has resulted in the inhibition of cell proliferation and 
caspase-dependent death of human prostate cells (Caccamo et al., 2005). 
Numerous Ca2+-dependent and Ca2+- independent enzymes have been discovered to 
be involved in apoptotic DNA degradation (Zhivotovsky, Wade, Nicotera, & Orrenius, 
1994). The discovery of the caspase-3-activated endonuclease and its inhibitor, DNA 
fragmentation factor, caspase-activated DNase and its inhibitor CAD/ICAD, along with 
the involvement in nuclear apoptosis, led to a decline in research involving new 
nucleases, due to the likelihood of the identity of the apoptotic endonuclease activity 
having been determined (Enari et al., 1998), (X. Liu et al., 1998). Despite this, the 
incubation of isolated cell nuclei with Ca2+ and ATP, for example in the absence of 
caspase-mediated DNA cleavage activity, leads to a chromatin fragmentation pattern 
indistinguishable from that found in apoptotic cells. This opens up the possibility that 
other nucleases may still be involved in overall DNA degradation. 
 
4.6 Intracellular ion homeostasis 
Ca2+ signals have been discussed to trigger apoptosis and lead to the activation of 
caspases, resulting in the cleavage of key components of the Ca2+ regulatory system, 
disturbing Ca2+ homeostasis. According to scientists at the University of Tokyo, the type 
1 IP3 receptor is cleaved by caspase 3 during apoptosis, and this cleavage led to a 
decrease in calcium channel activity during degradation of the receptor (Hirota, Furuichi, 
& Mikoshiba, 1999). Additionally, caspase 3 is also capable of cleaving the plasma 
membrane Ca2+- ATPase (Schwab et al., 2002). For the enduring control of cellular Ca2+ 
homeostasis as well as the cleavage-associated function loss during apoptosis, this 
enzyme is imperative, as Ca2+ overload results in secondary cell lysis or necrosis. 
Furthermore, caspase-3 is also involved with the cleavage of the Na+/Ca2+- exchanger 
during apoptosis. 
An additional ion pump present in the plasma membrane which can function as a 
caspase substrate during apoptosis is the Na+, K+- ATPase. Previous studies have 
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revealed that shrinkage in volume, characteristic of apoptotic cells, is complemented by a 
net efflux of ions due to inactivation of the Na+, K+- ATPase (Mann, Bortner, Jewell, & 
Cidlowski, 2001). Apoptosis is augmented via Bcl-2-sensitive activation of outward K+ 
currents. The β-subunit of the Na+, K+- ATPase appears to be the caspase target as it 
regulates the K+ affinity of the enzyme at the extracellular site. In addition to the role in 
cell shrinkage during apoptosis, inactivation of the Na+, K+- ATPase promotes the 
apoptotic process by lowering the intracellular K+ concentration for optimal caspase 
activity (Vu, Bortner, & Cidlowski, 2001). 
 
4.7 Cell death execution and the role of AIF 
AIF, as mentioned previously, is an N-terminally anchored flavoprotein, located in the 
inner mitochondrial membrane. The protein has to be freed from its membrane anchor 
before the release into the cytosol and translocation to the nucleus. There it initiates 
significant DNA fragmentation and chromatin condensation. Available evidence suggests 
that AIF plays a crucial role in cell death only among certain cell types, for instance in 
some tumor cells and in neurons (Joza et al., 2001), (Norberg, Orrenius, & Zhivotovsky, 
2010).  The type of death stimulus also determines whether AIF will be important in the 
cell death process. AIF triggers should preferably inhibit intracellular Ca2+ homeostasis or 
induce early lysosomal permeabilization to allow for the AIF-mediated pathway to be an 
essential mechanism of apoptosis. Both of these are frequent components of cell death 
signalling, mainly after treatment with cytotoxic compounds and in ischemia-reperfusion 
injury. 
Several studies propose a critical role for AIF in neuronal cell death. The 
microinjections of neutralizing AIF antibodies, along with the downregulation of AIF, 
have been found to suppress glutamate, hypoxia, and NMDA induced neuronal death 
(Liou et al., 2005). Furthermore, the knockdown of AIF in PC12 cells has reduced the 
toxic effects aroused by MPP+ (1-methyl-4-phenylpyridinium), which interferes with 
oxidative phosphorylation in mitochondria and causes the depletion of ATP, resulting in 
cell death, inhibition of catecholamine synthesis, dopamine and cardiac norepinephrine 
reduction, inactivation of tyrosine hydroxylase, and Parkinson’s disease via the 
destruction of dopamine-producing neurons (Leem et al., 2014; Liou et al., 2005). Several 
in vivo observations demonstrate that the importance of the AIF-mediated pathway in 
neuronal cell death. For example, compared with wild type mice, AIF-deficient Harlequin 
(Hq) mice were immune to NMDA and kainic acid-induced neuronal damage in the 
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hippocampus (Klein et al., 2002). Harlequin mice that were subjected to 
hypoxia/ischemia were characterized with the ability to suppress cell death. When AIF 
processing was prevented via oral administration of HIV protease inhibitors, neuronal 
protection was observed among various mouse models. It has also been shown that 
inhibiting nuclear translocation of AIF leads to neuronal protection of a retinal 
degeneration rat model (Murakami et al., 2008).  
 
4.8 Role of calcium in other cell death scenarios 
Two fundamental features exist in cell death programs. One is that they are 
evolutionarily conserved, explained by the dual role of numerous components pertaining 
to both life and death signals. Second is that they incorporate the activation of one or 
more families of proteases and/or other enzymes responsible for degradation. In many 
cases, developmental cell death and death under pathological scenarios have similar 
morphological features including execution and signalling systems. This applies to not 
only apoptosis, but other cell death scenarios, for instance autophagic cell death, 
characterized by the presence of cytoplasmic vacuoles occurring frequently in both 
neuronal development and neurodegenerative diseases (Yuan, Lipinski, & Degterev, 
2003). The presence of biochemical pathways for cell death signalling and execution that 
are conserved has reduced previous focus on morphological characteristics. In spite of 
efforts to explain individual forms of cell death based on appearance, cell disassembly is 
always characterized by nuclear fragmentation, organelle disruption, and eventually, 
membrane lysis and phagocytosis. Similar to necrosis, apoptosis involves the 
mitochondria being partially or entirely damaged. In both, the cytoskeletal structure is 
compromised and molecules are exposed on the cell surface in order to promote 
recognition of the dying cell. Several execution routines are activated in parallel within 
injured cells, with one or another becoming more dominant, depending on the stimulus 
as well as the metabolic state of the tissue. Under pathological conditions, several 
protease families may collaborate to disassemble cells, aiming at different organelles or 
subcellular structures. Although the prevalence of one or the other death executing 
mechanism may be defined by factors as different as energy requirement, signalling 
molecules or in many cases the differentiation program within a given tissue, defines the 
mode of death. This applies especially to neurons, where spatial selectivity of death 
signals and promiscuity of execution systems can lead to the complex and relatively slow 
passing that takes place in neurodegenerative diseases. In brain ischemia, for example, 
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both caspase-dependent and caspase-independent death pathways are activated. Caspase-
independent pathways include Ca2+ activation of the calpain family of proteases. The 
predominance of one death pathway over the other can be explained by ATP availability 
for the activation of routines that are caspase-dependent (Orrenius, Zhivotovsky, & 
Nicotera, 2003). 
 
4.8.1 Calcium in necrosis 
Despite chemical toxicity being associated with multiple modes of cell death, toxic cell 
death was initially thought to be the necrotic type, often related to a disturbance of 
intracellular Ca2+ homeostasis. The killing of hepatocytes via the exposure to carbon 
tetrachloride, acetaminophen or bromobenzene may serve as classical examples. Cell 
death induced by acetaminophen and bromobenzene was studied extensively during the 
1970s and found to be preceded by metabolic activation mediated by cytochrome P-450, 
glutathione depletion, and disruption of Ca2+ homeostasis, usually monitored by cellular 
leakage of lactate dehydrogenase or the uptake of trypan blue. 
After apoptosis was recognised as a distinct form of cell death, two hypotheses related 
to its role were presented: 1) Apoptosis may be induced by harmful agents of lesser 
amplitude than those causing necrosis in the same cells. 2) Its induction may be more 
prone in certain cell populations primed for apoptosis (Wyllie, 1987). An early example 
of this is the discovery that increasing concentrations of the redox-cycling quinone, 2,3-
dimethoxy-1,4-naphthoquinone could stimulate proliferation, induce apoptosis, or lead 
to necrosis depending on the administered dosage (Dypbukt et al., 1994). Studies with 
arsenic trioxide have shown that at lower doses, Bax/Bak-dependent apoptosis is 
triggered, while at higher doses, the mitochondrial permeability transition and necrotic 
cell death is induced (Bustamante, Nutt, Orrenius, & Gogvadze, 2005; Nutt et al., 2005). 
This observation shows that in vivo, distinct cell death modalities may co-exist. 
Interference with specific signalling pathways or critical cell functions may result in cell 
killing by a different mechanism. A prime example is post-apoptotic necrosis due to 
intracellular Ca2+ overload following caspase cleavage. 
 
4.8.2 Calcium in autophagic cell death 
Morphologically defined via transmission electron microscopy as a type of cell death 
that occurs during the absence of chromatin condensation, autophagic cell death is 
accompanied by excessive autophagic vacuolization of the cytoplasm (Klionsky & Emr, 
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2000). Initially defined as a survival mechanism, with some reports indicating that cells 
presenting it can still recover upon withdrawal of the death-inducing stimulus, increased 
autophagy may be responsible for the destruction of cells as a result of a lengthened 
atrophy of the cytoplasm beyond a point of no return. 
In the past, it was found that, similar to apoptosis, autophagy could be induced by ER 
stress, proposing a possible link between Ca2+ and autophagy. Stimulated Atg7-deficient 
cells exhibit diminished influx, but not efflux, of calcium, and ER Ca2+ storage is 
increased. The stimulation of Ca2+ mobilization via thapsigargin, ionomycin, or vitamin 
D has been revealed to induce autophagy (Hoyer-Hansen et al., 2007). Furthermore, 
accumulation of GFP-LC3 was perturbed by BAPTA-AM, suggesting that the formation 
of autophagosomes is Ca2+- dependent. It was demonstrated that autophagy occurs by 
the Ca2+- dependent activation of AMP-activated protein kinase (AMPK), required for 
upstream activation of the Ca2+/calmodulin kinase β. 
An additional Ca2+/calmodulin-regulated kinase is the DAPK (death-associated 
protein kinase), also shown to be a crucial regulator of autophagy (Bialik & Kimchi, 
2010). This enzyme interacts with the LC3-binding protein, MAP1B, which is involved in 
autophagosome trafficking along microtubules. During the interaction, it phosphorylates 
Beclin-1, originally identified as a Bcl-2 interacting protein, disturbing the inhibitory 
Beclin-1-Bcl-2/XL interaction. On the contrary, interaction of MAP1B with TSC2, a 
negative regulator of mTOR, results in DAPK phosphorylation and inactivation 
(Harrison et al., 2008). 
Calcium plays a direct role in the induction of autophagy as observations have been 
made that calcium phosphate precipitates could induce autophagy in a number of 
different cell lines. Recently, Kroemer and colleagues have been able to show that the 
IP3R regulates autophagy via interaction with Beclin-1, setting up a functional and 
physical connection between the ER and mitochondria in both apoptosis and autophagy 
(Vicencio et al., 2009). A second link between Ca2+ and autophagy was perceived when 
cells that were treated with the autophagy inducer, fluspirilene, an inhibitor of Ca2+ 
fluxes, lowered intracellular Ca2+ levels, preventing calpain-mediated cleavage of Atg5, 
and increasing the levels of full-length Atg5 and the Atg5-Atg12 conjugate (Xia et al., 
2010). 
The cell death progression can be introduced in different intracellular compartments 
depending on the mode of death introduced. Cross-talk, which occurs between these 
different intracellular compartments or organelles, is vital for all cell death types. This 
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communication involves several molecular switches within the signalling network. P53 
can then be activated in response to DNA damage, or due to changes in the redox 
balance of mitochondria, and Bcl-2 family proteins may act at the mitochondrial, ER-, or 
the nuclear level. Nuclear p53 stimulates the transcription of pro-apoptotic and cell cycle-
arresting genes, but can also act to induce autophagy as a transcription factor. In contrast, 
p53 in the cytosol may trigger apoptosis and/or inhibit autophagy, although the 
molecular mechanisms of the function have not been found (Green & Kroemer, 2009). 
Furthermore, it has been recently discovered that DAPK moderates upstream signalling 
events that control autophagy induction via the activation of p53 in a p19ARF-
dependent manner, leading to the upregulation of both proteins. P53 then activates 
AMPK, suppressing mTOR signalling via TSC2m, upregulating the lysosomal protein, 
DRAM. 
An additional instance where cross-talk occurs between apoptosis and autophagy 
involves the pro-autophagic function of Beclin-1, mentioned previously. This function 
can be inhibited by both Bcl-2 and Bcl-XL (Shimizu et al., 2004). Although Beclin-1 
possesses a BH3-only domain, and all BH3-only proteins of the Bcl-2 family are well-
known apoptosis inducers, Beclin-1, on the contrary, protects against pro-apoptotic 
agents via the stimulation of autophagy. Upon growth factor withdrawal however, when 
autophagy precedes apoptosis, caspase-mediated cleavage of Beclin-1 inactivates 
autophagy and stimulates apoptosis through the promotion of pro-apoptotic factors 
being released from the mitochondria. A caspase-generated fragment of Beclin-1 appears 
to induce an amplified loop enhancing apoptosis (Djavaheri-Mergny, Maiuri, & Kroemer, 
2010). 
The hierarchy of inter-organelle cross-talk may result in different cell death modalities, 
depending on the nature and severity of the stimulus. In some scenarios, suppression of a 
specific intracellular compartment may lead to the shift of one cell death mode to 
another. An example of this would be the inhibition of mitochondrial energy 
metabolism, leading to a decrease in ATP production. This can lead to a shift from 
apoptosis to necrosis. Correspondingly, the inhibition of caspase activity may also cause a 
change from apoptosis to necrosis, or to autophagic cell death, while calpain-mediated 
activation of autophagy-regulated protein Atg-5 cleavage, leads to a shift from autophagy 
to apoptosis (Yousefi et al., 2006). 
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4.8.3 Calcium in anoikis 
Anoikis is a form of programmed cell death induced when anchorage-dependent cells 
detach from the surrounding extracellular matrix. This system of cell death comprises 
many varied forms of tissue-homeostatic, developmental and oncogenic processes. 
Despite the lack of knowledge regarding the mechanisms behind anoikis, the 
involvement of Ca2+ and ROS have been associated with its regulation in previous 
studies, similar to other cell death systems (A. E. Li et al., 1999).  
In specific tumour cells that have been treated with anticancer compounds, the 
calpain level considerably influenced detachment from the extracellular matrix (Niapour, 
Yu, & Berger, 2008). Additionally, a second study showed Ca2+- activated channels being 
associated with the regulation of anoikis (Elble & Pauli, 2001). For instance, in breast 
cancer cells, down-regulating Ca2+- activated chloride channels led to inhibition of 
detachment from the matrix. This inhibition was also seen via upregulation of these 
channels, which led to prominently less cell death via anoikis. 
Efforts to characterize the mechanisms associated with inhibition of anoikis have 
been undertaken. For instance, β-catenin, an important oncoprotein, has been discovered 
to down-regulate DAPK-2, resulting in anoikis resistance and the promotion of growth 
independent of anchorage (H. Li, Ray, Yoo, Erdogan, & Rosen, 2009). DAPK activity 
can also be controlled by protein phosphatase-2 (PP2A), a pathway associated with 
ceramide-induced anoikis (Widau, Jin, Dixon, Wadzinski, & Gallagher, 2010). It appears 
that similar proteins may be involved in the regulation of multiple Ca2+- dependent cell 
death systems, but the mechanism behind the regulation remains to be further 
investigated. 
 
5.   ROS generation 
Reactive oxygen species (ROS) generation, which has been mentioned previously to 
be associated with mitochondrial calcium influx, plays a major role in mitochondria-
mediated cell death induction. ROS is a general term that encompasses oxygen 
derivatives, including radical and non-radical, which are oxidizing agents and/or are easily 
converted into radicals (Halliwell, 2006). Formed by the partial reduction of molecular 
oxygen, ROS, and in particular oxygen itself, have been considered for a while to 
represent a challenge for living organisms, due to the intrinsic toxicity in its unavoidable 
partial reduction. Living organisms, as a result, have been forced to adapt with developed 
defence strategies (Fridovich, 1998). This, however, does not clarify reasons why 
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evolution has conserved so many specific mechanisms for ROS production, as it is 
common among many species. A moderate level of such species is physiological and 
required for life and ROS are mainly known to be physiologically involved in cell 
signalling via influencing the redox state of signalling proteins (Barja, 1993). Despite this, 
it has been long-known that ROS in excess lead to toxicity in cells and organisms. 
Among healthy cells, the continuous production of ROS is balanced via various 
detoxification reactions regulated by various antioxidant systems. Only excessive ROS 
production or a defect in protective systems results in oxidative stress and pathological 
indications. In normal conditions, the ROS concentration is kept within restricted 
confinements and assists in the redox balance within the cell (Linnane & Eastwood, 
2006). The redox balance can be defined as the ratio between oxidizing and reducing 
species, which is also involved in the regulation of signalling pathways such as protein 
kinase and phosphatase activities as well as gene expression via the modulation of 
transcription factors(Fruehauf & Meyskens, 2007).  
ROS, in excess, employ their detrimental effects via two main routes: (1) direct 
alteration of cellular or extracellular macromolecules, which interrupts normal function, 
resulting in pathological defects and (2) changes in their physiological action on the redox 
state of factors dealing with signal transduction, resulting in over- or under- functioning 
of signalling pathways. 
 
5.1 ROS generation in mitochondria 
ROS formation in cells occurs by means of both endogenous as well as exogenous 
sources. The exogenous sources of ROS consist of UV and visible light, drugs, 
environmental toxins, and ionizing radiation. The endogenous sources include xanthine 
oxidase, the ER’s cytochrome P-450 enzymes, plasma membrane NADPH oxidases, and 
flavin oxidases. However, despite the wide range of sources, the major source of ROS is 
usually considered to be derived from the mitochondrial respiratory chain, located in the 
inner mitochondrial membrane, with other enzyme systems in the mitochondria 
contributing as well. 
Mitochondria contribute greatly to the generation of ROS within a cell, generally via 
the respiratory chain (Lenaz, 1998, 2001). The significance of mitochondrial ROS 
production is indirectly revealed by the results of mitochondrial antioxidant enzyme 
deficiency. In general, mitochondria consist of an isozyme of superoxide dismutase 
56 
 
(SOD-2) and glutathione peroxidase (GPx); the lack of either results in severe damage to 
the cell (Esposito et al., 2000; Melov et al., 1999).  
 
5.2 Mitochondrial respiratory chain overview 
The cellular respiratory chain is made up of reducing equivalents, or hydrogen atoms, 
from mitochondrial oxidations of the TCA cycle, from pyruvate oxidation, fatty acid and 
amino acid catabolism, and other oxidative reactions, to molecular oxygen reducing it to 
water. The free energy decrease accompanying electron transfer is subjugated in order to 
generate an electrochemical proton gradient (∆µOH+) via proton translocation, out from 
the mitochondrial matrix. The generated proton gradient is incorporated as a source of 
energy to synthesize ATP from ADP and Pi via the ATP synthase complex through a 
process known as oxidative phosphorylation (OXPHOS). It can also be used to drive 
other energy-linked reactions such as NADH/NADP+ transhydrogenation and up-
gradient ion movements across the inner membrane. The ATP synthesized is transported 
from the mitochondria to the cytoplasm in exchange with ADP via the ATP/ADP 
translocase. 
The mitochondrial respiratory chain is made up of four major multi-subunit 
complexes designated as Complex I (NADH-Coenzyme Q), Complex II (Succinate 
Dehydrogenase), Complex III (Ubiquinol-Cytochrome c reductase), and Complex IV 
(Cytochrome c oxidase). The respiratory complexes are functionally joined via smaller 
redox components, for instance Coenzyme Q, which is imbedded in membrane lipids 
and cytochrome c, located in the outer face of the inner membrane. The best fit unit 
stoichiometry between complexes in beef heart mitochondria is 1 Complex I : 1.3 
Complex II : 3 Complex III : 6.7 Complex IV (Schagger & Pfeiffer, 2001). Additionally 
there are 0.5 ATP synthase and 3 to 5 units of the ADP/ATP translocase, catalysing the 
equimolar exchange of ADP and ATP across the inner membrane, for each cytochrome 
oxidase, and one NADH/NADP+ transhydrogenase for every Complex I. 
The representation of the respiratory chain as a collection of arbitrarily strewn 
enzymes in the lipid bilayer, based on the random collision model (Hackenbrock, 
Chazotte, & Gupte, 1986), has changed following the discovery of respiratory 
supercomplexes as supramolecular functional respiratory units (Hatefi, Haavik, & 
Griffiths, 1962). 
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5.3 Mitochondrial respiratory chain as a source of ROS generation 
The major sites of superoxide formation within the respiratory chain are regarded to 
be complexes I and III. Further sites, however, may have importance and physiological 
relevance. Recent on-going studies have shown that complex II may also be a prominent 
source for ROS generation (Grimm, 2013; Lemarie, Huc, Pazarentzos, Mahul-Mellier, & 
Grimm, 2011).  It is worth stressing that mitochondria from different tissues may vary 
conspicuously in their capability to produce ROS using different substrates; this ability is 
linked to animal species and age (Kwong & Sohal, 1998). 
 
5.3.1 Complex I 
Complex I of the mitochondrial respiratory chain, also known as NADH CoQ 
reductase, functions to oxidize NADH and reduces CoQ in the lipid bilayer of the inner 
mitochondrial membrane. This reaction is accompanied by translocation of four protons 
from the matrix into the intermembrane space. 
Many prosthetic groups assist with electron transfer within the enzyme complex: 
flavin mononucleotide (FMN) is the entry point for electrons, which are transferred to a 
series of iron-sulphur clusters following entry. Different enzymes have different numbers 
of iron-sulphur clusters (T. Ohnishi et al., 1998). However, most of them share the same 
midpoint potential. N2, an iron-sulphur cluster, has the highest midpoint potential (Em 
between -150 and -50 mV) and is considered to be the direct electron donor to 
ubiquinone. N2 is most likely located in the connection between the peripheral and the 
membrane arm of complex I. Magnetic interaction measurements with the semiquinone 
radical, corresponding to a distance of about 10 angstroms, suggests that the ubiquinone 
head group could somehow reach up into the peripheral arm of the complex (Ohnishi & 
Salerno, 2005). This assumption has been further developed into a hypothesis that there 
is an amphipathic ramp that guides ubiquinone into the catalytic site (Brandt, Kerscher, 
Drose, Zwicker, & Zickermann, 2003).  
The involvement of complex I in ROS production has been supported by evidence 
since the late 1970s (Takeshige & Minakami, 1979). In early in vitro experiments, the 
addition of NADH at low concentrations results in copious ROS production detected by 
lipid peroxidation. The addition of NADH at high concentrations, but in the presence of 
the complex I inhibitor, rotenone, also induced peroxidation. Water-soluble CoQ 
homologues used as electron acceptors from isolated complex I resulted in H2O2 
production, while CoQ6 and CoQ10 were inactive (Cadenas, Boveris, Ragan, & Stoppani, 
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1977). More current studies have confirmed that complex I is a major source of 
superoxide production in many different types of mitochondria. The production of 
superoxides by complex I is higher during the reverse electron transport direction from 
succinate to NAD+, whereas during the forward electron transport, superoxide 
production is much slower(Jezek & Hlavata, 2005; Korshunov, Skulachev, & Starkov, 
1997; Turrens, 2003). ROS production based on reverse electron transfer requires high 
membrane potential and is inhibited by uncouplers and by processes dispersing 
membrane potential (Kushnareva, Murphy, & Andreyev, 2002; Starkov & Fiskum, 2003). 
Rotenone increases ROS generation during forward electron transfer and inhibits it 
during reverse electron transfer (Genova et al., 2001; Herrero & Barja, 2000; Lambert & 
Brand, 2004a; S. T. Ohnishi et al., 2005; Vinogradov & Grivennikova, 2005). 
Identification of the oxygen reducing site has been under extensive investigation and 
several prosthetic groups in the enzyme have been suggested to be the direct reductants 
of oxygen. These groups include FMN, ubisemiquinone, and iron sulphur cluster N2 
(Fato et al., 2009; Lenaz, Baracca, Fato, Genova, & Solaini, 2006). In an isolated complex 
I, fully reducd FMN is considered the major electron donor to oxygen to form 
superoxide anion (Galkin & Brandt, 2005). In mitochondrial membranes, however, the 
identification of flavin as the site of oxygen reduction is incompatible with the finding 
that two classes of inhibitors both acting of the iron sulphur clusters in the enzyme have 
opposing effects with rotenone enhancing ROS production and stigmatellin inhibiting it 
(Fato et al., 2009). A possible explanation is that two sites for oxygen reduction exist in 
the complex represented by flavin and an iron-sulphur cluster, with the latter being 
predominant in membrane particles and the former becoming available following the 
isolation of complex I. 
ROS production via complex I is the highest during reverse electron transfer, 
however, the site of oxygen reduction in this case is not very well defined (Murphy, 
2009). It has been hypothesized that the generation of ROS reflects a dynamic balance 
between the flavosemiquinon (semiflavin or SF) and the CoQ semiquinone (SQ) (S. T. 
Ohnishi, Shinzawa-Itoh, Ohta, Yoshikawa, & Ohnishi, 2010). In a purified complex I, 
during catalytic electron transfer from NADH to decyl ubiquinone, the superoxide 
generation site is shifted mostly to SQ. A quinon-pocket binding inhibitor (Rotenone or 
piericidin A) inhibits the catalytic formation of the SQ, enhancing the formation of SF 
and increasing the overall superoxide generation. This suggests that if electron transfer 
was inhibited under pathological conditions, superoxide generation from the SF would 
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be increased. The identifcation of SQ as the electron donor to oxygen, rather than N2, is 
in contrast with the findings that when SQ reduction to QH2 is blocked by stigmatellin 
no ROS is produced (Fato et al., 2009). Furthermore, studies in CoQ-depleted and 
reconstituted mitochondria indicated that endogenous CoQ is not required for 
superoxide generation (Genova et al., 2001).  Along with complex I, complex III is also a 
a major site of superoxide formation. 
 
5.3.2 Complex III 
Complex III, also known as ubiquinol cytochrome c reductase, represents a 
convergence point for reducing equivalents from various dehydrogenases: it catalyzes the 
transfer of electrons from ubiquinol in the lipid membrane (CoQH2) to water-soluble 
cytochrome c on the outer surface of the inner membrane, and in parallel, links this 
redox reaction to the translocation of protons across the membrane, converting the 
energy associated with electron flow into an electrochemical proton gradient. 
The formation of ROS in complex III is dependent on the mechanism of electron 
transfer, the Q-cycle (Crofts, 2004). In the Q-cycle, QH2 delivers the first electron at the 
outer positive site, known as site o or P, of the inner membrane to the Rieske iron-
sulphur protein and hence to cytochromes c1 and c. This results in the release of two H
+ 
in the inter-membrane space and formation of an unstable semiquinone anion QO- at the 
Qo site, which is immediately oxidized to Q by the low-potential cytochrome b562 (or bI) 
at the cytosolic side. The electron is then delivered to the high-potential cytochrome b562 
(or bH) at the internal negative side, known as i or N and bH is then reoxidized by CoQ at 
site I (Qi) forming another semiquinone. The cycle is completed by oxidation of a second 
molecule of QH2.   
Since the electron transfer from cytochrome bL to bH occurs against the electrical 
gradient (from the positive to the negative side), the process is slowed significantly during 
high electrochemical potential. This impedance extends the lifetime of Qo and allows 
reaction of the semiquinone with O2 to take place, forming superoxides (Jezek & 
Hlavata, 2005). 
Antimycin A, an inhibitor acting at the Qi site, is known not to completely inhibit the 
electron flow from ubiquinol to cytochrome c: the antimycin A-insensitive reduction of 
cytochrome c is mediated via superoxide radicals. According to the Q-cycle, antimycin A 
blocks ubiquinone reduction via cytochrome bH at center i, at the inner or negative side 
of the membrane. The antimycin-stimulated production of ROS is inhibited by inhibitors 
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acting at center o (at the outer or positive side) where ubiquinol reduces both the Rieske 
iron-sulphur cluster as well as cytochrome bL. The site of one-electron reduction of 
oxygen in the presence of antimycin can be located at center o, ubisemiquinone 
(Casteilla, Rigoulet, & Penicaud, 2001).  
Myxothiazol was found to enhance ROS production using different respiratory 
substrates in the absence of antimycin, with the effect being reversed using stigmatellin 
(Starkov & Fiskum, 2001). It has been found that proximal Qo site inhibitors, acting 
close to the b566 niche, induce superoxide formation in yeast submitochondrial particles 
supplemented with decyl-ubiquinol; the effect is not modified by antimycin, revealing 
that the source of radicals is not at the Qi site (Muller, Roberts, Bowman, & Kramer, 
2003). It has also been suggested that the oxidation of ubiquinol at center o is biphasic, 
with delivery of the first electron to the Rieske iron sulphur cluster, leaving a 
semiquinone that in absence of further oxidation by cytochrome bL would interact with 
oxygen forming superoxide (Muller et al., 2003). 
 
5.3.3 Complex II 
Complex II specifically, consists of four subunits: SDHA, SDHB, SDHC, and SDHD. 
It is the smallest complex in the respiratory chain and the only one to be entirely made of 
nuclear-encoded DNA. Complex II is an entry point for reducing equivalents, along with 
complex I, generated from the oxidation of succinate to fumarate of the tricarboxylic 
acid (TCA) cycle (Fig. 2). Electrons from complex II reduce coenzyme Q  to ubiquinol 
before continuing down the respiratory chain. Additionally, this complex is unique 
because it is the only one that doesn’t contribute to pumping protons across the IMM 
(Rutter, Winge, & Schiffman, 2010). Based on the crystal structure of complex II and a 
schematic representation, SDHC and SDHD are hydrophobic subunits anchored to the 
IMM (Fig. 2) (Sun et al., 2005; Yankovskaya et al., 2003). The transmembrane domains of 
SDHC and SDHD consists of a redox group, heme b, whose function within complex II 
has been defined as a protein-bound prosthetic group (H. J. Kim, Khalimonchuk, Smith, 
& Winge, 2012). It has been suggested that this redox group has a structural role in 
stabilizing the two hydrophobic subunits, however this is still controversial. Other 
possibilities include involvement in trans-membrane electron transfer and/or the 
preventions of reactive oxygen species formation during electron transfer from FAD to 
ubiquinone by acting as a capacitor during high electron flux (Yankovskaya et al., 2003). 
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Ultimately, its specific role in the transfer of electrons within complex II is so far 
unverified (Lemarie & Grimm, 2009; Oyedotun, Sit, & Lemire, 2007).       
  
  
  
  
    
 
   
  
 
          
 
 
 
 
 
The SDHB subunit has been shown in eukaryotic cells to be associated with the 
hydrophobic, membrane-anchored subunits SDHC and SDHD. Together with SDHA, 
SDHB forms the hydrophilic group responsible for oxidizing succinate to fumarate in 
the TCA cycle as the catalytic core of complex II. Within the hydrophobic sub-complex, 
electrons are transported from the FAD cofactor in SDHA to the three [Fe-S] clusters 
located in SDHB (Fig. 2) (Rutter et al., 2010; Sun et al., 2005). The enzymatic activity of 
this part of complex II is known as the succinate dehydrogenase (SDH) activity (Fig. 3) 
(Lemarie et al., 2011). The SDHC and SDHD sub-complex consists of two CoQ-binding 
sites which are QP (proximal to the iron sulphur clusters) and QD (distal to the iron 
sulphur clusters) (Rutter et al., 2010; Sun et al., 2005). An incomplete formation of the 
reduced semiquinone is presented by the first electron transfer. By the second electron 
transfer, with the production of ubiquinol, the semiquinone radical is stabilized for 
complete reduction (J. Guo & Lemire, 2003; Rutter et al., 2010). This two-step process is 
a mechanism that protects the complex from excessive electron leakage. The electron 
transfer in complex II beginning from succinate and ending at the QP site makes up the 
Figure 11. Complex II structure and function. The four subunits of the complex are shown, the SDHA and 
SDHB hydrophilic subunits along with SDHC and SDHD hydrophobic subunits anchored to the inner 
mitochondrial membrane. The electron flow of reducing equivalents generated from the oxidation of succinate 
to fumarate, coupled with the reduction of FAD to FADH2, is shown. Adapted from (Lemarie & Grimm, 2011). 
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succinate CoQ oxidoreductase (SQR) activity. This can be measured via an enzymatic 
assay (Lemarie et al., 2011).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.3.4 Complex II in apoptosis 
The connection between complex II and apoptotic cell death emerged only recently 
based on its role in Leigh syndrome or Subacute Necrotizing Encephalomyelopathy 
(SNEM), a neurodegenerative disease that influences the central nervous system and is 
associated with neuronal cell death, eventually resulting in impaired motor functions 
(Finsterer, 2008). This link was established via investigations on mutations in SDHA, 
which were connected to the disease (Bourgeron et al., 1995). Many studies involving 
neuronal cells have displayed pro-apoptotic effects upon specific complex II inhibition 
(McLaughlin, Nelson, Silver, Erecinska, & Chesselet, 1998; Pang & Geddes, 1997). This 
has been observed when using the irreversible complex II inhibitor 
thenoyltrifluoroacetone (TTFA), which binds at the quinone reduction site in Complex 
II, preventing ubiquinone from binding and ultimately inhibiting the SQR activity. 3-
nitropropionic acid (3-NP) and the competitive inhibitor methylmalonate are both 
reagents that target the succinate-binding site in SDHA, specifically inhibiting the SDH 
Figure 12. Complex II succinate dehydrogenase (SDH) and succinate CoQ oxidoreductase (SQR) 
activity. SDH activity is defined as the flow of electrons from the FAD cofactor in SDHA to the three [Fe-S] 
clusters located in SDHB. SQR activity is defined as the flow of electrons from succinate and ending at the QP 
site.  Adapted from (Lemarie & Grimm, 2011). 
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activity, but achieving an anti-apoptotic effect by inhibiting TTFA-induced cell death 
(Brusque et al., 2002; Lemarie et al., 2011). The tumor-suppressor gene function of 
SDHB, SDHC and SDHD subunits were discovered as most prominent indications that 
complex II is involved in apoptosis regulation (Astuti et al., 2001; Baysal et al., 2000; 
Niemann & Muller, 2000). The following has been proposed to explain its involvement 
in tumourigenesis: the accumulation of succinate in mitochondria as a result of complex 
II inhibition and its successive transport to the cytosol inhibits HIF1α prolylhydroxylase 
(PHD), leading to HIF1 stability and a pseudo-hypoxic state for the cell. Glycolysis is 
then favoured and this promotes tumor formation via the Warburg effect, resulting 
potentially also in the inhibition of apoptosis (Gogvadze, Zhivotovsky, & Orrenius, 
2010). 
Complex II inhibition can also lead to the formation of sub-lethal levels of 
superoxides, resulting in genomic instability or tumorigenesis. Past studies have revealed 
that such moderate oxidative stress results in cell proliferation (Fruehauf & Meyskens, 
2007; Guzy, Sharma, Bell, Chandel, & Schumacker, 2008; T. Ishii et al., 2005; Senoo-
Matsuda et al., 2001; Slane et al., 2006). On the other hand, complex II has been 
proposed to act as a sensor for cell death in that it assumes a direct role in apoptosis. The 
first study showing complex II as a transmitter of apoptosis signals observed that 
following mitochondrial outer membrane permeabilization, complex II, along with 
complex I, are inhibited in a caspase-dependent manner, contributing to apoptotic cell 
death via the generation of reactive oxygen species (ROS) and collapse of the 
mitochondrial potential (Ricci, Gottlieb, & Green, 2003). ROS generation is a common 
occurrence when respiratory chain complexes are integrated into the apoptosis signalling 
process. This is accomplished via the production of ROS in lethal doses, in contrast to 
the reduced levels, which contribute to tumor formation. This occurs when the electron 
flow of the respiratory chain is suddenly blocked. The exact mechanism by which ROS is 
generated at complex II has not been fully resolved. In the few studies that have been 
done however, various sites for superoxide production were identified, based on the 
respective chemical inhibitors used or the specific sequence of the subunit mutations 
investigated. The CoQ -binding site formed via SDHB, SDHC, and SDHD was 
proposed, possibly through the stabilization of the semiquinone radical (Szeto, Reinke, 
Sykes, & Lemire, 2007; Tran, Rothery, Maklashina, Cecchini, & Weiner, 2006). The FAD 
in SDHA was also identified as a potential site along with an undefined locale between 
the SDHA-embedded FAD and a downstream blockade (Guzy et al., 2008; Lemarie et 
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al., 2011; Yankovskaya et al., 2003). Following the initial implication of the involvement 
of complex II in apoptosis signalling, a later study revealed that apoptosis induced via the 
nerve growth factor (NGF) withdrawal depends on a functional complex II in neurons 
(S. Lee et al., 2005). This observation was further supported through the demonstration 
that NGF deprivation activates the transcription factor c-Jun, and ultimately apoptosis 
via PHD3, a prolyl-hydroxylase involved in HIF1α degradation. In this particular case, 
the apoptosis induction is independent of HIF1α, but instead occurs via KIF1Bβ, a 
motor protein involved in anterograde transport of synaptic vesicles. Its connection to 
apoptosis induction is still unknown (Schlisio et al., 2008). Ultimately, data from these 
studies indicate that complex II of the mitochondrial respiratory chain can be seen as a 
sensor for apoptosis induction. 
 
6.   Complex II in apoptosis is dependent on pH 
Recent studies have been able to expand on the scope of the involvement of complex 
II in apoptosis, particularly a mechanistic outline of how it is activated for induction of 
cell death was gained. A genetic high-throughput screen led to the isolation of many 
different apoptosis genes, which have included SDHC and SDHD (Albayrak & Grimm, 
2003; Albayrak et al., 2003; Grimm & Kachel, 2002; Grimm & Leder, 1997). 
Overexpression of SDHC has been shown to cause robust apoptosis. Cells deficient of 
SDHC and ultimately lacking an intact complex II were significantly more resistant to 
anticancer drugs such as etoposide, cisplatin, doxorubicin, and paditaxel, along with 
proapoptotic cytokines (Albayrak et al., 2003; Lemarie & Grimm, 2009; Oostveen, Au, 
Meijer, & Scheffler, 1995). This has been observed with very many diverse signals for 
apoptosis. Based on the efficiency and kinetics of SDHC’s pro-apoptotic effects upon its 
overexpression, it is likely that this subunit has a direct effect on the assembly of the 
complex (Gebert et al., 2011). All inhibition of complex II activity occurred before any 
signs of cell death were observable, which suggests that this inhibition is an early cellular 
response (Albayrak et al., 2003). The proapoptotic agents used, along with mutations in 
SDHB, SDHC, and SDHD, have been shown to reduce the SQR activity of complex II 
without impairing the SDH activity (J. Huang & Lemire, 2009; Lemarie et al., 2011; 
Senoo-Matsuda et al., 2001; Szeto et al., 2007; Zhao, Rothery, & Weiner, 2006). This 
suggests that how complex II is inhibited for apoptosis induction is crucial when SQR 
activity is blocked while the enzymatic SDH activity is still intact. The resulting massive 
leakage of electrons from complex II to molecular oxygen can lead to enough superoxide 
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generation to induce apoptosis (Lemarie et al., 2011). When the integrity of complex II 
was investigated via blue native gel assays, it was discovered that apoptosis induction is 
linked to the specific disintegration of the complex via the release of SDHA and SDHB 
from the membrane-anchoring subunits (SDHC and SDHD) into the mitochondrial 
matrix. Because these subunits are still enzymatically active, they can efficiently remove 
electrons from the substrate succinate, but due to the separation from downstream the 
acceptors (SDHC and SDHD), the electron flow is blocked. The electrons are then 
transferred to molecular oxygen instead, forming excessive ROS and inducing apoptosis 
(Albayrak et al., 2003; Cecchini, 2003; Lemarie et al., 2011; Nakamura et al., 1996). 
Additionally, it was observed that over a long incubation period with 3-NP, oxidative 
stress results and leads to cell death, although much less efficiently. This is the most likely 
scenario occurring in patients with Leigh syndrome, with mutations in SDHA, as 
mentioned previously. The studies on complex II disintegration explained the data on the 
differential inhibition of two enzymatic activities of the complex, the SDH and SQR 
activities. This contributes to the understanding of the activation of complex II for 
apoptosis induction. 
In addition, evidence has been found that the specific disintegration of the complex 
can be accomplished through intracellular acidification, or lowering of the pH, both in 
the mitochondria as well as the cytosol. This is a universal and early change during the 
apoptotic process (Lagadic-Gossmann, Huc, & Lecureur, 2004). This change in pH, 
probably via the protonation of amino acid side chains in complex II subunits, appears to 
impact on interactions within complex II and drive the release of SDHA and SDHB 
from the membrane-bound subunits (Lemarie et al., 2011). The experimental evidence 
was gathered by incubating isolated mitochondria in pH 7.3 as well as pH 6.7 buffers. 
The lower pH buffer showed a release of SDHA and SDHB, also observed in 
mitochondria from cells undergoing apoptosis. Furthermore, transfection of NHE1, a 
sodium/hydrogen exchanger, maintained the physiological pH, and inhibited the 
dissociation of the complex. How direct this effect is remains unknown and the pH 
sensor function is certainly not the only mediator of apoptosis via acidification. 
Endonucleases, caspases, along with proapoptotic Bcl2 family members have all been 
shown to be activated via the apoptotic pH drop (Lagadic-Gossmann et al., 2004). 
The generation of ROS occurs as a result of complex II dissociation. These 
superoxides act in a pleiotropic way within the cell for the induction of apoptosis. They 
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crosslink proteins, produce ceramide, oxidize proteins within the mitochondrial 
permeability transition (PT) pore, and damage DNA (Circu & Aw, 2010). Because 
various complexes within the respiratory chain are directly impacted by ROS, as is the 
case in isolated mitochondria as well as in intact cells, ROS can also establish a feed-
forward loop of respiratory chain inhibition, ROS formation, and further inhibition of 
the entire chain (Hervouet et al., 2008; Murphy, 2009; Y. Zhang, Marcillat, Giulivi, 
Ernster, & Davies, 1990). This is achieved via posttranslational modifications of the 
subunits by lipid peroxidation adducts, carbonylation or nitration of residues, resulting in 
a block of their activities (Choksi, Nuss, Boylston, Rabek, & Papaconstantinou, 2007; 
Requejo, Hurd, Costa, & Murphy, 2010; Trnka, Blaikie, Smith, & Murphy, 2008). 
Superoxides that are generated via ischemia or reperfusion prevent the correct 
glutathionylation of SDHA in complex II, facilitating its nitration by peroxynitrite on 
tyrosine residues and diminishing its activity (C. L. Chen et al., 2008; Y. R. Chen, Chen, 
Pfeiffer, & Zweier, 2007). The results from molecular studies have indicated a model in 
which apoptosis leads to an early cellular pH drop resulting in the dissociation of 
complex II subunits SDHA and SDHB from SDHC and SDHD in a way that its SDH 
activity is maintained, while the SQR activity is abolished (Fig. 4). This results in the 
catalytic formation of ROS and cell death induction via oxidative stress. As shown, 
complex II is a mitochondrial sensor for pH change as an early response mechanism in 
apoptotic cells (Lagadic-Gossmann et al., 2004). Although the connection between the 
dissociation of complex II subunits and oxidative stress gives some answers, it also raises 
questions. The exact process, for example, that activates downstream apoptosis signals 
via complex II disintegration remains to be found.  
Figure 13. Complex II dissociation for 
apoptosis induction. The specific 
disintegration of the complex is indicated by 
the schematic representation of the specific 
release of the SDHA and SDHB subcomplex 
into the matrix in response to pH drop and 
acidification. This dissociation uncouples the 
two enzymatic activities succinate 
dehydrogenase (SDH) and succinate 
coenzyme Q oxidoreductase (SQR) for 
superoxide production, ROS generation, and 
apoptosis induction.  
 7.   Complex II, the influence of tumorigenic mutations on apoptosis 
One of the key characteristics of cancer cells is their ability to continuously inhibit 
apoptosis. This allows them to constantly grow under several adverse conditions. On the 
other hand, the induction of apoptosis can also be seen as the basis for the therapeutic 
effects achieved by chemotherapeutic drugs (Wallace & Starkov, 2000). Therefore, the 
sensitivity of cancer cells to apoptotic signals determines both tumorigenesis as well as 
the clinical outcome of treatment. Due to the wide range of cell death signals acting on 
malignant cells, many cellular mediators of apoptosis are impaired in cancers. 
Cancer cells remodel their metabolism. Consequently, the respiratory chain activity is 
reduced while glycolysis is increased, also known as the Warburg effect (P. P. Hsu & 
Sabatini, 2008; Vander Heiden, Cantley, & Thompson, 2009). This effect is achieved via 
a series of biochemical alterations that give malignant cells a growth advantage. Lactate, 
which is the end product of glycolysis, sustains tumor growth by changing the 
microenvironment of tumor cells, diminishing oxidative phosphorylation. This affects 
complex II as a general mediator of apoptosis signals. The electron flow of the 
respiratory chain is disrupted during its activation for apoptosis, so a reduced flow should 
theoretically reduce its apoptotic effect, although this has not been clearly shown. Still, 
when the activity of the respiratory chain is reduced, the cells’ ability to generate ROS is 
equally decreased (Anastasiou et al., 2011). Further investigations have shown that the 
HIF1α transcription factor is activated during hypoxia and enhances glycolysis by tilting 
the balance between pyruvate dehydrogenase (PDH) and lactate dehydrogenase (LDH) 
in favor of the latter (J. W. Kim, Tchernyshyov, Semenza, & Dang, 2006; Papandreou, 
Cairns, Fontana, Lim, & Denko, 2006; Semenza et al., 1996). HIF1α establishes an 
efficient respiratory chain inhibition via the Bcl-2 family member BNIP3 (K. Guo et al., 
2001; Rikka et al., 2011). Its microRNA-210 target reduces respiratory chain complex IV 
activity and it even initiates the direct downregulation of SDHB expression (Cervera, 
Apostolova, Crespo, Mata, & McCreath, 2008; Z. Chen, Li, Zhang, Huang, & Luthra, 
2010; Dahia et al., 2005). 
Specific tumor mutations, in addition to inhibition of the respiratory chain, also 
influence complex II function as it consists of tumor suppressor proteins (Astuti et al., 
2001; Baysal et al., 2000; Niemann & Muller, 2000). Mutations leading to loss of function 
in SDHB, SDHD, and more rarely in SDHC, may prompt carriers to develop 
paragangliomas. These tumors originate from neuronal cells in paraganglia from the skull 
base to the pelvic floor of chromaffin-negative glomus cells derived from the embryonic 
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neural crest. These cells are part of the sympathetic nervous system and function 
normally as distinct chemoreceptors located along blood vessels, particularly in the aortic 
and carotid bodies. Mutations in complex II can lead to head and neck paragangliomas 
(PGL), extra-adrenal PGL, as well as paragangliomas of the medulla of the adrenal gland 
known as pheochromocytomas (PH). These SDHB, SDHC, and SDHD mutations 
account for approximately 15% of all hereditary cases of paragangliomas (Rutter et al., 
2010). Because they show loss of heterozygosity via somatic mutation of the normal 
allele, genes encoding for SDHB/C/D are considered classical tumor suppressor genes 
(Baysal, 2008). Mutations of the same subunits have also been discovered in 11 to 16 
percent of all patients with sporadic PGL, but are absent in sporadic PH (Amar et al., 
2005; Burnichon et al., 2009; Feichtinger et al., 2011; Waldmann et al., 2009). Mutated 
SDHB in tumors is considered a high-risk factor for the development of malignant 
tumors, poor prognosis and metastasis (Amar et al., 2007; Boedeker et al., 2007). 
Mutations in complex II have also been found in other types of cancers; for example 
mutations in SDHB are linked to renal cell carcinomas and neuroblastomas, and SDHB 
or SDHD mutations were found in papillary thyroid cancer (Neumann et al., 2004; 
Ricketts et al., 2008; Schimke, Collins, & Stolle, 2010). Mutations in these subunits have 
also been detected in hereditary PGL-associated gastrointestinal stromal tumors (GIST) 
as well as sporadic GIST (Janeway et al., 2011; McWhinney, Pasini, & Stratakis, 2007). 
Although many germ-line mutations were found in the iron-sulfur subunit (SDHB) and 
in the two small membrane-anchoring subunits SDHC and SDHD of complex II, only 
one mutation in SDHA was detected so far that leads to PGL (Bayley, Devilee, & 
Taschner, 2005; Burnichon et al., 2010). The abundance of complex II within the IMM 
of carrier patients is reduced in all these mutations. Specifically, mutations in SDHA, 
SDHB, SDHC, SDHD, and SDHAF2, a complex II assembly factor, all result in the 
complete absence or sharp decrease in complex II and its corresponding enzymatic 
activity, both in PGL and PH tumors (Douwes Dekker et al., 2003; Gimenez-Roqueplo 
et al., 2001; Gimenez-Roqueplo et al., 2003; Hao et al., 2009; van Nederveen et al., 2009). 
This decrease in enzymatic activity is even found in the absence of mutations in the 
coding sequence of complex II-subunits. In PGL/PH, even individual SDH genes can be 
downregulated, which suggests that the downregulation of tumor proteins involved in 
the respiratory chain can have comparable effects as mutations in the protein sequence 
(Blank et al., 2010; Feichtinger et al., 2011; Habano et al., 2003; Putignani et al., 2008). 
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The inhibition of the mitochondrial respiratory chain is quite prevalent in cancer and 
tightly connected to apoptosis resistance. In both cases, when complex II is 
downregulated as a consequence of the general shift from oxidative phosphorylation to 
glycolysis or through specific complex II subunit mutations, the result is a reduction in its 
activity and ability to contribute to ROS production and apoptosis induction upon 
receiving pro-apoptotic signals leading to the desensitization of tumor cells. The 
proposed mechanism by which complex II triggers apoptosis stresses its specific 
dissociation or disintegration. Recent studies have revealed that the assembly of the 
complex is regulated, suggesting that its disassembly is reversible. Two key assembly 
factors specific for complex II have been discovered, one responsible for the assembly of 
SDHA flavination, known as SDH5 or SDHAF2, and another for SDHB, known as 
SDHAF1 (Ghezzi et al., 2009; Hao et al., 2009). In line with the role in apoptosis, 
Tcm62, discovered in yeast as a complex II assembly factor and also known as prohibitin 
(PHB) in mammalian cells, has been shown to inhibit cell death following growth factor 
withdrawal (Dibrov, Fu, & Lemire, 1998; Vander Heiden et al., 2002). Both function as 
mitochondrial chaperones and have been shown to be required for mitochondrial 
respiratory function (Dibrov et al., 1998; Klanner, Neupert, & Langer, 2000; Nijtmans, 
Artal, Grivell, & Coates, 2002; Nijtmans et al., 2000). This is a possible indication that 
complex II can be re-assembled by members of this chaperone family during apoptosis, 
decreasing ROS formation and cell death. A recent study also hinted at the association of 
cardiolipin, a mitochondrial lipid in the IMM, with complex II assembly (Schwall, 
Greenwood, & Alder, 2012). Since cardiolipin is known as having a role in apoptosis 
regulation (Crimi & Esposti, 2011), this study may help to establish a crucial link to 
diseases of cardiolipin deficiency, particularly the X-linked cardioskeletal myopathy and 
neutropenia known as Barth syndrome, caused by mutations in the tafazzin gene, which 
functions as an acyltransferase in lipid metabolism. Cells taken from Barth syndrome 
patients are characterized by a reduced apoptosis (Gonzalvez et al., 2008). Based on 
reports of these studies, it is clear that efforts to pharmaceutically target complex II for 
apoptosis induction in tumor cells seem promising (Dong et al., 2011; Dong et al., 2008; 
Neuzil et al., 2007). 
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8.   Conclusion of introduction 
Although much progress has been made in the investigation of how complex II 
functions as a general apoptosis sensor, there are still many unanswered questions. One 
of these questions involves whether or not complex II is mediating only accidental cell 
death, in other words, during cell stress, or is there also involvement in developmental or 
programmed cell death. Another issue involves the exact molecular details in which the 
complex senses pH change for disintegration prior to apoptosis. It has been assumed 
that amino acid side chains are protonated, but it could also be achieved by an indirect 
effect. 
Another key issue that requires further investigation is how the complex can be 
reassembled and by which mechanism. The chaperones presented serve as prime 
candidates for the regulation of the integrity of the complex and of apoptosis induction. 
Furthermore, the various mutations observed within complex II, both in 
neurodegenerative diseases as well as tumors, have been described using the context of 
the proposed model for apoptotic activation of complex II. This model still remains to 
be fully tested, particularly the consequences of a reduced electron flow on the 
dissociation of the complex, along with ROS generation. Tissue specificity of complex II 
subunit mutations for certain tumors need to be further studied as well. Overall, further 
investigations on the role of complex II in apoptosis will help to better understand the 
complex’s involvement in both proliferation and degenerative diseases, and help to 
develop therapeutic treatments. 
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Objectives and hypothesis 
 
Made up of only four subunits, complex II is the smallest protein complex of the 
mitochondrial respiratory chain and the only complex to be fully encoded by nuclear 
DNA. Located in the mitochondrial matrix, anchored to the inner membrane, complex 
II is a major site of ROS generation by many structurally diverse toxic reagents that 
specifically inhibit the complex before any other molecular changes connected with cell 
death are detectable.  The results indicate that complex II dissociation is a precursor to 
apoptosis induced by anti-cancer compounds such as arsenic trioxide, shown via 
established novel fractionation and FRET assays. Moreover, this study sheds light on 
how the structure of the complex may be dependent on prohibitin (PHB) and cardiolipin 
(CL) expression as well as mitochondrial calcium levels. 
Anti-cancer drugs and pathological signals such as A elicit toxic effects by generating 
excessive reactive oxygen intermediates (ROIs), followed by cell death and tissue 
destruction. The mitochondrial respiratory chain is the main site for the formation of 
these ROI. This formation is induced mainly by inhibition of the various complexes that 
make up the respiratory chain.  When the flow of electrons is blocked, they are diverted 
to molecular oxygen and form ROIs.  Previous studies in the laboratory have found that 
complex II is a major site of ROI generation by many structurally diverse toxic reagents 
that specifically inhibit the complex before any other molecular changes connected with 
cell death are detectable. Made up of only four subunits, complex II is the smallest 
protein complex of the mitochondrial respiratory chain and the only complex to be fully 
encoded by nuclear DNA.  The SDHC and SDHD proteins form the hydrophobic 
membrane-anchoring components, which are associated with two hydrophilic subunits 
facing the mitochondrial matrix: SDHB, an iron-sulphur protein, and SDHA, a FAD-
containing protein.  The lab has recently shown that ROI formation is caused by a 
specific disintegration of complex II.  The hydrophilic SDHA and SDHB subunits that 
are exposed to the mitochondrial matrix dissociate from the membrane spanning 
components.  These two subunits remain enzymatically active, facilitating the transfer of 
electrons from succinate to molecular oxygen and thereby cause ROI formation.  Given 
that this response can be observed with many structurally diverse compounds that all 
lead to the formation of ROIs and ultimately cell death, it is suitable for an assay to 
inform about apoptosis potential of both pathological signals as well as anti-cancer 
compounds.  Moreover, it has the potential to uncover toxic side effects early in the 
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development of drug compounds.  Sensitive assays were developed for the specific 
detection of the dissociation and consequent inhibition of complex II.  These assays 
consist of a western blot or an ELISA test for the release of the SDHA and SDHB 
subunits when they dissociate from the complex into the matrix of the mitochondria.  
Furthermore, the Förster or fluorescence resonance energy transfer (FRET) of GFP-
variant fusion proteins of complex II subunits was employed.  With the validation of 
these assays, factors responsible for the reassembly of complex II and the inhibition of 
ROS production and apoptosis, for example specific assembly factors, proteins, and 
lipids, went under investigation. 
The specific role of complex II in apoptosis has been shown through the usage of 
various pro-apoptotic compounds. These compounds, including many anticancer drugs, 
led to the dissociation of the SDHA/SDHB subunits from the complex and partial 
inhibition of the succinate CoQ oxidoreductase (SQR) activity without impairment of the 
succinate dehydrogenase activity (SDH), causing uncoupling, production of ROIs, and 
apoptosis (Fig. 1).The basis for our study is to further understand the mechanism behind 
this complex II-mediated cell death pathway and the motivation lies behind the 
hypothesis that it can be explained by the dependence of the complex’s structure on 
prohibitin (PHB), cardiolipin (CL) expression as well as mitochondrial calcium levels. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Schematic representation of specific complex II inhibition, adapted from 
(Lemarie and Grimm, 2011).6 
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 Materials and Methods 
 
1.   Reagents 
The following products were purchased from Sigma-Aldrich: 2-mercaptoethanol 
(M7522), acrylamide (40% solution, A7168), actinomycin D (A1410), agarose (A9539), 
ammonium persulfate (A3678), ampicillin sodium salt (A9518), blotting filter papers (25 
mm thickness, LC2010), bongkrekic acid (BA, B6179), bovine serum albumin (BSA, 
A7906), calcium chloride (C7902), cycloheximide (C7698), dimethyl sulfoxide (D2650), 
DMEM AQmediaTM (D0819), doxorubicin (D1515), EGTA (E4378), etoposide 
(E1383), faecal calf serum (F7524), glucose (G7021), HEPES (H3375), ionomycin 
(I3909), kanamycin (K1876), LB-broth (L3022), L-glutamine (G7513), magnesium 
sulphate heptahydrate (63138), menadione (M5625), NP-40 (I3021), Polybrene® 
(H9268), propidium iodide solution (1mg/ml, P4864), puromycin dihydrochloride 
(P8833), sodium azide (S8032), sodium butyrate (30,341-0), sodium citrate (S1804), 
sodium deoxycholate (30970), sodium pyruvate (S8636), staurosporine (S4400), TEMED 
(T9281), Triton X-100 (T8532), Trypsin-EDTA (T4174), TWEEN® (P5927) and yeast 
extract (Y1625).  
10x PBS (14200-067), DAPI (D3571), DiOC6 (D273), DMEM (21969-035), library 
efficiency® DH5α TM chemocompetent bacteria (18263-012), MAX efficiency DH5α 
(18258-012), oligofectamine (12252-011), OPTI-MEM (22600134), 
penicillin/streptomycin (100U/ml and 100 μg/ml, respectively, 15070-063), PicoGreen 
(P7589), pLenti7.3/V5-TOPO® TA cloning kit (K5310-00), PureLinkTM HiPure plasmid 
filter purification kit (K2100-07), Rhod-2/AM (R1245MP), TMRE (T669) and Trypsin-
EDTA solution (0.5%, 15400-54), were from Invitrogen or Molecular Probes. Note that 
all the oligos (both primers and siRNAs) were also purchased from Invitrogen.  
The following reagents were purchased from Fermentas (part of Thermofisher): 5x 
protein loading buffer (R0891), 6x DNA loading dye (R0611), 50x TAE buffer (#B49), 
Bradford (500-0006), GeneRulerTM 1kb DNA ladder (SM0314), GeneRulerTM 1kb plus 
DNA ladder (SM1334), PageRulerTM prestained protein ladder (SM1811 or SM0671), 
ProteoBlockTM protease inhibitor cocktail (R1321) and Phusion® polymerase (F530-L). 
All the restriction endonucleases from FastDigestTM series as well as T4 DNA ligase were 
also purchased from Fermentas.  
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0.5M Tris-HCl pH 6.8 solution (161-0799), 1.5M Tris-HCl pH 8.8 solution (161-
0798), 10x TGS buffer (161-0772) and SDS solution (10% w/v, 161-0416) were from 
Bio-Rad Laboratories; HyperfilmTM high performance chemoluminescent film 
(28906837), protein G sepharoseTM 4 fast flow (17-0618-01), superpose-12 10/300 GL 
gel filtration/size-exclusion chromatography column (17-5173-01) from GE Healthcare; 
and CaspaTagTM caspase-8 in situ assay kit Sulforhodamine (APT503), CaspaTagTM 
caspase-8 in situ assay kit fluorescein (APT408), PureProteome magnetic protein G beads 
(LSKMAGG10) and PVDF membrane (IPVH00010) were from Millipore.  
QuickChange II site-directed mutagenesis kit (#200523) and StrataClone mammalian 
expression vector systems (#240230) were from Agilent Technologies; potassium 
chloride (101984) and sodium chloride (10241) from BDH Laboratory Supplies; 
polyvinyl alcohol mounting medium with DABCO (10981) and saponine (47036) from 
Fluka; and pAdVantageTM vector (E1711) and Wizard SV gel PCR clean-up system 
(A9282) from Promega; jetPEITM (101-10) from Polyplus-transfection, BIOMOL 
GmbH; Effectene (301427) and SuperFect (301307) from QIAGEN; XfectTM (631317) 
from Clontech.  
GelRedTM nucleic acid gel stain (41002) from Biotium; trypton (0123-17-3) was from 
DIFCO laboratories; TNF-α (522-008-C050) from Enzo Lifesciences; PhusionTM DNA 
polymerase (F-553) from Finnzymes;; zVAD-fmk (O103) from MP Biomedicals; LB-agar 
(852323) from OXOID Ltd.; enhanced chemoluminescent reagent (#32106) from 
PIERCE; mitochondria isolation kit for cultured cells (89874) and paraformaldehyde 
(28908) from PIERCE Thermo Scientific. Calcium free DMEM (E15-078) was 
purchased from PAA Laboratories GmbH. Please refer to the appropriate sections for 
the details of antibodies used. 
 
2.   Cell Culture 
HeLa (human cervical carcinoma), HEK293T (human embryonic kidney), MEF WT 
(mouse embryonic fibroblasts), and MEF PPIF-/- (mouse embryonic fibroblasts) were 
cultivated in high glucose (4.5 g/L) Dulbecco’s modified eagle medium (DMEM, Sigma-
Aldrich). The culture media was supplemented with 10% heat inactivated foetal calf 
serum (FCS, Sigma-Aldrich), 2 mM L-glutamine (Sigma-Aldrich), 2 mM sodium pyruvate 
(Sigma-Aldrich), penicillin (100 U/mL, Invitrogen), and streptomycin (100 μg/mL, 
Invitrogen). Cells were cultured in tissue culture flasks or dishes and maintained in 5% 
atmospheric CO2 at 37
 oC in a humidified incubator. Cells were routinely passaged to a 
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new tissue culture dish or flask by detaching them with trypsin-EDTA solution (final 
concentration of 0.05% diluted in phosphate buffered saline, Sigma-Aldrich). 
 
3.   Plasmid Vectors 
All genes were cloned into mammalian expression vectors with Cytomegalovirus 
(CMV) promoters and U6 promoter for the expression of shRNA. The pcDNA3.1 
(Invitrogen) vector was used for the expression of genes in cells. pLenti7.3 (Invitrogen) 
was used for the production of lentiviruses. pLKO.1 (Sigma-Aldrich) was used for the 
production of lentiviruses for the expression of shRNA. pCMV-SC-CF (Agilent 
technologies) was used to tag a gene with a FLAG®. Apoptosis inducing genes were 
isolated from a genetic screen for apoptosis inducers (Albayrak et al) and subsequently 
tagged C-terminally with hemaglutinin (HA-tag). ShRNA for cardiolipin synthase (CLS1) 
was purchased as a MISSION shRNA bacterial glycerol stock (NM-019095) from Sigma. 
 
4.   Cloning 
Standard molecular biology techniques were used for cloning. Genes of interest were 
cloned either by recombinant PCR, restriction digest cloning, INFUSION cloning or 
TOPO cloning. It should be made clear that wherever SDHB and SDHD genes are 
fused for targeting to the mitochondria in FRET, only the localization sequence 
(targeting) was used for fusion and not the entire gene that contains the respective 
targeting sequence. 
 
4.1   Cloning of FRET acceptor YFP-SDHB 
The FRET acceptor (YFP-SDHB fusion protein) was constructed using PCR 
amplification and subcloning techniques involving PhusionTM DNA polymerase 
(Thermo Fisher Scientific) with the following sets of primers: 5’-
ACTCTCGAATTCGCCGCCACC ATGGCGGCG-3’ (SDHB, forward) and 5’-
CTCGCCCTTGCTCACCATACCACCAGAACCACCAACTGAAGCTTTCTTCTCCT
T-3’ (SDHB, reverse), 5’-
GAGAAGAAAGCTTCAGTTGGTGGTTCTGGTGGTATGGTGAGCAAGGGC-3’ 
(YFP, forward) and 5’-GAAGATGCGGCCGCCTAGCCGAGAGTGATCCC-3’ (YFP, 
reverse). 
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4.2   Cloning of FRET donor CFP-SDHD 
The FRET donor (CFP-SDHD fusion protein) was constructed using PCR 
amplification and subcloning techniques involving PhusionTM DNA polymerase (Thermo 
Fisher Scientific) with the following sets of primers: 5’-
ACTCTCGAATTCGCCGCCACCATGGCGGTTCT-3’ (upper SDHD, forward) and 
5’-CTCCTCGCCCTTGCTCAACAT   TGCAGCCTTGGAGC-3’ (upper SDHD, 
reverse), 5’-CACCATTCTGGCTCCAAGGCTGCAATGTTGAGCAAGGGCG-3’ 
(CFP, forward) and 5’-
CTTGGAGCCAGAACCACCAGAACCACCGGCGGCGGTCAC-3’ (CFP, reverse), 
5’-ACCGCCGCCGGTGGTTCTGGTGGTTCTGGCTCCAAGGCT-3’ (SDHD, 
forward) and 5’-GAAGATGCGGCCGCCTAGAGCTTCCACAGCATG-3’ (SDHD, 
reverse). 
 
5.   DNA electrophoresis and DNA Recovery 
The DNA electrophoresis was performed using agarose (Sigma-Aldrich) gels. Briefly, 
agarose (usually 1% w/v) was dissolved in TAE buffer (Fermentas). The Gel Red™ 
nucleic acid stain (Biotium) was then added (1/20000 dilution), cooled and poured into 
custom-made DNA gel electrophoresis cassettes to solidify. The DNA was mixed with 
6x DNA loading dye (Fermentas) and separated by gel electrophoresis in TAE buffer 
(Fermentas). The GeneRuler™ 1kb plus DNA ladder or GeneRuler™ 1kb DNA ladder 
(Fermentas) was used for size estimation.  
Upon completion of DNA electrophoresis, the piece of agarose containing the DNA 
of interest was excised under the UV lamp and subsequently DNA was recovered using 
Wizard SV gel and PCR clean-up system (Promega). Briefly, a gel piece was mixed with 
binding buffer to dissolve agarose. The dissolved gel and the buffer were transferred to a 
spinning column, centrifuged, washed twice, and eluted with DNAase / RNAase-free 
H2O or TE buffer. 
 
6.   Transformation of E. coli 
Plasmid DNA was transformed into chemo-competent, library efficient DH5α E. coli 
bacteria or MAX efficient DH5α E. coli bacteria (Invitrogen). Aliquots stored in -80°C 
were thawed on ice, the corresponding plasmid DNA was added to the cells. After 30 
minutes of incubation on ice, the cells were treated by heat shock (45 seconds at 42°C) 
with a subsequent quick chill on ice (2 minutes). Then 1ml of SOC medium (2% 
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tryptone, 0.5% yeast extract, 10mM NaCl, 10mM MgSO4, 2.5mM KCl, 20mM glucose) 
was added to the transformed cells, which were incubated for 1 hour at 37 °C in a shaker 
to allow bacteria to express the resistance gene. Afterwards, bacteria were given either LB 
medium containing appropriate antibiotics (usually 100μg/ml of Ampicillin or 50μg/ml 
Kanamycin) or were plated onto LB agar containing the appropriate antibiotics (usually 
100μg/ml of Ampicillin) and cultured over night in a 37°C incubator. 
 
7.   Extraction of DNA from bacteria 
For the extraction of plasmid DNA from transformed bacteria, the bacteria were 
grown (3ml for miniprep and 250ml for maxiprep) in Lauria-Bertani broth supplemented 
with yeast extract (10g/L, Sigma-Aldrich) in a presence of appropriate antibiotics 
overnight in a shaking incubator at 37°C. The plasmid DNA was extracted from the 
bacteria using the Plasmid Maxi Prep kit (QIAGEN) or the PureLinkTM HiPure plasmid 
filter purification kit (Invitrogen). The resulting DNA pellet was resuspended in 500-
1000μl of DNase, RNase free water or TE buffer and the concentration measured using 
NanoDrop (ThermoScientific) or with PicoGreen (Molecular Probes). Briefly, DNA was 
sequentially diluted to make a concentration of approximately 0.1μg/μl. 1μl of diluted 
DNA was added to a well of 96-well plate. 1μl of standard DNA (0.1μg/μl) was also 
included as a reference. Then 50μl of TE buffer was added to each well followed by 50μl 
of diluted PicoGreen (1:200 in TE buffer). The plate was incubated 5 minutes. The 
fluorescence was measured with FLUOstar OPTIMA (BMG Labtech) with excitation at 
480nm and emission at 520nm. 
 
8.   Plasmid Vector Transfections 
HeLa cells were plated onto either a 24-well (2-2.4*104 cells/well) or 6-well (1-1.2*105 
cells/well) plate approximately 15 hours prior to the transfections. HEK293T cells were 
plated onto either a 24-well (10-12*104 cells/well) or 6-well (5-6*105 cells/well) 
approximately 15 hours prior to the transfections. Effectene (QIAGEN) was used for 
HeLa cells and either jetPEITM (Polyplus-transfection, BIOMOL GmbH), SuperFect 
(QIAGEN), or Xfect (Clontech) for HEK293T cells for DNA transfections. Briefly, 
plasmid DNA (0.2μg per 24-well plate or 0.8μg per 6-well plate) was mixed in EC buffer 
with Enhancer, incubated for 5 minutes, Effectene reagent was added (2.5 μl or 5 μl for 
24- or 6-well plate, respectively), incubated for 10 minutes, and the DNA-lipid mix was 
added to the cells for Effectene transfection. For jetPEITM transfections, DNA was 
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diluted in 150 mM sodium chloride (1 μg or 2 μg for 24- or 6-well plate, respectively), 
jetPEITM was added (2 μl or 4 μl for 24- or 6-well plate, respectively), incubated for 25 
minutes and the DNA-lipid mix was added to the cells. For SuperFect transfections, 
DNA was diluted in DMEM (1 μg or 2 μg for 24- or 6-well plate, respectively), 
SuperFect was added (5 μl or 10 μl for 24- or 6-well plate, respectively), incubated for 10 
minutes and the DNA-lipid mix was added to the cells. For Xfect transfections, DNA 
was diluted in Xfect Reaction buffer (1μg or 7,5μg for 24- or 6-well plate, respectively) 
and was mixed with the same volume of reaction buffer with the Xfect polymer. After 
vortexing and incubating for 10 minutes, complexes were transferred drop wise onto the 
HEK293 cells. Transfection mixes were removed from the plate after 5-6 hours, fresh 
medium added and incubated. 
 
9.   Mitochondria Isolation and Fractionation 
Mitochondria were isolated with an established protocol (Gogvadze, Orrenius, & 
Zhivotovsky, 2003), re-suspended in the protocol’s mitochondria buffer and kept at -
80°C. Briefly, after trypsinisation, cell were harvested, washed with PBS and centrifuged 
for 5 minutes at 2100 rpm. 400μl to 600μl of mitochondria lysis buffer [Buffer A: (20mM 
HEPES pH 7.5, 1.5mM MgCl2 (6H2O), 10mM KCl, 1mM EDTA, pH 7.4), Lysis Buffer: 
12ml Buffer A with 3ml sucrose 1.25M)] was added to the pellet and left for 2 minutes 
on ice. Meanwhile a dounce homogenizer (Wheaton 357542) was washed with cold lysis 
buffer and homogenized by 60-80 strokes. 200μl of lysis buffer were added and lysed 
cells were left on ice for 20 minutes. A centrifugation step followed (3000rpm) for 10 
minutes in which step the nuclei and debris were pelleted. The supernatant, which 
contained the mitochondria, was re-centrifuged at 13000rpm for 20 minutes. The pellet 
contained the isolated mitochondria and the supernatant constituted the cytosolic 
fraction. For greater mitochondria purity but smaller yield a commercial kit from 
PIERCE (Thermofisher, UK) was also used. 25ng/ml of Proteinase K (Sigma, UK) was 
applied to isolated mitochondria for 30 min at 4oC and PMSF was used to stop the 
reaction. 
Six different mitochondrial fractionation techniques were investigated for the 
separation of the matrix from the inner membrane. The first one consists of HDP buffer 
incubation. HDP hypotonic lysis buffer was used for the extraction of soluble 
mitochondrial proteins. Samples were filter-sterilized and stored at 4 degrees Celsius.  
The buffer is made up of 10 mM HEPES (pH 7.9) and the technique consists of 
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exposure to ice for 30 minutes plus sonication (4x 10 second blasts) and centrifugation at 
20,000 RPM for 30 minutes to pellet non-Matrix membrane components. The second 
one consists of mitochondria lysis buffer incubation. The mitochondrial pellet is left in 
the isolation buffer and put on ice for 30 minutes plus sonication (4x 10 second blasts) 
and centrifugation at 20,000 RMP for 30 minutes to pellet non-Matrix membrane 
components. The third one is an osmosis technique where the mitochondrial pellet is 
incubated in ddH2O for 30 minutes and then centrifuged at 20,000 RPM for 30 minutes 
to pellet non-Matrix membrane components. The fourth technique, which was ultimately 
selected as the most successful to use, involves freeze thaw using liquid nitrogen with the 
mitochondrial pellet suspended in mitochondrial lysis buffer. The samples are frozen 
using 15-second submersions in liquid nitrogen and left to thaw at room temperature. 
This is repeated 4 more times before centrifugation at 20,000 RPM for 30 minutes to 
pellet non-Matrix membrane components. The fifth technique involves a combination of 
osmosis and freeze thaw using liquid nitrogen. The mitochondrial pellet is incubated in 
ddH2O for 15 minutes and then put through 5 cycles of freeze thaw as described 
previously.  The pellet is then centrifuged at 20,000 RPM for 30 minutes to pellet non-
Matrix membrane components.  The sixth technique consists of incubation of the 
mitochondrial pellet in sodium carbonate, as an osmosis effect, for 30 minutes prior to 
centrifugation. 
 
10.   Quantification of Cell Death 
Mitochondria dyes TMRE (tetramethylrhodamine, ethyl ester) and DiOC6 (3,3′-
dihexyloxacarbocyanine iodide) were used in conjunction with propidium iodide to 
quantify apoptosis (Chiara et al., 2008; Majewski et al., 2004). In short, floating and 
adherent cells were harvested and centrifuged at 2100 RPM. Supernatant was discarded, 
cells were re-suspended in 150μl of PBS and DioC6/PI mix was added. Cells were 
incubated in total for 90 minutes and were then analysed using FACS (BD Biosciences) 
with the CellQuest programme (BD Biosciences, UK). FlowJo (TreeStar Inc.) was used 
for data analysis. 
 
10.1   Propidium Iodide Staining 
The supernatant and the adherent cells were harvested, centrifuged (1500rpm, 5 
minutes) and re-suspended in lysis buffer (0.1% sodium citrate and 0.1% Triton X-100 in 
PBS) containing propidium iodide (PI, 20μg/ml). Upon lysis of cells, the resulting nuclei 
81 
 
were acquired with flow cytometer (FACSCaliburTM, BD Biosciences) using the FL-2 
channel to quantify the percentage of cell population with subG1/G0 DNA content. The 
pan-caspase inhibitor, zVAD-fmk (MP Biomedicals), was used at a concentration of 
20μM. 
 
10.2   DiOC6 / TMRE Staining 
To quantify the percentage of cells undergoing mitochondrial inner membrane 
depolarization, supernatant and the adherent cells were harvested, centrifuged (1500rpm, 
5 minutes) and resuspended in 100-200μl of PBS containing 40nM DiOC6 or 40nM 
TMRE for 40 minutes in the incubator and further incubated for 40 minutes at room 
temperature in the dark. Cells were then analyzed using a flow cytometer (BD 
Biosciences) with the FL-1 (for DiOC6 staining) or FL-3 (for TMRE staining) channel. 
Bongkrekic acid (Sigma-Aldrich), a blocker of the permeability transition pore, was used 
at a concentration of 75μM. 
 
11.   Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis 
(SDS-PAGE) and Immunoblotting 
Cells were trypsinized, centrifuged (1500rpm, 5 minutes) and lysed or cells were 
directly lysed on the plate by adding RIPA buffer. Total cell lysates were then incubated 
on ice for 30 min and subsequently centrifuged for at least 45 minutes (13x103 rpm) at 
4°C. The resulting supernatant, which contained soluble proteins, was transferred to a 
new tube and used immediately or stored at -20°C until use. 
Protein concentration was determined using the Bradford assay (BioRad). To obtain a 
standard curve, BSA of known concentration was sequentially diluted (from 0-6 μg/μl) 
and placed on a flat-bottom 96-well plate. To each well, 199μl of Bradford (diluted 5 
times in water) was added and the absorbance measured at 595nm using FLUOstar 
OPTIMA (BMG Labtech). The resulting absorbance values were plotted against BSA 
concentration and used as a standard curve to measure the protein concentration. 
Following the protein concentration measurement, 20-100 μg of the total cell lysate 
was separated by SDS-PAGE (stacking gel: 4.8% polyacrylamide, 125mM Tris-HCl pH 
6.8, 0.1% SDS, 0.1% APS, 0.1% TEMED; resolving gel: 10-15% polyacrylamide, 375 
mM Tris-HCl pH 8.8, 0.1% SDS, 0.1% APS, 0.05% TEMED) in TGS-running buffer 
(25 mM Tris-HCl, 192 mM Glycin, 0.1% w/v SDS). PageRulerTM prestained protein 
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ladder (Fermentas) was used for the protein size estimation. Proteins were then 
transferred to a nitrocellulose or PVDF membrane (Millipore) in transfer buffer (20% 
methanol in TGS buffer). Conditions used for the transfer were as follows: limited to 500 
mA and 20 volts. Proteins were transferred for 90 minutes (if two gels were transferred 
together) or 60 minutes (if only one gel was transferred) in a semi-dry transfer system 
from Bio-Rad. 
The membranes were blocked with 5% skim milk powder (Sigma-Aldrich) or 3% BSA 
(Sigma-Aldrich) in PBS containing 0.1% Tween (PBS-T) for minimum of 30 minutes, 
incubated with the primary antibody, washed three times with PBS-T (15 minutes each), 
and incubated with horseradish peroxidise-conjugated isotype-matched secondary 
antibody. The membrane was then washed as before, treated with enhanced 
chemoluminescent reagent (PIERCE) and subjected to autoradiography using high 
performance chemoluminescence film (GE Healthcare). 
Antibodies used for immunoblotting and immunoprecipitation are listed below: 
 SDHA from santa cruz (sc-27992): Dilution of 1:500 
 SDHB from santa cruz (sc-271548): Dilution of 1:200 
 SDHC from Abcam (ab125411): Dilution of 1:800 
 SDHD from Millipore (AB110): Dilution of 1:800  
 GRP75 from santa cruz (sc-13967): Dilution of 1:500 
 COX4 from santa cruz (sc-133478): Dilution of 1:500   
 
12.   Immunofluorescence Assay 
HeLa and HEK293T cells, seeded on coverslips (CS), were transfected with YFP-
SDHB and/or CFP-SDHD with Effectene (Qiagen, UK) and jetPEITM (Polyplus-
transfection, BIOMOL GmbH) respectively, and grown for 24 hours, then fixed in 4% 
paraformaldehyde in PBS for 20 min at 4°C. After a blocking step with 3% BSA in Tris-
HCl 50 mM, NaCl 155 mM, pH 7.6 and 0.02% saponine (TBSS) for 30 min at room 
temperature (RT), cells were incubated with the primary antibody (Table B.3.) for 2 
hours at RT. Cells were rinsed five times in TBSS and then incubated with the secondary 
anti-rabbit Alexa Fluor 594 antibody at a dilution of 1/500 in TBSS. Cells were washed 
five times in TBSS and incubated 30 minutes in DAPI (2 µg/ml, Invitrogen, UK) at RT, 
before being mounted in polyvinyl alcohol mounting medium with DABCO (Sigma). 
Cells were examined with confocal laser-scanning microscope (Leica) with a 63x 
objective and analyzed with LAS AF software. 
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12.1   Mitochondrial Staining 
Mito Tracker® Red CM-H2XRos (MitoTracker) and tetramethylrhodamine ethyl ester 
(TMRE) were used at a concentration of 50 nM (Molecular Probes) for the visualization 
of mitochondria. Both probes were diluted in cell culture medium and added to the cells 
for 15-20 minutes at 37ºC. When specific mitochondrial staining was visible, medium 
with dyes was removed, the cells washed three times with DMEM and fresh medium 
(minimum quantity, ~250 μl per a well of 24-well plate) was added. 
 
13.   Production of Lentiviral Particles 
Virulent media was produced in HEK293FT cells (Invitrogen, UK) using the 
following optimised protocol for lentiviral production: Plasmids encoding Vesicular 
Stomatitis Virus Glycoprotein (pVSV-G), group antigen and reverse transcriptase 
(pGag.Pol) and mRNA export helper protein (pRev) were isolated from ViraPower™ 
lentiviral packaging mix (Invitrogen). Expression vector for the pAdVantage was from 
Promega. The cell line used was 293FT cells from Invitrogen.  
The day before the transfection, 293FT cells were plated onto 10cm2 dishes so that 
the plate would be approximately 50-60% confluent on the day of transfection. Two 
hours prior to transfection, the medium was replaced with fresh DMEM, 5%FCS, 5.4μg 
of the pVSV-G, 3.8 μg of the pRev, 7.8 μg of the pGag.Pol, 9 μg of the pAdVantage and 
20 μg of the lentiviral transgene plasmid were mixed in a 2 ml eppendorf tube and made 
up to 437.5 μl with H2O. Then 62.5 μl of 2 M CaCl2 was added, mixed thoroughly and 
incubated for 5 minutes. Meanwhile, 500μl of 2xHBS (50mM HEPES, 281mM NaCl, 
1.5mM Na2HPO4 pH 7.08-7.1, filter sterilized) was prepared in a 15ml conical tube and 
the DNA/CaCl2 mixture was added drop by drop to the 15ml conical tube while 
vigorously shaking the tube on a vortex machine. The mix was immediately added to the 
dish drop by drop.  
The culture medium was replaced with fresh warm medium containing sodium 
butyrate (1mM, Sigma-Aldrich), dissolved in PBS, on the following morning (16 hours 
post transfection). Note that sodium butyrate was freshly prepared every time. After 2 to 
3 days post transfection what decides about the duration?, the supernatant was harvested 
and centrifuged (500g, 10 minutes, RT) to remove cells and large debris, then passed 
through a 0.45μm sterile filter. Note that 0.2μm filter should not be used as it can 
damage viral outer glycoproteins was the virus never concentrated and if so how?. 3T3-
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IkBα-/- cells were transduced for 6 h in the presence of polybrene (6 μg/ml, Sigma) for 
the reconstitution with IκBα variants (pLenti7.3-G.O.I.). After infection, cells were 
sorted through a BD FACSAriaIIu fluorescent activated cell sorter for eGFP since the 
pLenti7.3 vector allows the expression of a fluorescent marker along with the gene of 
interest through a bi-cistronic vector system. 
 
13.1   Calculation of Viral Titre and Viral Production of FRET 
constructs 
In order to measure the viral titre, the cells of interest (HEK293T or HeLa cells) were 
seeded on the 12-well plate to make a plate ~30% confluent on the day of transduction. 
On the day of the transduction the viral stock was diluted (three different dilution to 
achieve accurate measurements) in 400μl of DMEM containing polybrene® 
(hexadimethrine bromide, 6μg/ml, Sigma-Aldrich). The diluted viruses were added to the 
cells and incubated for 48 hours to allow integration of genome and the expression.  
The FRET constructs were cloned into 3rd generation lentiviral vectors (kind gift 
from Prof Nicholas Mazarakis, Imperial College) containing a cPPT (central polypurine 
tract) and WPRE (Woodchuck hepatitis posttranscriptional regulatory element) 
sequences. Cloning was done using the IN-FUSIOn technology from Clontech and viral 
production was done using standard techniques. Briefly, 293T cells were transfected with 
packaging plasmids and the transfer vector plasmid containing the gene of interest using 
the calcium phosphate transfection protocol. 48 hours post transfection virulent 
supernatants were collected and either frozen or used directly to transduce target cells. 
 
13.2   Production of Stable Cell Lines 
The cell line of interest was seeded on a well of 6-well plate 15 hours prior to the 
transduction. On the following day, cells were transduced with the viral supernatant 
supplemented with 1 μg/ml of Polybrene® (Sigma-Aldrich) for 6 hours or overnight. 
The viral supernatant was then removed, fresh medium added and incubated for a 
further two to three days. The medium was replaced with DMEM containing puromycin 
(varying concentration, 5 μg/ml for HeLa cells) after 72-96 post-infection and further 
cultivated for three days for the selection. Upon completion of the selection, cells were 
maintained in DMEM containing 1 μg/ml of puromycin to retain the resistance. 
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14.   Densitometry Analysis 
A scanned image of a western blot was uploaded onto ImageJ programme and 
converted to 8-bit image (image → type → 8-bit). The image was then inverted (Edit → 
invert) and appropriate fields selected using “rectangular selection” tool. The plot profile 
(analyse → plot profile) was created and the background intensities were removed by 
drawing a straight line using “straight line selection.” Then distinctive peaks were 
separated with “straight line selection” and the intensities of bands were analysed upon 
selection of the appropriate area with “wand tool” followed by the measurement (analyse 
→ measure). Note that pressing the “Shift” key during line drawing allowed me to draw a 
straight line and “Ctrl+D” allowed me to approve my line draw. 
 
15.   Statistical Analysis 
Statistical analysis was performed using the unpaired student’s t-test. In experiments 
involving transient transfections data presenting induction and inhibition effects were 
normalized. For this, GFP transfection was performed and the transfection efficiency 
analyzed in parallel. Three independent experiments (n=3) were used for all FRET, cell 
death, and ROS assays. Error bars are S.D. SDS-PAGE gels are representative of at least 
three independent experiments. All activity assay results are presented as means ± 
standard errors of the means (s.e.m.) of at least four independent experiments.  A two-
tailed student T-test (equal variance) was used to determine statistical significance (p ≤ 
0.05). 
 
16.   Commonly Used Buffers 
2x HBS 
50mM HEPES, 280mM NaCl, 1.5mM Na2HPO4 pH 7.06-7.08 
 
PBS 
137mM NaCl, 2.7mM KCl, 8mM Na2HPO4 and 2mM KH2PO4. Adjust pH to 7.4 
 
RIPA buffer 
150mM NaCl, 1% NP40, 0.5% w/v sodium deoxycholate, 0.1% w/v SDS, 50mM Tris-
HCl pH 8 
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SOC medium 
2% tryptone, 0.5% yeast extract, 10mM NaCl, 10mM MgSO4, 2.5mM KCl and 20mM 
glucose 
 
Sodium-dodecyl sulfate gel 
[Stacking gel] 
4.8% polyacrylamide, 125mM Tris-HCl pH 6.8, 0.1% SDS, 0.1% APS and 0.1%TEMED  
[Resolving gel] 
10-15% polyacrylamide, 375mM Tris-HCl pH 8.8, 0.1% SDS, 0.1% APS and 0.05% 
TEMED 
 
TAE buffer 
40 mM Tris-acetate and 1 mM EDTA at pH 8.3 
 
TBS 
50mM Tris-HCl (pH 7.4), 155mM NaCl 
 
TE buffer 
100 mM Tris-HCl (pH 7.5) and 10 mM EDTA (pH 8.0) 
 
TGS buffer 
25mM Tris, 192mM Glycin and 0.1% w/v SDS 
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 Fig. 1. Western blot for monitoring 
complex II disintegration by As2O3. 293T 
cells were treated with increasing 
concentrations of As2O3 12 hours prior to 
mitochondria isolation and freeze/thaw 
fractionation. The western blot for the 
matrix fraction was probed using antibodies 
against SDHA, GRP75, and COX IV. 
SDHA is the marker for the dissociation of 
complex II, GRP75 is a mitochondrial 
matrix marker, COX IV is a mitochondrial 
inner membrane marker. 
 
Fig. 2. Freeze/Thaw fractionation for detecting complex II disintegration upon As2O3 
treatment. 293T cells were treated with 5 and 10 µM of As2O3 10 hours prior to freeze/thaw 
fractionation. 4 µg of protein was loaded into each lane. The western blot was probed using antibodies 
against SDHA (70 kDa), GRP75 (74 kDa) and COX IV (17 kDa). SDHA is the marker for the 
dissociation of complex II, GRP75 is a mitochondrial matrix protein marker, and COX IV is a 
mitochondrial inner membrane protein marker that is degraded during cell death induction. 
 
Results 
1. As2O3 in complex II disintegration for ROS production & cell death  
For detecting the dissociation of complex II we established a Western blot assay based 
on freeze/thaw and sub-cellular fractionation to monitor the SDHA release into the 
mitochondrial matrix. As stimulus for cell death we chose As2O3, which induces Ca
2+ 
influx into mitochondria (Keinan, Pahima, Ben-Hail, & Shoshan-Barmatz, 2013). The 
SDHA protein accumulated in the mitochondrial matrix fraction after 10 hours of As2O3 
treatment before substantial cell death was observed (figs. 1, 2, 3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SDHA 
GRP75  
COX IV 
5 μM 10 μM 1.25 μM UNT. 2.5 μM 
SDHA 
GRP75  
Matrix Fraction  Membrane Fraction 
COX IV 
UNT. 5 μM 10 μM 
SDHA 
GRP75  
COX IV 
5 μM 10 μM UNT. 
Treated           Treated           
89 
 
Fig. 3. Cell death induction in 293T cells with 
varying incubation times and concentrations 
of As2O3. 293T cells were treated with 
increasing concentrations of As2O3 and then 
harvested for FACS analysis at the indicated time 
points to determine the percent cell death present 
within each sample. 
Fig. 4. Cell death induction in HeLa cells with 
varying incubation times and concentrations of 
As2O3. HeLa cells were treated with increasing 
concentrations of As2O3 and then harvested for FACS 
analysis at the indicated time points to determine the 
percent cell death present within each sample. 
Fig. S5. Cell death induction of HeLa cells with varying concentrations and incubation times of As2O3. HeLa cells 
were treated with increasing concentrations of As2O3 and then harvested for FACS analysis at the indicated time 
points, respectively, to determine the percent cell death present within each sample. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To monitor the disintegration of complex II in intact cells with a non-invasive 
method, we engineered a pair of FRET constructs for SDHB and SDHD fused to EYFP 
and CFP at the C- and the N-terminus, respectively, which are spatially tightly aligned 
(figs. 5, 6). The stable fluorescence signals indicated the productive assembly of the 
complex as complex II components are otherwise degraded (Lemarie et al., 2011). Upon 
treatment of the cells with 10 M As2O3 we observed after an initial drop and recovery a 
strong reduction of the FRET efficiency (fig. 7). After 10 and 15 hours, respectively, 
HEK and HeLa displayed a reduction of the FRET ratios (fig. 8). This was observed 
before any sizable cell death could be observed (figs. 3, 4). Potentially induced by the 
stress of the experimental set-up with the confocal microscope the FRET ratio increased 
without treatment over time, an effect that was reversed upon transfection (fig. 9). 
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Fig. 5. Crystal structure of complex 
II with location of FRET fusions 
highlighted. The distance between the 
N-terminus of SDHD (left circle) and 
the C-terminus of SDHB (right circle) is 
approximately eight Ångström. Adapted 
from (Sun, F. 2005). 
FRET YFP Acceptor Protein Construct 
FRET CFP Donor Protein Construct 
 YFP SDHB 
MT-seq. 
SDHB 
linker 
CFP  SDHD 
MT-seq. 
SDHD 
SDHD linker 
FRET YFP Acceptor 
Channel 
FRET CFP Donor 
Channel 
TMRE Channel 
FRET YFP Acceptor - 
TMRE Channel 
Overlap 
FRET CFP Donor - 
TMRE Channel 
Overlap 
FRET YFP Acceptor – CFP 
Donor - TMRE Channel 
Overlap 
Fig. 6. Diagram and localisation of complex II FRET constructs. (a) The FRET acceptor construct 
consists of YFP fused to the C-terminus of SDHB via a linker sequence. The FRET donor construct consists of 
CFP fused to the N-terminus of SDHD. MT-seq. represents the N-terminal mitochondrial-targeting sequence 
that is cleaved off upon the protein’s import into mitochondria. For the donor construct, a sequence of the 
mature SDHD sequence was duplicated on the N-terminus of CFP, following the MT-seq. to ensure recognition 
cleavage recognition. (b) Images of HeLa cells were taken using a Leica SP5 confocal microscope following 
transient co-transfection of both FRET YFP acceptor and FRET CPF donor constructs and a TMRE stain. 
a. 
b. 
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Fig. 7. FRET monitoring complex II 
disintegration by As2O3. HeLa cells in a 96-well 
plate were co-transfected with both FRET 
constructs and monitored over a 13.6-hour period 
upon addition of 10 µM As2O3. The plots show 
signals from the different channels: YFP (red), CFP 
(blue), FRET (yellow), and FRET efficiency over 
time in sec x1,000 (black, bottom panel). 
Fig. 8. FRET efficiency upon treatment with As2O3. (a) 293T cells were treated with NaOH, the solvent for 
As2O3 as a control, and compared with HeLa cells treated with 10 μM As2O3 for 10 hours. A determination for 
FRET efficiency was made in triplicate for both sets prior to treatment and 10 hours post treatment. The two 
sets of measurements were used to calculate the percent decrease in FRET efficiency ratio with a positive value 
representing a decrease and a negative value representing an increase. (b) HeLa cells were treated with NaOH, 
the solvent for As2O3 as a control, and compared with HeLa cells treated with 10 μM As2O3 for 15 hours. A 
measurement for FRET efficiency was made in triplicate for both sets prior to treatment and 15 hours post 
treatment. The two sets of measurements were used to calculate the percent decrease in FRET efficiency ratio 
with a positive value representing a decrease and a negative value representing an increase. 
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The transfection of an expression plasmid for prohibitin (PHB), the mammalian 
homologue of the yeast complex II assembly factor Tcm62p (Dibrov et al., 1998), 
efficiently reduced the disintegration of the complex by As2O3 (fig. 10). In agreement 
with reactive oxygen species (ROS) generation by the released SDHA/SDHB subunits, 
ROS accumulated upon As2O3 application and were reduced by the expression of PHB 
(fig. 11). The dissipation of the mitochondrial membrane potential m as a marker for 
cell death was likewise diminished by PHB (fig. 12).  
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Fig. 9.  Changes in FRET efficiency over time in non-transfected HeLa cells and stably transfected 
HeLa cells with FRET constructs. HeLa cells were either left untransfected or transfected with empty vector 
pcDNA3. A measurement for FRET efficiency was made in triplicate immediately following transfection and 
(a) four hours post transfection and (b) fifteen hours post transfection. The two sets of measurements were 
used to calculate the percent decrease in FRET efficiency ratio with a positive value representing decrease and a 
negative value representing an increase.  
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Fig. 10. Effect of prohibitin on FRET efficiency 
upon treatment with As2O3.  HeLa cells were 
transfected with pcDNA3 and prohibitin (PHB) 24 
hours prior to treatment with As2O3. Cells were treated 
with the carrier alone or with 10 μM As2O3 for 15 
hours. FRET efficiency as a measure of complex II 
dissociation was assessed prior to treatment and 15 
hours later in triplicates. The two sets of measurements 
were used to calculate the percent decrease in FRET 
efficiency ratio with a positive value representing a 
decrease and a negative value representing an increase. 
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Since PHB could target a range of client proteins, we wanted to more specifically 
target the enzymatic activity of complex II with 3NP, a compound that blocks the 
catalytic centre of SDHA. This inhibitor reduced both the amount of ROS as well as the 
extent of cell death by As2O3 (fig. 13). The importance of ROS formation in cell death 
caused by As2O3 was revealed when MnSOD was introduced into the cells (fig. 14a). The 
PT-pore has been shown to respond to oxidative stress (Crompton, 1999) and 
cyclophilin D (cypD, PPIF) overexpression as well as its knock-out inhibit this complex 
(Baines et al., 2005; Y. Li et al., 2004; D. T. Lin & Lechleiter, 2002; Nakagawa et al., 2005; 
Schubert & Grimm, 2004). In both scenarios we noticed a significant inhibition of the 
dissipation of m upon As2O3 treatment (fig. 14b, c). We observed an only slightly 
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Fig. 11. Effect of prohibitin on 
ROS generation upon treatment 
with As2O3.  HeLa cells were 
transfected with the empty vector or 
PHB 24 hours prior to treatment 
with 10 µM As2O3 and harvested 
after 15 hours for MitoSOX staining 
to determine mitochondrial ROS 
with FACS analysis. 
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Fig. 12. Effect of prohibitin on cell 
death upon treatment with As2O3.  
PHB inhibits cell death upon 10 µM 
As2O3 treatment for 25 hours as 
measured by DiOC6 and PI. 
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reduced influx of Ca2+ into mitochondria by As2O3 in comparison to ionomycin, a Ca
2+-
specific ionophore (fig. 15). 
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Fig. 13. 3NP inhibition of mitochondrial ROS production and cell death in HeLa cells 
treated with As2O3. (a) HeLa cells were treated for 15 hours with 10 µM As2O3 and then 
harvested for MitoSOX staining with FACS analysis. 1 mM 3-NP was added to the cells 8 hours 
prior to harvest. The FACS results were used to determine the percent cells with increased ROS 
generation present within each sample. (b) HeLa cells were treated with 50 µM menadione and 
stained with MitoSOX as a negative control for 3NP inhibition. (c) HeLa cells were treated for 30 
hours with 10 µM As2O3 and harvested for FACS analysis. 1 mM 3-NP was added to the cells 24 
hours prior to harvest. The FACS results were used to determine the percent cell death present 
within each sample. 
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Fig. 14. Manganese Superoxide (MnSOD) and 
Cyclophilin D (CypD) inhibition of cell death in 
HeLa cells with As2O3 treatment. (A) HeLa cells 
were transfected with pcDNA3 as a control or 
MnSOD 24 hours prior to treatment, then treated for 
25 hours with 10 µM As2O3 and harvested for FACS 
analysis to determine the percent cell death present 
within each sample. Transfection efficiency was 
approximately 67.58%. (B) HeLa cells were transfected 
with pcDNA3 as a control or CypD 24 hours prior to 
treatment, then treated for 25 hours with 10 µM 
As2O3 and harvested for FACS analysis to determine 
the percent cell death present within each sample. 
Transfection efficiency was approximately 64.07%. (C) 
WT and CypD knockout MEF cells were treated for 16 
hours with 15 µM As2O3 and harvested FACS analysis 
to determine the percent cell death present within each 
sample. 
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Fig. 15. Mitochondrial Ca2+ influx upon As2O3 or 
ionomycin treatment. HeLa cells were treated with 
10 µM As2O3 for 15 hours or with 10 µM ionomycin 
for 15 hours and harvested for Rhod2-AM staining 
with FACS analysis to determine the percent cells 
with increased mitochondrial Ca2+. 
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2. Ca2+ influx by ionomycin induces complex II for cell death 
When compared with As2O3, Ca
2+ influx into mitochondria with ionomycin, a Ca2+-
specific ionophore, was more efficient (fig. 16). It likewise caused the disintegration of 
complex II, which was reversed by the expression of PHB (fig. 17). This complex II 
assembly factor also specifically reduced ROS and cell death by ionomycin (figs. 18, 19; 
fig. 20). The incubation of isolated complex II in Ca2+ -containing buffer led to the 
release of the SDHA/SDHB sub-complex observed in blue native gel electrophoresis 
(fig. 21). To more directly address the mechanism of Ca2+-mediated complex II 
disintegration, we reconstituted complex II from mitochondrial membranes into 
nanoscale bilayers (nanodiscs) as described (Schwall et al., 2012). Complex II 
reconstituted in bilayers with an inner membrane-biomimetic lipid composition (POPC, 
POPE and CL in a 2:2:1 molar ratio) displayed a Ca2+-dependent release of SDHA, 
whereas complexes lacking dimeric phospholipid cardiolipin (CL) (POPC and POPE in 
equimolar concentrations) displayed no such Ca2+-coupled disintegration (fig. 22). 
Consistent with this trend, succinate:ubiquinone oxidoreductase activity, which requires 
an intact holoenzyme, was reduced in a Ca2+-dependent manner for complexes in the 
presence of CL, whereas succinate dehydrogenase activity, which reflects catalytic activity 
of the soluble SDHA/SDHB dimer only, was not affected by Ca2+ (fig. 23). 
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Fig. 16. Dissociation of complex II upon calcium influx via 
ionomycin treatment. HeLa cells stably expressing the complex 
II FRET constructs were treated with DMSO, the solvent for 
ionomycin as a control, and compared with HeLa cells treated 
with 10 μM Ionomycin for 4 hours. A measurement for FRET 
efficiency was made in triplicate for both sets prior to treatment 
and 4 hours post treatment. The two sets of measurements were 
used to calculate the percent decrease in FRET efficiency ratio 
with a positive value representing a decrease and a negative value 
representing an increase. 
Fig. 17. Effect of prohibitin on FRET efficiency upon 
treatment with Ionomycin.  HeLa cells were transfected 
with empty vector or PHB 24 hours prior to treatment with 
10 μM ionomycin or the carrier DMSO as a control. A 
calculation for FRET efficiency was made in triplicate for all 
four sets prior to treatment and four hours post treatment. 
Data are represented as in Fig. 10. 
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Fig. 20. Menadione as a negative control for the 
activity of PHB. HeLa cells were treated with 50 µM 
menadione as a negative control for PHB inhibition 
and stained with MitoSOX. 
Fig. 18. Effect of prohibitin on ROS 
generation upon treatment with ionomycin. 
HeLa cells were transfected with pcDNA3 as a 
control or PHB 24 hours prior to treatment 
with 10 µM ionomycin and after eight hours 
harvested for MitoSOX staining to determine 
ROS. 
Fig. 19. Effect of prohibitin on cell death 
upon treatment with ionomycin. HeLa cells 
were transfected with pcDNA3 or PHB 24 
hours prior to treatment for 20 hours with 10 
µM ionomycin and harvested for DiOC6 and 
PI stain with FACS analysis. 
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Fig. 21. Integrity of complex II in different 
buffers. Isolated mitochondria from 293T cells 
were incubated in the indicated buffers and 
complex II integrity was checked through Native 
Page gel electrophoresis. The incubation time was 
30 min. An SDHA antibody was used to visualize 
the complex.  
Fig. 22. Complex II reconstituted in bilayers. Complex II was reconstituted into nanodiscs containing cardiolipin (IM-mimetic) or 
lacking cardiolipin (POPC/POPE Control), incubated with the indicated concentrations of Ca2+, then subjected to Ni-NTA affinity 
chromatography along an imidazole gradient. Subunits co-eluting with the nanodisc scaffolding protein (MSP1E3D1) in fractions E1 
and E2 were stably associated with the nanodiscs; subunits emerging from the column at earlier fractions were not stably associated. 
(Upper panels) SDS-PAGE analysis of the column fractions. The fluorescent FAD signal was used as a marker for the soluble catalytic 
dimer as FAD is covalently bound to Sdh1p. FT: flow through; W1A-W3B: wash steps; E1-E3 elution steps. (Lower panels) 
Quantification of FAD band intensity comparing the predominant middle Wash fraction (W2B in most cases or W3A under some 
conditions) and combined selected Wash with E1 and E2 (which represents the total of the catalytic dimer in the predominant wash 
and all that remains connected to the membrane dimer within nanodiscs). A larger ratio indicates a less stable complex (ie. more 
catalytic dimer is not stably associated with nanodiscs and washes off the column prior to E1 and E2). Error bars are representative of 
s.e.m. for at least three separate experiments and statistical differences are represented in relation to addition of 0 mM Ca2+ (* = p ≤ 
0.05; ** = p ≤ 0.01). (Kindly provided by Nathan Alder and Christine Schwall from University of Connecticut) 
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Fig. 24. Malonate ROS inhibition of HeLa cells 
treated with ionomycin. HeLa cells were left 
untreated or treated for 8 hours with 10 µM 
ionomycin, with or without 8 mM malonate, and 
harvested for MitoSOX stain with FACS analysis to 
determine ROS generation in each sample. 
 
 
 
 
 
 
 
 
 
 
 
 
 
To further ensure that the cellular effects observed upon Ca2+ influx were caused by 
complex II, we blocked the enzymatic activity of complex II using malonate as well as 3-
NP. The cellular parameters that could be lowered by prohibitin (figs. 18, 19), the 
formation of ROS and subsequent cell death, were specifically reduced (figs. 24, 25, fig. 
26). The importance of oxidative stress for ionomycin-induced cell death was further 
emphasised by the increased survival when ROS were squelched by the expression of 
mitochondrial MnSOD (fig. 27). When we blocked the PT-pore with overexpressed or 
knocked-out cypD we observed a reduction of the percentage of cell death (figs. 28, 29).  
 
 
 
 
 
 
 
 
 
 
 
 
 
A. B.
**
* **
Figure 2.
Fig. 23. The activities of complex II are selectively Ca2+-dependent. (A) Succinate dehydrogenase 
(SDH, PMS-mediated) activity monitoring the presence of the catalytic dimer is overall not Ca2+-dependent. 
(B) Succinate: quinone oxidoreductase (SQR, DB-mediated) activity monitoring the presence of the 
holoenzyme is Ca2+-dependent reflecting the decreased affinity between the catalytic and membrane dimers. 
Error bars are representative of s.e.m. for at least four separate experiments and statistical differences are 
represented in relation to addition of 0 mM Ca2+ (* = p ≤ 0.05; ** = p ≤ 0.01). (Kindly provided by Nathan Alder 
and Christine Schwall from University of Connecticut) 
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Fig. 25. 3NP cell death inhibition of HeLa cells treated 
with ionomycin. HeLa cells were treated for 24 hours with 
10 µM ionomycin with or without 1 mM 3-NP and then 
harvested for DiOC6 and PI stain with FACS analysis.  The 
FACS results were used to determine the percent cell death 
within each sample. 
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Fig. 26. Menadione as a negative control. 
HeLa cells were treated with 50 µM 
menadione and assayed with the MitoSOX 
staining protocol as a negative control for 
malonate inhibition. 
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Fig. 27. Manganese Superoxide 
(MnSOD) and inhibition of cell death in 
HeLa cells with ionomycin treatment.  
HeLa cells were transfected with pcDNA3 
as a control or Manganese Superoxide 
Dismutase (MnSOD) 24 hours prior to 
treatment with 10 µM ionomycin for 20 
hours and harvested for DiOC6 and PI stain 
with FACS analysis. The FACS results were 
used to determine the percent cell death. 
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Fig. 28. Cyclophilin D (CypD) 
overexpression inhibits cell death in 
HeLa cells with ionomycin treatment.  
HeLa cells were transfected with 
pcDNA3 as a control or Cyclophilin D 
(CypD) 24 hours prior to treatment, 
treated for 20 hours with 10 µM 
ionomycin and harvested for DiOC6 and 
PI stain with FACS analysis to determine 
the percent cell death. 
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3. Cardiolipin depletion activates complex II for cell death induction 
While in cell death scenarios with the extrinsic signalling pathway, the cellular 
cardiolipin content is reduced (Crimi & Esposti, 2011), under our cell death conditions 
that engage the intrinsic pathway cardiolipin remained unchanged (fig. 30). The 
headgroup of this lipid has been shown to bind Ca2+, which induces those lipids to 
coalesce into homotypic clusters and exhibit lateral phase separation, thereby causing a 
decrease in the surface area of monolayers and a consequent immobilization of 
cardiolipins (Killian et al., 1994). This is connected with a reduction of its interaction 
with respiratory chain complexes (Powell, Knowles, & Marsh, 1987). We therefore 
investigated the cellular consequences when complex II lacks cardiolipin association. We 
targeted the expression of cardiolipin synthase-1 (CLS1) in the inner mitochondrial 
membrane (fig. 31) and found that this led to a reduction of the FRET ratio indicating a 
disintegration of complex II (fig. 32) at a time point when no overt cell death was visible 
(fig. 33). This could be reversed by the transfection of PHB (fig. 34). ROS were also 
produced by the knock-down of CLS1, which were likewise reduced by PHB expression 
(fig. 35, fig. 20), as was the induction of cell death indicated by DiOC6 staining (fig. 36). 
Conversely, an increase of CLS1 reduced cell death by ionomycin and As2O3 (fig. 37). 
The complex II-specific inhibitor 3-NP reduced both ROS and cell death caused by 
CLS1 knock-down fig. 38, fig. 39). MnSOD transfection supported the role of ROS in 
this scenario (fig. 40). To test the involvement of the PT pore in the signal created by the 
absence of cardiolipin, we transfected the cells with a plasmid for cypD, knocked-down 
CLS1 in WT and in cypD KO cells, and observed cell death reduction in both the 
absence of cypD as well as in upregulation (fig. 41, fig. 42, fig. 43).  
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Fig. 29. CypD knockout inhibits cell death by 
ionomycin treatment. WT and CypD knockout 
MEF cells were treated for 16 hours with 10 µM 
ionomycin and harvested for FACS analysis to 
determine the percent cell death present within 
each sample. 
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Fig. 30. Cardiolipin levels upon As2O3 and ionomycin treatment. (A) HeLa cells were treated with NaOH (solvent for As2O3) as a control or 
10 µM As2O3 for 15 hours, The cells were harvested for immunofluorescence staining with FACS analysis using human anti -cardiolipin IgG as the 
primary antibody (1:500) and alexa-fluor 488 goat anti-human IgG (1:500) as the secondary antibody. The histogram plot shows the cardiolipin level 
(FL1 intensity) of harvested, untreated, or As2O3-treated cells probed using primary only, secondary only, both as negative controls, or probed with 
both. (B) The histogram plots represent the cardiolipin levels based on FL1 intensities in the untreated and As2O3-treated cell populations, 
respectively. (C) The percent cardiolipin level based on the flow cytometry histogram plots is organised into a bar gr aph format. (D) HeLa cells 
were treated with DMSO (solvent for ionomycin) as a control or 10 µM ionomycin for 4 hours. The cells were harvested for immunofluorescence 
staining with FACS analysis using human cardiolipin IgG as the primary antibody (1:500) and alexa-fluor 488 goat anti-human IgG (1:500) as the 
secondary antibody. The histogram plot shows the cardiolipin level (FL1 intensity) of harvested, untreated, or As2O3-treated cells probed using 
primary only, secondary only, both as negative controls, or probed with both. (E) The histogram plots represent the cardiolipin expression levels 
based on FL1 intensities in the untreated and ionomycin treated cell populations respectively. (F) The percent cardiolipin level based on the flow 
cytometry histogram plot is organised into a bar graph format. 
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Fig. 31. Verification of cardiolipin synthase (CLS1) shRNA knockdown. (A) HeLa cells were transfected with shRNA 
SCR (pLKO.1 puro) or shRNA CLS1. The cells were harvested for immunofluorescence staining with FACS analysis 24 hours 
post transfection using human anti-cardiolipin IgG as the primary antibody (1:500) and alexa-fluor 488 goat anti-human IgG 
(1:500) as the secondary antibody. The histogram plot shows the cardiolipin level (FL1 intensity) of harvested shRNA SCR or 
shRNA CLS1 cells probed using primary only, secondary only, both as negative controls, or probed with both. (B) The 
histogram plots represent the cardiolipin levels based on FL1 intensities in the shRNA SCR and shRNA CLS1 transfected cell 
populations, respectively. (C) The normalised plot for percent cardiolipin level takes into account the 53.2% transfection 
efficiency. 
Fig. 32. Dissociation of complex II upon knockdown of 
cardiolipin synthase 1 (CLS1) measured via FRET 
efficiency. HeLa cells stably expressing the complex II FRET 
constructs were transfected with an empty shRNA pLKO 
vector and compared with HeLa cells transfected with shRNA 
CLS1. An calculation for FRET efficiency was made in 
triplicate for both sets immediately following transfection and 
24 hours post transfection. The two sets of measurements 
were used to calculate the percent decrease in FRET efficiency 
ratio with a positive value representing a decrease and a 
negative value representing an increase. 
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Fig. 33. Cell death kinetics upon knockdown of cardiolipin synthase (CLS1). HeLa cells were transfected with 
shRNA pLKO.1 puro empty vector or shRNA CLS1 and at the indicated time points harvested for FACS analysis to 
determine the percent cell death present within each sample. 
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Fig. 35. Effect of prohibitin on ROS generation upon 
knockdown of CLS1. HeLa cells were transfected with a 
scrambled shRNA or an shRNA against CLS1, together with 
either pcDNA3 or an expression plasmid for PHB at a 1:1 ratio. 
The cells were harvested for MitoSOX 48 hours post 
transfection to determine ROS. 
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Fig. 34. Effect of prohibitin on FRET efficiency upon 
knockdown of CLS1. HeLa cells were co-transfected with a 
scrambled shRNA or an shRNA against CLS1, together with 
pcDNA3 or an expression plasmid for PHB. An initial 
measurement for FRET efficiency was made in triplicates for all 
four sets immediately following the transfections and 24 hours 
post co-transfection. Data are represented as in Fig. 1D. 
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Fig. 36. Effect of prohibitin on cell death upon knockdown 
of CLS1. HeLa cells were transfected with a scrambled shRNA 
or an shRNA against CLS1, together with either pcDNA3 or an 
expression plasmid for PHB at a 1:2 ratio. The cells were 
harvested for DIOC6 and PI stain to quantify cell death 72 
hours post transfection. 
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Fig. 37. Cardiolipin synthase (CLS1) upregulation inhibits cell death by As2O3 and ionomycin. (A) HeLa cells were transfected 
with pcDNA3 (empty vector) or pcDNA3 containing CLS1 cDNA. The cells were harvested for immunofluorescence staining with 
FACS analysis 24 hours post transfection using human cardiolipin IgG as the primary antibody (1:1000) and alexa-fluor 488 goat anti-
human IgG (1:1000) as the secondary antibody. The histogram plot shows the cardiolipin level (FL1 intensity) of harvested pcDNA3 
(empty vector) or CLS1 upregulated cells probed using primary only, secondary only, both as negative controls, or probed with both. 
(B) The histogram plots represent the cardiolipin level based on FL1 intensities in the pcDNA3 and pcDNA3-CLS1 transfected cell 
populations, respectively. (C) The normalised plot for the percent cells with increased cardiolipin level takes into account the 41.7% 
transfection efficiency. (D) HeLa cells were transfected with pcDNA3 as a control or CLS1 24 hours prior to treatment, then treated 
for 25 hours with 10 µM As2O3 and harvested for FACS analysis to determine the percent cell death present within each sample.  
Transfection efficiency was approximately 62.1%. (E) HeLa cells were transfected with pcDNA3 as a control or CLS1 24 hours prior to 
treatment, then treated for 20 hours with 10 µM ionomycin and harvested FACS analysis to determine the percent cell death present 
within each sample. Transfection efficiency was approximately 44.4%. 
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Fig. 38. 3NP inhibition of mitochondrial ROS generation in 
HeLa cells upon knockdown of CLS1. HeLa cells were 
transfected with a scrambled shRNA or an shRNA against CLS1 
and harvested for MitoSOX stain 48 hours post transfection 
with 3-NP treatment 8 hours prior to harvest. 
Fig. 39. 3NP inhibition of cell death in HeLa cells upon 
knockdown of CLS1. HeLa cells were transfected with a 
scrambled shRNA or an shRNA against CLS1. The cells were 
harvested for DIOC6 and PI staining to quantify cell death 72 
hours after transfection with 3-NP treatment 24 hours prior to 
harvest. 
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Fig. 40. Manganese Superoxide Dismutase (MnSOD) inhibits cell death induced by cardiolipin synthase (CLS1) 
knockdown. (A) HeLa cells were transfected with shRNA SCR and pcDNA3 (2:1 ratio), shRNA SCR and MnSOD (2:1 
ratio), shRNA CLS1 and pcDNA3 (2:1 ratio), and shRNA CLS1 and MnSOD (2:1 ratio). 72 hours post transfection the cells 
were harvested for FACS analysis. Transfection efficiency was approximately 61.48%. (B) HeLa cells were co-transfected 
with Caspase-2 at a ratio of 2:1 as a negative control for MnSOD inhibition. 
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Fig. 41. CypD upregulation inhibits cell death induced by cardiolipin synthase (CLS1) knockdown. HeLa cells 
were transfected with a scrambled shRNA or an shRNA against CLS1 together with an empty vector or an expression 
construct for CypD (1:1 ratio) and harvested for DIOC6 and PI stain 72 hours post transfection. 
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Fig. 42. CypD knockout inhibits cell death induced by cardiolipin synthase (CLS1) knockdown. WT and cypD 
knockout MEF cells were transfected with shRNA SCR or mouse shRNA CLS1 and harvested for DiOC6 and PI staining with 
FACS analysis after 72 hours to determine the percent cell death present within each sample. 
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Figure 43. Cardiolipin synthase (CLS1) knockdown verification in WT and cypD
-/-
 MEF cells. WT 
MEF cells were transfected with shRNA SCR (pLKO.1 puro) or mouse shRNA CLS1, The cells were 
harvested for immunofluorescence staining with FACS analysis 24 hours post transfection using human 
cardiolipin IgG as the primary antibody (1:500) and alexa-fluor 488 goat anti-human IgG (1:500) as the 
secondary antibody. (A) The histogram plot shows the cardiolipin expression (FL1 intensity) of harvested 
shRNA SCR or shRNA CLS1 cells probed using primary only, secondary only, both as negative controls, or 
probed with both. (B) The histogram plots represent the cardiolipin expression levels based on FL1 
intensities in the shRNA SCR and shRNA CLS1-transfected cell populations respectively. (C) The normalised 
plot for percent cardiolipin level takes into account the 70.4% transfection efficiency. (D) CypD KO MEF 
cells were transfected with shRNA SCR (pLKO.1 puro) or mouse shRNA CLS1. The cells were harvested for 
immunofluorescence staining with FACS analysis 24 hours post knockdown using human cardiolipin IgG as 
the primary antibody (1:500) and alexa-fluor 488 goat anti-human IgG (1:500) as the secondary antibody. The 
histogram plot shows the cardiolipin levels (FL1 intensity) of harvested shRNA SCR or shRNA CLS1-
transfected cells probed using primary only, secondary only, both as negative controls, or probed with both. 
(E) The histogram plots represent the cardiolipin levels based on FL1 intensities in the shRNA SCR and 
shRNA CLS1-transfected cell populations, respectively. (F) The normalised plot for percent cardiolipin level 
takes into account the 78.8% transfection efficiency. 
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Fig. 44. Test of the stability of complex II subunits upon As2O3 treatment HeLa cells were 
either treated using 1 M NaOH (As2O3 solvent) or treated for 15 hours with 10 µM As2O3. 50 µg of 
protein were used to probe for the expression levels of SDHA, SDHB, SDHC, and SDHD. GAPDH 
was used as a loading control for each probe.   
10 µM As2O3 (12 HR) 10 µM As2O3 (25 HR) 10 µM As2O3 (30 HR) 
10 µM Ionomycin  
(24 HR) 
10 µM Ionomycin  
(8 HR) 
10 µM Ionomycin  
(20 HR) 
CLS1 KD (48 HR) CLS1 KD (72 HR) CLS1 KD (96 HR) 
Fig. 44-1. Differences in cell death 
population shifts between As2O3, 
ionomycin (calcium influx), and 
cardiolipin synthase knockdown over 
time. HeLa cells were treated with 10 
µM As2O3, 10 µM ionomycin, and 
transfected with shRNA CLS1 (CLS1 
KD) for three increasing time 
increments. The cells were then 
harvested at the respective time points 
and stained using DiOC6 and PI and 
evaluated using flow cytometry to assess 
for cell death pattern. 
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Discussions 
1. Summary of the study 
Massive Ca2+ influx into mitochondria is critically involved in cell death induction but 
it is unknown how this activates the organelle for cell destruction. In my study, I showed 
using multiple approaches including subcellular fractionation and FRET in intact cells as 
well as in vitro reconstitutions that increased mitochondrial Ca2+ prompts complex II of 
the respiratory chain to disintegrate, thereby releasing an enzymatically competent sub-
complex. This generates excessive reactive oxygen species for cell death induction (fig. 
45). The dissociation of complex II subunits is prevented in vitro when cardiolipin is 
substituted with a lipid devoid of Ca2+ binding. Cardiolipin is known to associate with 
complex II and to coalesce into tight homotypic clusters upon Ca2+ binding. When 
complex II is deprived of this lipid, it disintegrates for ROS formation and cell death (fig. 
45). My results reveal Ca2+ binding to cardiolipin and complex II disintegration as a 
pivotal step for oxidative stress and cell death induction.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 45. Schematic representation of inducers Ca
2+
, cardiolipin reduction, and arsenic trioxide used on 
complex II for dissociation with ROS and PT pore activation for cell death. Upon inducing the dissociation of 
the complex, a developed Förster resonance energy transfer (FRET) assay was used to detect it. Following 
disintegration of the complex, superoxides form and ROS generation occurs, detected via MitoSOX staining and 
flow cytometry analysis. Downstream of ROS generation is the activation of the PT pore along with caspases for 
apoptosis or cell death. This was measured by DiOC and PI staining along with flow cytometry analysis. Each step 
has its respective inhibitors.        
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Complex II of the respiratory chain (RC) recently emerged as a prominent regulator 
of cell death. In both cancer cells as well as neurodegenerative diseases, mutations in 
subunits have been found along with numerous germline and somatic mutations reported 
in association with hereditary cancer syndromes indirectly affecting this complex (Alston 
et al., 2012; Astuti et al., 2001; Baysal et al., 2000). Anticancer compounds were 
developed that target complex II and cause cell death in a tumour-specific way 
(Kluckova, Bezawork-Geleta, Rohlena, Dong, & Neuzil, 2013; Lemarie et al., 2011). This 
protein aggregate is specifically activated for cell death via the dissociation of its SDHA 
and SDHB subunits from the membrane-anchoring proteins via mitochondrial Ca2+ 
influx. The SDH activity contained in the SDHA/SDHB subcomplex remains intact and 
then generates, in an uncontrolled fashion, excessive amounts of reactive oxygen species 
(ROS) for cell death. Our mechanistic understanding of how complex II is activated for 
cell death induction has been made clearer following the results of this study. 
 
2. Calcium activates complex II for cell death induction 
In this work we showed that massive mitochondrial Ca2+ influx causes complex II 
disintegration for ROS formation, and cell death induction (fig. 16, 17, 18, 19). The 
agonist-releasable Ca2+ concentration in the ER is in the mM range (Bygrave & Benedetti, 
1996) and high sub-mM concentrations still mediate physiological responses in 
mitochondria (Giorgi et al., 2009). Hence, only when a considerable amount of this ion 
accumulates in mitochondria is cell death induced. This is facilitated through the close 
apposition of the ER with mitochondria or the massive influx of the ion from the 
extracellular space. These two organelles form a highly dynamic interconnected network 
within which they cooperate to generate Ca2+ signals. The mitochondria play an 
important role in influencing Ca2+ signal released from the ER.  The mitochondria assist 
in the recovery phase by rapidly sequestering Ca2+ and then later returning it to the ER. 
Under normal signalling conditions, there is a continuous flow of Ca2+ between these two 
organelles. Most of the Ca2+ resides within the lumen of the ER except during Ca2+ 
signalling when a small amount is intermittently released to the cytoplasm and then re-
sequestered with a proportion passing through the mitochondria (fig. 46). At equilibrium, 
the bulk of internal Ca2+ resides in the ER where it functions as a reservoir of signal Ca2+ 
as well as an essential component in sustaining the activity of the chaperones responsible 
for protein processing (Rizzuto & Pozzan, 2006).  
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Adjustments in the operation of the ER/mitochondrial interaction provide a pathway 
for cell death activation (P. Pinton et al., 2008). The main component connecting cell 
death to ER-mitochondria interactions is a change in Ca2+ homeostatic mechanisms, 
resulting in massive and/or a prolonged mitochondrial Ca2+ overload. It has been well-
recognised that Ca2+ is an important regulator of both cell proliferation as well as cell 
death. The switch from a life to a death signal occur when its normal distribution 
between the ER and the mitochondria becomes distorted, resulting in a breakdown of 
mitochondrial function. Previous studies have shown that the reduction in the Ca2+ 
amount that can be released from ER to mitochondria decreases the probability of Ca2+-
dependent cell death (Ferri & Kroemer, 2001; Kaufman, 2002)(fig. 46). Conversely, 
conditions that increase ER Ca2+ storage have the opposite effect on Ca2+-dependent cell 
death. In this context, it has been demonstrated that over-expression of the anti-
apoptoticBcl-2 protein can influence the distribution of Ca2+ within the 
ER/mitochondrial interface (P. Pinton et al., 2008). Specifically, compared to controls, 
Fig. 46. The ER-mitochondria interaction controls Ca2+-mediated cellular responses to different 
physiopathological stimuli. Under normal conditions, Ca2+ released from the ER to mitochondria triggers a boost 
in cellular metabolism as well as ATP production. Mitochondrial Ca2+ overload induced by apoptotic stimuli or ER 
stressors, on the other hand, sensitizes the organelle to release caspases cofactors. Conversely, anti-apoptotic 
elements or cell survival signals prevent Ca2+ accumulation in the mitochondrial matrix through emptying 
intracellular stores (Bcl-2 overexpression) or via the inhibition of Ca2+-releasing channels (Akt activation) (Giorgi, De 
Stefani, Bononi, Rizzuto, & Pinton, 2009).          
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Bcl-2 over-expressing cells show an approximately 30% reduction in Ca2+ levels within 
both the ER and the Golgi apparatus due to increased Ca2+ leakage from the lumen of 
the organelles (Foyouzi-Youssefi et al., 2000; P. Pinton et al., 2000).             
For our findings to be relevant for cell death caused by mitochondrial Ca2+ 
accumulation, complex II should respond only to very high Ca2+ concentrations as 
observed in figure 22. Ca2+ has a high affinity to cardiolipin with a kD in the µM range 
(Brenza, Neagle, & Sokolove, 1985) making it likely that it is the abundance of this lipid 
in the inner mitochondrial membrane that limits its efficient removal from complex II. 
While it is difficult to obtain consistent measurements of free Ca2+ levels within 
mitochondria due to pH and heavy metal ions interferences, the 3:1 molar ratio of Ca2+ 
to cardiolipin in the system (300-350 micro-molar cardiolipin to 1 mM Ca2+) where we 
begin to see effects, is within a physiological range. Moreover, high Ca2+ levels are 
generated in the proximity of the Ca2+ channels near the inner mitochondrial membrane 
where complex II is also localized. This effect is not captured by the Ca2+ measurements 
currently employed that monitor the total ion concentration in the mitochondrial matrix.  
 
3. Calcium concentration in the ER regulates apoptosis sensitivity 
The role Ca2+ plays in cell death induction extends beyond just mitochondrial influx 
and complex II dissociation, but incorporates upstream signals involving the ER as 
detailed in the previous section as well. In studies involving Ca2+ homeostasis, proteins of 
the Bcl-2 family, localized in organelles fundamentally involved in Ca2+ handling, 
specifically the mitochondria and the ER, are observed and investigated. Bcl-2 has been 
detected in association with the outer mitochondrial membrane, with the ER, and with 
the nucleus; a cytoplasmic form of Bcl-2 is also known to exist (P. Pinton & Rizzuto, 
2006). Although it is widely accepted that only Bcl-2 bound to membranes is involved in 
the inhibition of cell death. The mechanism as well as the importance and function of 
Bcl-2 in different cellular locations are still a considered a controversial matter. 
The first association between Bcl-2 and Ca2+ homeostasis was established in 1993, 
when the overexpression of Bcl-2 was revealed to inhibit the decrease in Ca2+ 
concentration of the ER, observed upon the removal of interleukin-3 in hematopoietic 
cell lines (Baffy, Miyashita, Williamson, & Reed, 1993). This effect was not secondary to 
the antiapoptotic effect of Bcl-2, preventing both the energy loss and the loss of ER Ca2+ 
during apoptosis, as the overexpression of Bcl-2 was also reported to decrease the 
amount of the ER Ca2+ that was released (Lam et al., 1994). Following these studies, 
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detailed subcellular analyses of Ca2+ homeostasis and the complex signals regulating 
mitochondria participation took place. In these experiments, an aequorin chimera 
targeted to the ER, and ultimately mitochondria, was transiently coexpressed with Bcl-2 
in HeLa cells (P. Pinton, Rimessi, Romagnoli, Prandini, & Rizzuto, 2007). The cells 
overexpressing Bcl-2 showed an enhanced survival upon ceramide treatment (P. Pinton 
et al., 2001), which agrees with previously conducted studies (Rippo et al., 2000; J. Zhang 
et al., 1996). Compared with controls, cells overexpressing Bcl-2 displayed an 
approximately 30 percent reduction in Ca2+ levels within both the ER as well as the Golgi 
apparatus. Consequently, the increase in Ca2+ concentration shown in these cells by 
stimuli coupled to IP3 generation were reduced both in the cytoplasm as well as in the 
mitochondria (P. Pinton et al., 2000). 
The ability of antiapoptotic proteins to reduce ER Ca2+ concentration was further 
confirmed and expanded in studies that employed other approaches and genetically 
altered cell models, specifically a genetically encoded Ca2+ indicator via the redesigning of 
the binding interface of calmodulin and a calmodulin binding peptide (Foyouzi-Youssefi 
et al., 2000; Palmer, Jin, Reed, & Tsien, 2004). In addition, it was demonstrated that 
embryonic fibroblasts from mice (MEFs) in which proapoptotic Bax and Bak had both 
been knocked out revealed a major reduction in ER Ca2+ concentration and that silencing 
of Bcl-2 in these cells restored ER Ca2+ concentration to the same levels as the control 
(Danial & Korsmeyer, 2004). Supporting studies have also shown that double knockout 
MEFs are resistant to a variety of apoptotic stimuli (Scorrano et al., 2003) Collectively, 
the results from these studies propose that Ca2+ movement from the ER to the 
mitochondria is an essential process in some apoptotic pathways. 
Comparable data have also been obtained using unrelated antiapoptotic proteins. The 
most prominent example was provided by an oncogene expressed in human 
hepatocellular carcinoma or hepatocarcinoma, liver cancer. This oncogene is generated 
by integrating the hepatitis B virus genome in the gene encoding the protein SERCA1 
(sarco-endoplasmic reticulum Ca2+ ATPase type 1). The viral activation was shown to cis-
activate SERCA1 chimeric transcripts with the splicing of exons 4 and/or 11. The 
encoded protein is devoid of most of the cytosolic N and P domains as well as critical 
Ca2+-binding regions of the transmembrane region. As a result, this protein is incapable 
of active Ca2+ pumping (Chami et al., 2000) and is involved in the neoplastic phenotype. 
It is speculated that the mutated SERCA is capable of interfering with the activity of 
endogenous pumps and/or act as a Ca2+ leak pathway from the ER. These data are 
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consistent with the observations that the overexpression of SERCA in HeLa cells 
increases the susceptibility of cells to apoptotic agents (Ma, Mann, Lee, & Gallinghouse, 
1999; Paolo Pinton, Ferrari, Di Virgilio, Pozzan, & Rizzuto, 2001). This was further 
reinforced by the study involving antiapoptotic coxsackie viral protein 2B, which was 
shown to reduce ER Ca2+ levels (Campanella et al., 2004). 
Under these circumstances, the observation that Bcl-2 also downregulates Ca2+ influx 
through the plasma membrane is not surprising. In principle, depletion of the ER Ca2+ 
store could lead to the activation of capacitative Ca2+ influx (Putney, 1990), inducing a 
prolonged potentiation of Ca2+-mediated effects on apoptosis. ER depletion of a similar 
degree has been found to lead to a substantial activation, over 50%, of store-dependent 
Ca2+ influx (Hofer, Fasolato, & Pozzan, 1998). Contrarily, Bcl-2 expression prominently 
reduces the Ca2+-mediated effects on apoptosis, increased by Ca2+ re-entry into cells in 
which the Ca2+ store had been fully depleted by SERCA blockers (P. Pinton et al., 2000). 
This effect, which may represent a long-term adaptation to lower ER Ca2+ concentration 
levels, is most likely due to the reduction of the number of functional channels in the 
plasma membrane (Vanden Abeele et al., 2002). Through analysis of the mechanism of 
neuroendocrine differentiation, present in a variety of carcinomas, it was shown that in 
androgen-sensitive human prostate adenocarcinoma cells, the same Ca2+ signaling 
alternation was observed upon Bcl-2 expression and upon the induction of 
neuroendocrine differentiation, in which partial ER depletion led to the reduction of the 
capacitative Ca2+ current (Vanoverberghe et al., 2004). 
 
4. The role of mitochondria in the ER-calcium scenario 
Mitochondria can be seen as the main figure of the double-sworded effect Ca2+ has on 
cell life and death (fig. 47). It has been shown that despite the low affinity of 
mitochondrial Ca2+ transporters, large Ca2+ fluxes take place across the mitochondrial 
membranes when a physiological stimulus prompts a rise in Ca2+-mediated effects on 
apoptosis, because organelles are not exposed to the lower bulk of this increase, but to 
the microdomains generated within proximity of open Ca2+ channels. The strategic 
location of mitochondria, which is close to the source of the rise in Ca2+ concentration 
levels, allows them to be exposed to these levels, which meet the affinity of their 
transporters and allows for the large and rapid accumulation of the cation in the matrix 
(P. Pinton et al., 1998). This accumulation has an important physiological function as it 
stimulates intramitochondrial effectors, such as Ca2+-dependent dehydrogenases of the 
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Krebs cycle, and allows for the prompt tuning of organelle metabolism, ATP production, 
to the increased needs of an activated cell, without leading to cell death or activation of 
apoptosis (Jouaville, Pinton, Bastianutto, Rutter, & Rizzuto, 1999). 
Recent works have indicated that other Ca2+-dependent metabolic checkpoints are 
operative, namely the aspartate/glutamate metabolite carriers. These were shown to be 
activated by Ca2+ and in turn, recombinant expression of wild-type aspartate/glutamate 
metabolite carriers enhanced ATP production upon cell stimulation (Lasorsa et al., 2003). 
Different mechanisms can finely tune amplitude and kinetics of mitochondrial Ca2+ 
responses. For instance, Ca2+ uptake can be increased or decreased via protein kinases 
(PKs), such as protein PKC (protein kinase C) or p38 mitogen-activated PKs (Montero, 
Lobaton, Moreno, & Alvarez, 2002; P. Pinton, Leo, Wieckowski, Di Benedetto, & 
Rizzuto, 2004). 
Mitochondria are important checkpoints of the apoptotic process as they are 
responsible for the release of caspase cofactors (Kroemer, Galluzzi, & Brenner, 2007). As 
detailed in the introduction, the apoptotic intrinsic pathway is activated by the release of 
several mitochondrial proteins into the cytosol. The main component in this intricate 
activation process is cytochrome c. The majority of cytochrome c is tightly bound to the 
mitochondrial inner membrane, due to its electrostatic interactions with acidic 
phospholipids. Cytochrome c is an irreplaceable component of the mitochondrial 
electron transport chain, shuttling electrons from complexes III to IV, and is essential to 
life (Garrido et al., 2006). Once released in the cytoplasm, this protein is responsible for 
the assembly of a caspases activating complex together with Apaf-1 and caspase 9. As 
described in the introduction, this is known as the ‘apoptosome’. The induction of the 
rearrangement and heptaoligomerization of Apaf-1 follows the release of cytochrome c 
into the cytosol. Each of the complexes of Apaf-1 can recruit up to seven caspase 
molecules, leading to proteolytic self-processing and consequent activation (Hill, Adrain, 
& Martin, 2003).  
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5. The ER-mitochondria cross-talk 
The endoplasmic reticulum controls multiple cellular processes including the 
translocation of soluble and membrane proteins into the secretory pathway, 
detoxification of metabolites and biosynthesis of lipids. It also functions as the principal 
internal store of calcium ions that mediate signalling, ATP production and apoptosis 
(Voeltz, Rolls, & Rapoport, 2002). Imaging studies using high-resolution 3D electron 
tomography has revealed that the extended ER network forms close contacts with 
secretory pathway compartments and with the mitochondria (Marsh, Mastronarde, 
Buttle, Howell, & McIntosh, 2001). As much as 20% of the mitochondrial surface is in 
direct contact with the ER, emphasizing the dynamic and highly regulated 
communication between the ER and the mitochondria (Rizzuto et al., 1998b). The close 
proximity between these two organelles have led to the model that ER-mitochondria 
communication may occur via direct transfer rather than vesicular traffic. In support of 
this model, biochemical studies have revealed that the ER communicates with the 
mitochondria via mitochondria-associated membranes (MAMs) (Vance, 1990). These 
ER-associated membranes contain multiple phospholipid- and glycosphingolipid-
synthesizing enzymes, including fatty acid-CoA ligase 4 and phosphatidlyserine synthase-
Fig. 47. Schematic representation of Ca2+-linked stimuli triggering the activation of cell metabolism 
or apoptosis.Adapted from (P. Pinton, Giorgi, Siviero, Zecchini, & Rizzuto, 2008). 
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1, and support the direct transfer of lipids between the ER and mitochondria (Piccini et 
al., 1998; Stone & Vance, 2000). 
Along with supporting lipid transfer, the apposed ER and mitochondria also exchange 
Ca2+ ions, which regulate processes ranging from ER chaperone-assisted folding of newly 
synthesized proteins to the regulation of mitochondria-localized dehydrogenases 
involved in ATP-producing Kreb’s cycle reactions and the activation of calcium-
dependent enzymes that execute cell death programs (Berridge, 2002; Rimessi, Giorgi, 
Pinton, & Rizzuto, 2008). The mitochondria-associated membrane contains major Ca2+ 
handling proteins as well as Ca2+ sensing ER chaperones that may participate in the 
adjustments of cellular Ca2+ signals. It has been reported that the sigma-1 receptor acts as 
a novel ‘ligand-associated’ chaperone, targeting MAM specifically (Hayashi & Su, 2007). 
They discovered that sigma-1 receptors arrange to form a Ca2+ sensitive chaperone 
machinery with BiP and extend Ca2+ signaling from the ER into mitochondria via the 
stabilization of IP3R-3s at MAM. This represents the first investigation of an ER 
chaperone influencing mitochondrial Ca2+ signaling from the side of the ER lumen. 
The ER and mitochondria appear to be physically and physiologically coupled, having 
a profound functional significance (Hajnoczky et al., 1995; Rizzuto et al., 1998a). The 
release of Ca2+ from ER stores via IP3Rs has been implicated in multiple models of 
apoptosis as being directly responsible for mitochondrial calcium overload (Hajnoczky, 
Davies, & Madesh, 2003; P. Pinton et al., 2002), due to the privileged communication of 
the IP3R with the closely adjacent mitochondria (Csordas, Thomas, & Hajnoczky, 1999). 
It is becoming more apparent that ER-mitochondrial calcium signaling is crucial in 
several models of apoptosis (Demaurex & Distelhorst, 2003; Orrenius et al., 2003; 
Rizzuto et al., 2003; Scorrano et al., 2003). The requirement of IP3R for calcium-
dependent cell death is illustrated by the resistance to apoptosis of cells with antisense 
knockdown or genetic deletion of the IP3R gene (Blackshaw et al., 2000; Jayaraman & 
Marks, 1997; Khan et al., 1996; Sugawara, Kurosaki, Takata, & Kurosaki, 1997). Initial 
evidence had suggested that Ca2+-dependent apoptotic death was mediated by the type 3 
IP3R (Khan et al., 1996), but successive studies have found that the type 1 isoform can 
also mediate apoptosis (Assefa et al., 2004; Boehning et al., 2003; Hirota et al., 1999). 
Intriguingly, a group discovered that Bcl-2 and IP3R-1 physically interact at the ER 
surface and suggested a model in which Bcl-2 family members regulate IP3R-1 
phosphorylation to control the rate of ER Ca2+ leakage from intracellular stores and 
better monitor apoptosis (Korsmeyer, 1995). In further support of this view, the 
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reduction of ER Ca2+ concentration in Bax/Bak knockouts is reversible via the siRNA 
silencing of IP3R-1 (Oakes et al., 2005). 
Other mechanisms have been proposed. Bcl-XL was shown to directly bind to the 
IP3R and sensitize it to low agonist doses. Bax prevents the effect of Bcl-XL. both in 
terms of its binding to the IP3R and the capacity of modifying the sensitivity to IP3 (C. 
White et al., 2005). The expression of Bcl-XL reduced ER Ca
2+ concentration in type 3 
but not type 1 or 2 IP3R-expressing cells. In contrast, Bcl-XL enhanced the spontaneous 
concentration of Ca2+-mediated signaling via Bcl-XL interaction with all isoforms of the 
IP3R (C. Li et al., 2007). Recent data has revealed that in this complex scenario, type 3 
IP3Rs, localized in the MAM, have a selective function in the induction of apoptosis by 
selectively transmitting apoptotic Ca2+ signals into mitochondria, whereas type 1 IP3Rs 
focus on mediating cytosolic Ca2+ assortment (Mendes et al., 2005). In support of this, 
siRNA silencing of IP3R-3 blocked apoptosis, whereas the transfection of IP3R-1 
antisense contructs was ineffective in doing so (Blackshaw et al., 2000). Mitochondria 
appear to be the downstream effectors of this MAM-associated pathway, as the 
knockdown of type 3 IP3R dramatically decreased agonist-induced mitochondrial Ca2+ 
uptake (Hayashi & Su, 2007).                       
 
6. Complex II, a source of reactive oxygen species generation 
As mentioned in the introduction, the mitochondrial respiratory chain is a major 
source for ROS generation, which has been shown in our study to induce cell death via 
the specific dissociation of complex II triggered by calcium influx. In general, intact 
mammalian complex II has not been widely accepted as a major source of ROS 
generation (Brand, 2010; Drose & Brandt, 2012; Kowaltowski, de Souza-Pinto, Castilho, 
& Vercesi, 2009; Murphy, 2009). It was not until a recent study in which complexes I and 
III were inhibited, and a low succinate concentration level was induced, was complex II 
shown to compensate and generate superoxides at high rates, in this case, in isolated rat 
skeletal muscle mitochondria in both the forward reaction, with electrons supplied by 
succinate from the Kreb’s cycle, and the reverse reaction, with electrons supplied from 
the reduced ubiquinone pool (Quinlan et al., 2012). 
It has been observed that the loss of function of complex II can lead to the 
accumulation of succinate from the Kreb’s cycle and increased ROS generation in 
mammalian cells (Iverson, Maklashina, & Cecchini, 2012; Ralph, Moreno-Sanchez, 
Neuzil, & Rodriguez-Enriquez, 2011). This is emphasized for mutations in complex II 
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subunits C and D located in the vicinity of the Qp site that have been associated with 
specific forms of cancer such as hereditary paragangliomas and pheochromocytomas 
(Bardella, Pollard, & Tomlinson, 2011; Iverson et al., 2012; Ralph et al., 2011). Mutations 
in SDHA lead to Leigh syndrome, a progressive neurodegenerative disease (Ackrell, 
2002; Iverson et al., 2012). Despite this, unbiased investigations showing that a disease 
associated mutation directly causes an increased ROS generation by mammalian complex 
II are rare. A group from Japan observed that a mutation in the SDHC subunit in 
transgenic mouse fibroblasts and conditional transgenic mice induces mitochondrial 
respiratory chain dysfunction and increased ROS generation (T. Ishii et al., 2011). 
However, definitive experiments excluding other respiratory chain complexes or matrix 
dehydrogenases as sources of ROS are not shown. This can be applied to an 
investigation showing an increased ROS production via a SDHD mutant in hamster 
fibroblasts (Owens et al., 2012). The same group from Japan have used non-mammalian 
model organisms for the analysis of oxidative stress associated with complex II 
mutations (Takamasa Ishii et al., 2013). Their results indicated that a mutation in SDHC 
in complex II from C. elegans caused hypersensitivity to increased oxygen concentrations 
(N. Ishii et al.) and induced an increase in ROS generation that was observed in 
succinate-fueled mitochondria and submitochondrial particles from the C. elegans mutant 
(Senoo-Matsuda et al.). However, the experiments with uncoupled submitochondrial 
particles large exclude that the observed ROS production might have been due to reverse 
electron transfer caused superoxide production via complex I. It was shown in a follow-
up study involving complex II from the parasitic helminth Ascaris suum, which functions 
in adult worms as the terminal oxidase of the anaerobic respiratory chain, catalysing 
fumarate reduction, that the succinate-dependent ROS generation of submitochondrial 
particles, that do not contain complex III and IV activities in their respiratory chain, was 
not influenced by a complex I inhibitor and was completely and partially suppressed by 
malonate or atpenin A5, respectively (Paranagama et al., 2010). . This indicates that 
complex II is the exclusive ROS source under these conditions. The ROS generation of 
succinate-fueled submitochondrial particles from A. suum L3 larvae, which contain a 
respiratory chain similar to mammalian mitochondria, was only affected by inhibitors 
specific to complex II and not by inhibitors of the other respiratory chain complexes. 
Detailed analysis of ROS generation pertaining to complex II has also been conducted 
with bacterial SQRs and fumarate reductases from E. coli (Messner & Imlay, 2002) with 
structural and functional similarity to mammalian complex II (Iverson et al., 2012). 
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6.1 Complex II, a modulator of ROS generation via complexes I and 
III 
In addition to the direct generation of ROS, complex II has been recognized as a 
modulator of the superoxide production by other mitochondrial enzymes, particularly the 
respiratory chain complexes I and III, which are generally regarded as main ROS sources 
in the mitochondria (Bleier & Drose, 2013; Drose, Bleier, & Brandt, 2011; Drose, 
Hanley, & Brandt, 2009). In a detailed analysis by Votyakova and Reynolds, it was 
determined that a drop in the mitochondrial membrane potential by only 5% reduces the 
hydrogen peroxide release of isolated mitochondria by 95% (Votyakova & Reynolds, 
2001). This finding indicates that a large membrane potential is necessary to drive 
electrons against the gradient of redox potentials from complex II into complex I. 
Further to this, investigations with different experimental systems, for instance intact 
mitochondria and coupled submitochondrial particles, revealed that different complex I 
inhibitors such as the Q-site inhibitor rotenone or inhibitors that compromise the 
primary electron acceptor FMN or NADH binding site suppressed ROS generation 
under conditions of reverse electron transfer (Grivennikova & Vinogradov, 2006; 
Lambert & Brand, 2004b; Y. Liu, Fiskum, & Schubert, 2002; Pryde & Hirst, 2011; 
Treberg, Quinlan, & Brand, 2011; Votyakova & Reynolds, 2001). ROS production is also 
reduced by complex II inhibitors that bind either to the dicarboxylate site or the Qp site if 
succinate is the prevalent substrate (Drose et al., 2011; Drose et al., 2009; Lambert & 
Brand, 2004b; Y. Liu et al., 2002; Treberg et al., 2011) Under these conditions, complex 
II activity is necessary for the reduction of ubiquinol that fuels the respiratory chain 
complexes III and IV to generate the proton-motive force required for reverse electron 
transfer. Inhibition of complex II reduces the membrane potential by hindering the 
electron supply for the downstream respiratory chain complexes. A high rate of ROS 
production is also observed when NADH-generating substrates and succinate are 
simultaneously supplied to isolated mitochondria (Muller et al., 2008; Zoccarato, 
Cavallini, & Alexandre, 2009; Zoccarato, Cavallini, Bortolami, & Alexandre, 2007; 
Zoccarato, Miotto, Cavallini, & Alexandre, 2011). It has been shown that under these 
conditions, electrons can flow downstream through complex I, resulting in the 
attenuation of reverse electron transfer (Zoccarato et al., 2007). It has been suggested by 
Zoccarato and colleagues that the ROS production is not caused by reverse electron 
transfer, but by a direct interaction between complexes I and II. 
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Under very specific conditions, complex II can also modulate the superoxide 
production at the Qo site of complex III (Dong et al., 2011; Drose et al., 2009; Quinlan, 
Gerencser, Treberg, & Brand, 2011). One requirement for this is that succinate is the 
main substrate. Another is that ‘oxidant-induced reductions’ are applied to complex III. 
The reduction of complex II activity leads to an increase of the ROS generation by 
antimycin A-inhibited complex III (Drose et al., 2011; Drose et al., 2009; Erecinska & 
Wilson, 1976; Malinska et al., 2010; Quinlan et al., 2011). This can be explained by an 
increased oxidation of the Q-pool, due to the superoxide generation at the Qo site, which 
is maximal at intermediate reduction states of the ubiquinone pool when the Qi site is 
blocked by antimycin A (Bleier & Drose, 2013; Drose & Brandt, 2008; Quinlan et al., 
2011).  
In summary, the differential effects of complex II on mitochondrial ROS production 
seem to be influenced by the succinate concentration and the activity of the other 
respiratory chain complexes, namely complexes I and III. It can be assessed by the 
distinct effects of complex II inhibitors. Complex II mainly produces ROS from reduced 
FAD at low succinate concentrations and when the downstream electron transfer chain 
is blocked. The block can occur either at the Qp site or further downstream at the Qo site 
of complex III. Inhibition of the Qi site via antimycin A should result in an increase of 
ROS generation via complex II under these conditions. This will not occur immediately 
as antimycin A will also induce superoxide at the Qo site of complex III. More 
importantly, inhibitors of the dicarboxylate binding site will hinder ROS production at 
complex II. With respect to this, oxaloacetate can act as a physiological suppressor or 
regulator of the ROS generation via complex II. In contrast, Qp site inhibitors will induce 
ROS generation at low succinate concentrations. A high succinate concentration and 
elevated complex II activity will suppress ROS generation from FAD, but induce 
superoxide production at complex I due to reverse electron transfer. The activities of 
complexes III and IV are required for the generation of a high membrane potential that 
is necessary for ROS via reverse electron transfer. This has not been considered in recent 
publications challenging the existence of a reverse electron transfer from complex II into 
complex I (Moreno-Sanchez et al., 2013; Ralph et al., 2011). ROS production under these 
conditions is therefore not only hindered by both classes of complex II inhibitors, but 
also by uncouplers, ionophores and complex I inhibitors. In addition, complex III 
inhibitors, which consist of stigmatellin, myxothiazol, or antimycin A, will inhibit 
succinate-dependent ROS via reverse electron transfer due to the membrane potential 
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collapsing upon complex III inhibition. Inhibition via antimycin A will however, increase 
superoxide generation at the Qo site. The overall ROS release from isolated mitochondria 
may appear almost unchanged, yet the ROS production is shifted from complex I to 
complex III. Both classes of complex II inhibitors will increase superoxide production at 
the Qo site of complex III when the Qi site is blocked and when succinate is the main 
substrate. Under these specific conditions, an intermediate succinate 
concentration/complex II activity results in an intermediate reduction of the Q-pool, 
favouring superoxide generation via complex III (Drose & Brandt, 2008).    
 
7. Cell death induction via complex II is mediated by cardiolipin level 
In support of our model, modulating the cardiolipin level determined the sensitivity to 
cell death induction. Its increase reduced cell death (fig. 37d and e), while its reduction 
activated complex II for ROS formation and the demise of the cell (fig. 34, 35, 36). The 
binding of Ca2+ to cardiolipin has previously been implicated in ROS formation without 
the identification of a specific cellular process (Grijalba, Vercesi, & Schreier, 1999). 
Cardiolipin’s role in cell death has been acknowledged with both pro- and anti-survival 
functions depending on its subcellular localisation (Crimi & Esposti, 2011). It is a unique 
glycerol-based phospholipid composed of four acyl groups and two phosphate moieties. 
In contrast to other phospholipids, the acyl groups of mammalian cardiolipin are 
essentially restricted to linoleic acid, required for the optimal function of many enzyme 
complexes involved in oxidative phosphorylation (Degli Esposti, 2002; Schlame, Rua, & 
Greenberg, 2000). Cardiolipin is considered to be a specific constituent of mitochondria, 
synthesized within the inner mitochondrial membrane. It can exit the mitochondria and 
reach the plasma membrane in some models of apoptosis (Sorice et al., 2004), thus 
suggesting that its intracellular location is vibrant and not restricted within the organelle 
of its origin (Cristea & Degli Esposti, 2004).  
In addition to being present within the inner mitochondrial membrane, cardiolipin is 
also found in the outer membrane, which makes up approximately 4% of the lipid 
content of mammals, and at the contact sites connecting the outer membrane with the 
inner membrane (Schlame, 2008). Several other independent studies have suggested that 
cardiolipin has either survival- or death-supporting roles in cells (Schlame, 2008; Schug & 
Gottlieb, 2009). It can act as the mitochondrial receptor for BID (Lutter et al., 2000b), 
oligomerizes the multidomain proapoptotic BAK and BAX molecules (Kuwana et al., 
2002) and retains cytochrome c in the cristae of mitochondria from which it is released 
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upon oxidation (Kagan et al., 2005). One recent study observed that the reduction of 
cellular cardiolipin content to 25% of its normal level through targeting CLS1 led to an 
increased sensitivity for apoptosis (Choi et al., 2007), while another publication with a 
more modest reduction of the lipid observed the opposite cellular effect (Z. Huang et al., 
2008). In both experiments stable cell clones were used, which could have introduced a 
selection bias. Mutations in tafazzin (Taz1p), a cardiolipin transacylase, have been shown 
to cause the X-linked Barth syndrome.  Such cells show a reduced apoptosis in the type 
II response to Fas receptor activation (Gonzalvez et al., 2008). However, these cells still 
contain cardiolipin as Taz1p only chemically modifies the lipid.  
Within the mitochondria, the effects of cardiolipin deficiency extend beyond 
bioenergetics to decreased mitochondrial protein import and agitation of mitochondrial 
fusion (Gebert et al., 2009; F. Jiang et al., 2000; Joshi, Thompson, Fei, Huttemann, & 
Greenberg, 2012). The harmful effects of cardiolipin deficiency outside the mitochondria 
include perturbation of cell integrity and high osmolarity glycerol signaling pathways as 
well as decreased vacuolar function (S. Chen, Tarsio, Kane, & Greenberg, 2008; Zhong, 
Gvozdenovic-Jeremic, Webster, Zhou, & Greenberg, 2005; Zhong, Li, Gvozdenovic-
Jeremic, & Greenberg, 2007; Zhou, Zhong, Li, & Greenberg, 2009). Disruption of 
cardiolipin synthesis has long been associated with aging and has been found to decrease 
the durability of yeast cells (Paradies, Petrosillo, Paradies, & Ruggiero, 2010; Zhou et al., 
2009). The significance of cardiolipin in human health is apparent from clinical findings 
that disruption of cardiolipin metabolism leads to the life-threatening Barth syndrome. In 
addition to cellular functions, cardiolipin is intricately involved in cellular metabolism 
(fig. 48). It interacts with components of the electron transport chain and is required for 
stabilization of electron transport chain supercomplexes and for ideal respiratory control 
(Bazan et al., 2013; K. Pfeiffer et al., 2003; M. Zhang, Mileykovskaya, & Dowhan, 2002, 
2005). Disturbance in iron-sulfur (Fe-S) biogenesis has been reported in cardiolipin-
deficient yeast cells, which suggests that iron homeostasis as well as enzymatic activities 
requiring Fe-S cofactors are dependent on cardiolipin biosynthesis (Patil, Fox, Gohil, 
Winge, & Greenberg, 2013).      
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Cardiolipin is also required for the transport of metabolites for energy metabolism by 
carrier proteins (Bisaccia & Palmieri, 1984; Fiermonte, Dolce, & Palmieri, 1998; 
Hoffmann, Stockl, Schlame, Beyer, & Klingenberg, 1994; F. Jiang et al., 2000; 
Kadenbach, Mende, Kolbe, Stipani, & Palmieri, 1982; Lange, Nett, Trumpower, & 
Hunte, 2001; Sedlak & Robinson, 1999). It is also required for enzymes in the carnitine 
shuttle (Noel & Pande, 1986; Pande, Murthy, & Noel, 1986). Additionally, evidence has 
shown that cardiolipin may also be required for cellular metabolism outside of the 
mitochondria. It is present in the membrane of peroxisomes (Zinser et al., 1991) and may 
affect β-oxidation and other metabolic activities of this organelle. The role of cardiolipin 
in mitochondrial protein import is a potential mechanism underlying the metabolic 
defects associated with cardiolipin deficiency and that defects in these functions may be 
Fig. 48. Functions of cardiolipin (CL) in metabolic pathways. Cardiolipin is most abundant in the inner 
membrane and is also present in the outer membrane of the mitochondria. It is required for activities of 
transporters and electron transport chain enzymes and for stabilization of electron transport supercomplexes. Loss 
of cardiolipin results in disruption of Fe-S biogenesis and decreased activity of Fe-S enzymes in the TCA cycle, 
electron transport, and other pathways. The mechanism linking cardiolipin and Fe-S biogenesis is unknown. It is 
possible that import of specific proteins required for Fe-S synthesis is defective in cardiolipin-deficient cells 
because it is required for the import of proteins through mitochondrial import complexes (TOM, SAM, and TIM). 
Cardiolipin is also present in the membrane of the peroxisome, an organelle that carries out β-oxidation of fatty 
acids, ether lipid synthesis and reactions of the glyoxylate cycle. The process by which cardiolipin is transported 
from the mitochondria to peroxisomes is unclear, but may involve mitochondria derived vesicles (MDVs). Acyl 
CoA produced by β-oxidation of long chain fatty acids in peroxisomes is transported to the mitochondria through 
the carnitine shuttle. The acyl CoA is transferred to carnitine in the peroxisome by carnitine acyltransferase (Cat). 
Acylcarnitine from the peroxisome crosses the mitochondrial membrane, facilitated by the carnitine/acylcarnitine 
translocase (Crc). Cardilipin is necessary for efficient activity of both mitochondrial carnitine enzymes in 
mammalian cells (Raja & Greenberg, 2014).   
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the physiological alterations that account for the vast discrepancy of clinical phenotypes 
seen in Barth syndrome patients. 
Cardiolipin is abundant in the membranes of bacteria, mitochondria, as well as 
hydrogenosomes, membrane-bound organelles in a number of anaerobic eukaryotes, and 
play a role in ATP synthesis via the generation of a transmembrane electrochemical 
gradient (Daum, 1985; de Andrade Rosa et al., 2006; Dowhan, 1997). The link cardiolipin 
has with energy transducing membranes is consistent with its crucial role in cellular 
bioenergetics. The physical interaction between cardiolipin and mitochondrial respiratory 
chain complexes as well as other membrane components helps in the development of a 
lipid scaffold, which functions to stabilize and increase the enzymatic activity of 
interacting proteins (Beyer & Klingenberg, 1985; Beyer & Nuscher, 1996; Sedlak & 
Robinson, 1999). Based on this, it is not surprising that disruption of cardiolipin 
synthesis affects the structure and function of mitochondrial respiratory chain complexes 
and transporters. In conclusion, the effects that are seen upon the disruption of 
cardiolipin levels in the mitochondrial respiratory chain extend beyond structure and 
function and can also be due to other effects of the lipid in cellular metabolism outside 
of the mitochondria. 
 
8. Cardiolipin and the binding of tBid in apoptotic associated 
processes   
Following death receptor engagement, the activation of caspase-8 results in the 
cleavage of Bid,  BH3-only protein, to a shortened form known as tBid (Gross et al., 
1999). tBid translocates to the OMM and induces the oligomerization of Bax and/or 
Bak, which results in OMM permeabilization. Immunoelectron microscopy suggested 
that tBid is focused, in a cardiolipin-dependent manner, to mitochondrial contact sites (J. 
Liu, Weiss, Durrant, Chi, & Lee, 2004; Lutter et al., 2000a). The binding of tBid to 
cardiolipin-enriched contact sites of the mitochondria was shown to at least require α-
helices 4-6 of tBid and was completely independent of the BH3 domain (α-3 helix) 
(Gross et al., 1999). Additionally, tBid binding to the mitochondria was significantly 
decreased in mitochondria from cells deficient in cardiolipin (Lutter et al., 2000a). 
However, it has been shown that mitochondria isolated from lymphoblastoid cells 
derived from Barth syndrome patients, which are devoid of tafazzin activity and 
therefore deficient in mature CL, effectively bind tBid (Gonzalvez et al., 2008). In this 
scenario, the levels of monolyso-CL (MLCL), or immature cardiolipin, which are 
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increased in Barth syndrome lymphoblastoid cells, are sufficient at directing tBid 
translocation to the OMM (Esposti, Cristea, Gaskell, Nakao, & Dive, 2003; Sandra et al., 
2005; Sorice et al., 2004). The interaction of tBid with the OMM may involve the 
negatively charged headgroup of CL and basic residues in helices 4-6 (J. Liu et al., 2005), 
but may also involve entry into the bilayer (Van Mau, Kajava, Bonfils, Martinou, & 
Harricane, 2005). Other phospholipids including phosphatidlycholine (PC) (Garofalo et 
al., 2003), phosphatidylglycerol (PG) and phosphatidylethanolamine (PE), allow tBid 
incorporation (Esposti, Erler, Hickman, & Dive, 2001). 
The binding of tBid to mitochondria also functions in other apoptotic associated 
processes, including cristae remodelling (Frezza et al., 2006) and mitochondrial 
fragmentation (Youle & Karbowski, 2005). Cristae remodelling during apoptosis, which 
facilitates the release of cytochrome c, is regulated by the rhomboid protease PARL and 
the dynamin-related protein OPA1 (Cipolat et al., 2006; Frezza et al., 2006; Yamaguchi et 
al., 2008). Mitochondrial PARL actively cleaves the OPA1 protein, which creates a 
soluble group of shortened OPA1 in the intermembrane space. Soluble OPA1 is crucial 
for the anti-apoptotic effects of PARL because it maintains the tailback configuration of 
cristae and the compartmentalization of cytochrome c (Cipolat et al., 2006; Frezza et al., 
2006; Gottlieb, 2006). The long and short forms of the OPA1 form heter-oligomers 
which are disrupted soon after the binding of tBid to the mitochondria enabling 
cytochrome c movement from the cristae (Cipolat et al., 2006; Frezza et al., 2006; 
Gottlieb, 2006). 
 
9. Cardiolipin and caspase-8 
As detailed in the introduction, there are two separate signalling pathways leading to 
apoptotic cell death: the intrinsic pathway and the extrinsic pathway. The intrinsic 
pathway is activated from inside the cell by the pro-apoptotic members of the Bcl-2 
protein family. The extrinsic pathway is activated from outside the cell via pro-apoptotic 
ligands and involves the clustering of death receptors at the cell surface. Pro-caspase-8 is 
known to be mainly localized within the cytosol, but has also been shown to be loosely 
associated with the outer mitochondrial membrane (Stegh et al., 2002; Stegh et al., 2000).  
Recent studies have demonstrated that Fas receptor activation induced the 
translocation of active caspase-8 to the mitochondria, a step dependent on the presence 
of mature cardiolipin in the outer mitochondrial membrane (Gonzalvez et al., 2008). The 
translocation of caspase-8 to the mitochondria was compulsory for efficient caspase-8 
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processing as well as activation. The role for cardiolipin in these processes was identified 
by using immortalized lymphoblastoid cells from Barth syndrome patients. As mentioned 
before, Barth syndrome is a genetic disorder characterized by mutations in the tafazzin 
gene, a transacylase responsible for catalysing the transfer of an unsaturated acyl chain 
from PC to MLCL, immature cardiolipin. The loss of tafazzin function results in a 
decrease of total cardiolipin level, a reduction in mature cardiolipin, and an increase in 
MLCL. Barth syndrome lymphoblastoid cells displayed strong resistance to death 
receptor activation (Gonzalvez et al., 2008). Treatment of mitochondria isolated from 
Barth syndrome lymphoblasts with recombinant tBid still induced Bak oligomerization 
and cytochrome c release (Gonzalvez et al., 2008). As mentioned previously, the abilities 
of tBid and Bax to promote OMM permeabilization and cytochrome c release in Barth 
syndrome lymphoblastoid cells may be due to increased amounts of MLCL. Upon 
further investigation, it was found that Fas-stimulated Barth syndrome-derived cells had 
substantial inhibition of Bid cleavage, suggesting a defect in caspase-8 activation. 
Additionally, isolated mitochondria from tafazzin-knockdown HeLa cells showed 
significantly reduced levels of mature, processed caspase-8 and Bid (Gonzalvez et al., 
2008). Based on this, mature cardiolipin must be essential for the activation of caspase-8 
during Fas-induced apoptosis in lymphoblastoid and HeLa cells.              
 
10. Förster resonance energy transfer (FRET) assay 
FRET between two fluorophores is observed over distances of less than 10 nm or 100 
angstroms (Förster, 1948). Because FRET efficiency is heavily dependent on the distance 
between the FRET pair and the relative orientation of the fluorophores, FRET can be 
used to detect changes in protein conformations as well as protein-protein interactions. 
On the other hand, the sensitive nature of FRET presents technical challenges to its 
measurement, particularly when applied to complicated experimental systems that are not 
well suited for detecting FRET.  
FRET between two fluorescent proteins (FP-FRET) has been widely incorporated 
into two general types of living-cell-based assays, with each presenting unique challenges. 
The first strategy incorporates measurement of intermolecular FRET between 
fluorescent proteins conjugated to opposing ends of a protein or an environmentally 
sensitive protein domain (Honda et al., 2001; Miyawaki et al., 1997; Pearce et al., 2000; 
Ting, Kain, Klemke, & Tsien, 2001; J. Zhang, Ma, Taylor, & Tsien, 2001). Although this 
strategy has proven to be quite successful, fluorescent proteins in these assays introduce 
130 
 
unique challenges related to the properties of fluorescent proteins themselves. The large 
size of fluorescent proteins (4.2 nm long by 2.4 nm diameter barrel) occupies much of 
the valuable FRET distance (Ormo et al., 1996; Patterson, Piston, & Barisas, 2000), 
resulting in FRET efficiencies being less than 30%. Fluorescent proteins come in a wide 
range of brightness. The two most commonly used ones are eCFP as the donor FP and 
eYFP as the acceptor FP. eCFP is fivefold less bright than eYFP. The spectra of 
fluorescent proteins are also quite broad and greatly overlapping, and this deters both 
exclusive donor excitation as well as the separation of donor and acceptor emissions. 
These are factors that severely limit the amount of contrast that can be obtained using an 
intramolecular FRET based strategy (Swedlow, Hu, Andrews, Roos, & Murray, 2002). 
These complications are also applicable to the use of intermolecular FRET to measure 
protein-protein interactions between two FP-labeled proteins. The oligomeric nature of 
FPs add to the complications associated with intermolecular FRET studies and makes 
things more difficult to interpret. For example, even the most commonly used FPs such 
as eCFP and eYFP are weakly dimeric (Zacharias, Violin, Newton, & Tsien, 2002), while 
non-Aequorea derived FPs, including dsRed and HcRed, tend to be obligate oligomers 
(Gurskaya et al., 2001; Wall, Socolich, & Ranganathan, 2000). This makes FRET 
experiments integrating FPs more difficult to design and execute.      
FRET constructs of SDHB and SDHD were used in our study to monitor the 
dissociation of complex II subunits for cell death induction. Based on points made 
previously, luckily, the two subunits of complex II are very close in proximity to one 
another as the N-terminus of SDHB is only eight angstroms away from the C-terminus 
of SDHD, so these two points of fusion were incorporated and used with much success 
(fig. 5, fig. 6a).  The possibility that the fluorescent proteins themselves are effecting a 
spurious interaction between the subunits was discounted because: (i) In the absence of 
correct assembly, SDHB, SDHC and SDHD are degraded (Lemarie et al., 2011). Any 
potential EYFP-CFP mediated complex between the fusion proteins with SDHB and 
SDHD, in the absence of productive complex II formation, would therefore be expected 
to be degraded, which is not what we see. (ii) The presence of SDH-specific chaperone 
prohibitin restores the FRET signal (fig. 10). Taken together, these results support the 
use of the FRET constructs as a non-invasive way to monitor the 
association/dissociation of the catalytic dimer with the membrane-anchoring subunits.  
In contrast to the instability of the components of complex II, when one of them is 
missing (Lemarie et al., 2011), sub-complex of SDHA and SDHB seems to be stable, 
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even during cell death induction (fig. 44). Hence, the complex behaves differently when 
its assembly is disturbed or when it specifically releases the SDHA/SDHB subcomplex 
for cell death induction. 
In addition to the disintegration for cell death induction we also observed an increase 
in FRET during non-lethal stress such as transfection and prolonged incubation after 
exposure to the confocal microscope potentially induced to counteract the stress (fig. 9). 
This indicates that the disintegration and assembly of complex II is dynamic and 
responds differentially to lethal and manageable cellular stress.  
 
11. Mitochondrial permeability transition pore, activated by calcium? 
The PT-pore has been regarded, in the pathological scenarios mentioned above, as the 
target for increased mitochondrial Ca2+ as its inhibition by bongkrekic acid and 
cyclosporin A results in a reduction of Ca2+-induced cell death (Lemasters, Theruvath, 
Zhong, & Nieminen, 2009). However, in the absence of a generally accepted structure for 
the PT-pore complex, how directly or indirectly this is accomplished is unknown and the 
identification of alternative targets for mitochondrial Ca2+ such as complex II is critical to 
explain the effects of this ion. 
In the PT-pore, large conductance permeability transition pores open that make the 
mitochondrial inner membrane abruptly permeable to all solutes of molecular weight up 
to approximately 1500 Da (Bernardi & Forte, 2007; Hunter, Haworth, & Southard, 1976; 
J. S. Kim, He, & Lemasters, 2003). In addition to Ca2+, numerous reactive chemicals, 
along with oxidative stress, induce opening of the PT pore, whereas cyclosporine A 
(CsA) and a basic pH more than 7, block the opening. As a consequence, mitochondrial 
depolarization, uncoupling of oxidative phosphorylation and large amplitude 
mitochondrial swelling triggered by colloid osmotic forces occur. 
As mentioned in the introduction, the composition of the PT pore remains 
questionable. In one particular model, the adenine nucleotide transporter (ANT) forms 
the inner membrane, the voltage dependent anion channel (VDAC) forms the outer 
membrane, the CsA binding protein cyclophilin D (CypD) forms the mitochondrial 
matrix, and other proteins form PT pores (Crompton, Virji, Doyle, Johnson, & Ward, 
1999; Halestrap & Brenner, 2003). More recent genetic knockout studies have challenged 
the validity of this model by showing that the mitochondrial permeability transition 
(MPT) still occurs in mitochondria deficient in ANT, VDAC, and CypD, although some 
properties are changed (Bernardi & Forte, 2007; Juhaszova et al., 2008; Kokoszka et al., 
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2004; Krauskopf, Eriksson, Craigen, Forte, & Bernardi, 2006). For example, in ANT 
deficient mitochondria, the ANT ligand, atractyloside, no longer stimulates PT pore 
opening, whereas in CypD-deficient mitochondria, MPT induction requires a higher level 
of Ca2+ and is not inhibited by CsA. 
An unconventional model proposes that damage by reactive chemicals, oxidative 
stress, thiol crosslinking and other disruptions cause misfolding of integral membrane 
proteins (He & Lemasters, 2002). Misfolding leads to the formation of hydrophilic 
surfaces that face the lipid bilayer, a thermodynamically unfavourable condition. 
Accordingly, misfolded membrane proteins collect at these hydrophilic surfaces to create 
aqueous transmembrane channels, which are budding PT pores. To prevent calamitous 
permeabilization and uncoupling of oxidative phosphorylation, CypD and other 
molecular chaperones acting from both sides of the inner membrane block conductance 
through these budding PT pores. CypD, similar to other cyclophilin proteins, is a cis-
trans peptidyl proline isomerase, a foldase, which may have a physiological role of 
encouraging refolding of the misfolded proteins back to their innate state (Waldmeier, 
Zimmermann, Qian, Tintelnot-Blomley, & Lemasters, 2003). CypD binding also makes 
PT pores sensitive to reversible Ca2+-induced opening, an action inhibited by CsA. When 
emerging PT pores formed by misfolded protein aggregates exceed the content of 
chaperones available to block their conductance, pore opening occurs in an unregulated 
manner. Such unregulated pore opening is insensitive to CsA inhibition and no longer 
requires Ca2+ to arise. Additionally, there are other poorly characterized chaperones 
involved in regulating conductance via emerging PT pores. Indirect evidence reveal that 
the Rieske iron sulphur protein (RISP) along with the heat shock protein Hsp27 may take 
part in regulating conductance of the PT pore (He & Lemasters, 2003, 2005). In 
particular, dephosphorylation of RISP may be a significant event promoting pore 
opening. 
In protein misfolding, any membrane protein may contribute to pore formation, but 
abundance and tendency to misfold determine the chance of a particular membrane 
protein to contribute to PT pore activation. As the most abundant inner membrane 
protein on a molar basis, ANT is often targeted as being the cause of misfolding due to 
damage. ANT experiences large conformation changes, and the atractyloside-stabilized 
conformation appears to be specifically more prone to damage resulting in misfolding 
and PT pore formation (Leung & Halestrap, 2008). Other proteins can also misfold and 
contribute to PT formation. For example, evidence suggests that other anion 
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transporters, such as the aspartate-glutamate and phosphate carriers, participate in the 
development of large conductance pores (Dierks, Salentin, Heberger, & Kramer, 1990; 
Dierks, Salentin, & Kramer, 1990; Leung & Halestrap, 2008; Leung, Varanyuwatana, & 
Halestrap, 2008; Schroers, Kramer, & Wohlrab, 1997). Because PT pore activation can 
occur from these membrane proteins, MPT can still occur in ANT-deficient 
mitochondria (Kokoszka et al., 2004). 
   The misfolded protein model would explain why completely exogenous pore-
forming peptides like mastoparan and alamethicin form CsA-sensitive PT pores (He & 
Lemasters, 2002; D. R. Pfeiffer, Gudz, Novgorodov, & Erdahl, 1995). Chaperones 
recognize and regulate mastoparan and alamethicin pores in the same way as endogenous 
PT pores. When pores formed by exogenous pore forming peptides are at low 
concentration, chaperones block their communication, but these structured pores open 
in response to increased matrix Ca2+ in a CsA-sensitive fashion. When the concentration 
of exogenous pore formers exhausts the supply of chaperones however, constitutively 
open CsA-insensitive pores form even in the absence of Ca2+. This result for mastoparan 
and alamethicin has been confirmed (He & Lemasters, 2002). Additionally, based on the 
misfolded protein model, mitochondria from CypD knockout mice are desensitized to 
Ca2+ induction of the MPT and require much higher Ca2+ to induce swelling of the 
mitochondria (Basso et al., 2005), consistent with the suggested role of CypD as the Ca2+ 
sensor of the MPT. 
Dynamic inspection of mitochondrial swelling after MPT proposes that the 
conductances of individual pores are heterogeneous (Massari, 1996). This disparity is 
consistent with a variable protein composition for individual PT pores. Protein 
misfolding promoting PT pore formation should not be equated with irreversible protein 
denaturation. Reversal of protein misfolding may be an important physiological function 
of CypD. When ANT is the primary misfolded membrane protein contributing to PT 
pore formations, bongkrekic acid via induction of the more stable ANT m-conformation 
may also be effective in the reversal of misfolding and pore opening (Halestrap & 
Brenner, 2003).   
Our data indicate that the cyclophilin D-sensitive PT-pore is eventually activated for 
cell death by the disintegration of complex II. This protein structure has been implicated 
in necrotic and apoptotic cell death (Baines et al., 2005; Nakagawa et al., 2005), in line 
with our observation that both necrosis and apoptosis are caused by arsenic trioxide, 
ionomycin, and CLS1 knockdown (fig. 12, 19, 36). PT-pore activation by Ca2+ has been 
134 
 
described to require additional stimuli for full activation but it was later recognized that a 
substantive Ca2+ influx into mitochondria can suffice to generate ROS and activate the 
PT-pore (Giacomello, Drago, Pizzo, & Pozzan, 2007; Lemasters et al., 2009; Peng & Jou, 
2010). While formally we cannot exclude additional, parallel pathways such as the 
activation of Bax/Bak or the involvement of other complexes of the respiratory chain 
(Ricci, Waterhouse, & Green, 2003; Scorrano et al., 2003), we observed that complex II 
activation by Ca2+ caused ROS formation and the specific complex II inhibitors 3-NP 
and malonate reduced ROS formation and cell death by ionomycin, arsenic trioxide and 
CLS1 knock-down (Figures 13a and 13c, 24 and 25, 38 and 39). 
 
12. Several functions of calcium in PT-dependent cell injury 
Numerous chemicals and radicals stimulate MPT. Normally the effect of these 
inducers is to decrease the threshold amount of Ca2+ required for the opening of the PT 
pore. In pathological scenarios where MPT contributes to cell killing, Ca2+ may have 
several roles. Primarily, increased Ca2+ alone along with its uptake into the mitochondria 
may lead to the onset of MPT. Secondly, other stressors may decrease the threshold for 
Ca2+- induced MPT so that Ca2+ is not changed but still permissive for the onset of MPT. 
Finally, stressors along with increased Ca2+ may act interdependently for MPT induction. 
 
 
12.1 Calcium overload induces MPT and cell death 
Increased Ca2+ alone can cause MPT and cell death, supported by experiments using 
Br-A23187, a Ca2+ ionophore (Qian, Herman, & Lemasters, 1999). In cultured rat 
hepatocytes, Br-A23187 leads to rapid mitochondrial depolarization and inner membrane 
permeabilization, shown by confocal microscopy from the mitochondrial release of 
tetramethylrhodamine methylester (TMRM), an indicating fluorophore, and the 
mitochondrial uptake of calcein, a 623 Da fluorophore normally impermeable to the 
inner membrane. Following induction of MPT via Br-A23187, necrotic cell death occurs 
from depletion of ATP. Necrosis is prevented if an alternative source of ATP comes 
from glycolysis. Caspase-dependent apoptosis then occurs secondary to the release of 
cytochrome c and other pro-apoptotic factors from the mitochondrial intermembrane 
space following rupture of the outer membrane. CsA prevents both necrosis as well as 
apoptosis induced by Br-A23187, confirming the important role of MPT in both cell 
death phenotypes. Likewise, following MPT-dependent ischemia-reperfusion injury, the 
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presence or absence of ATP determines whether apoptosis or necrosis occurs (J. S. Kim, 
Qian, & Lemasters, 2003). The term necrapoptosis describes death processes that begin 
with a common death signal or toxic stress, progressed by shared pathways, and then 
climax in either failure of the plasma membrane due to apoptosis or necrosis, dependent 
on various modifying factors (Lemasters, 1999, 2007). 
 
12.2 Calcium and Reye’s syndrome 
Reye-related syndromes are often fatal illnesses displaying symptoms of high fever, 
frenzied hepatic failure and encephalopathy, global brain dysfunction, in children and 
sometimes adults, associated with ingestion of aspirin, valproic acid, and other toxicants 
(Partin, Schubert, & Partin, 1971). Electron microscopy of liver and brain tissues from 
these patients reveals large-amplitude mitochondrial swelling, suggesting an onset of 
MPT. In isolated mitochondria from the liver, Reye-related toxicants do not induce MPT 
by themselves, but instead lower the Ca2+ threshold for MPT (Trost & Lemasters, 1996). 
The active metabolite of aspirin, salicylate, is directly cytotoxic to cultured rat 
hepatocytes (Trost & Lemasters, 1997). This cytotoxicity is blocked by CsA and confocal 
microscopy from this study reveals that CsA-sensitive mitochondrial depolarization and 
inner membrane permeabilization occur after exposure to salicylate. The tolerant role of 
Ca2+ in salicylate toxicity is shown by cytoprotection with the Ca2+ channel blocker, 
known as verapamil, an effect that is associated with decreased mitochondrial free Ca2+ 
measured by confocal microscopy using the Ca2+ indicator, Rhod-2. Likewise, in support 
of Ca2+’s role, increased extracellular Ca2+ promotes salicylate-induced cell death. 
Cooperation between salicylate and Ca2+ may help to explain the idiopathic nature of 
Reye’s syndrome. The overwhelming majority of individuals using aspirin experience no 
liver or brain toxicity, however, children with a prodromal viral illness may get higher 
mitochondrial Ca2+ loading, making them more vulnerable to MPT-dependent illness 
following exposure to salicylate, valproic acid and other Reye-related toxicants (Trost & 
Lemasters, 1997).          
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13. Role of calcium in oxidative stress-induced injury 
During oxidative stress and ischemia-reperfusion, the short-chain hydroperoxide, tert-
butylhydroperoxide (TBH), comparable to lipid hydroperoxides, forms. TBH is 
detoxified to t-butanol with oxidation of glutathione, NADPH, and NADH by the 
concerted action glutathione peroxidase, glutathione reductase, and the mitochondrial 
NADP/NAD transhydrogenase (Bindoli, Fukuto, & Forman, 2008; Sies & Moss, 1978). 
In isolated mitochondria, TBH is a potent inducer of MPT (Gunter & Pfeiffer, 1990). In 
cultured hepatocytes, TBH comparably induces MPT-dependent cell killing (Imberti, 
Nieminen, Herman, & Lemasters, 1993). Following TBH, sequential mitochondrial 
NAD(P)H oxidation occurs, along with increased mitochondrial free Ca2+ concentration, 
mitochondrial depolarization and inner membrane permeabilization, monitored with 
autofluorescence, Rhod-2, dichlorofluorescein, TMRM and calcein, respectively (fig. 49) 
(Byrne et al., 1999; Nieminen et al., 1997; Nieminen et al., 1995). These events lead up to 
ATP depletion and cell death. Chelation of intramitochondrial Ca2+ with BAPTA-AM 
prevents the increase of mitochondrial free Ca2+ and blocks increased mitochondrial 
ROS formation, but not early oxidation of mitochondrial NAD(P)H. By contrast, the 
inhibition of ROS generation with desferal or diphenylphenylene diamine delays, without 
blocking, increased mitochondrial Ca2+ following TBH. Therefore, NAD(P)H oxidation 
leads to mitochondrial Ca2+ loading, which promotes ROS formation and the MPT. Ca2+ 
loading of isolated mitochondria promotes ROS formation, though the mechanism 
remains unclear (Chacon & Acosta, 1991). Increased mitochondrial Ca2+ and ROS 
generation act simultaneously to induce MPT in this model of oxidative stress.        
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Fig. 49. The onset of MPT following oxidative stress in hepatocytes. Following exposure to TBH in 
hepatocytes, a cascade of sequences occurs: the oxidation of GSH and NAD(P)H (autofluorescence), 
increased mitochondrial free Ca2+ concentration, detected using Rhod2, increased mitochondrial ROS 
formation, detected using dichlorofluorescein or DCF, the MPT with inner membrane permeabilization, 
detected using calcein, and mitochondrial depolarization, detected using TMRM, and cell death. The MPT is 
prevented or delayed via the increased reduction of NAD(P)H with β-hydroxybutyrate (BHB), mitochondrial 
Ca2+ chelation with BAPTA, antioxidants (diphenylphenylene diamine or DPPD and desferal) and blockers 
of the MPT (trifluoperazine or TFZ and CsA). Adapted from (Byrne, Lemasters, & Nieminen, 1999; 
Nieminen, Byrne, Herman, & Lemasters, 1997; Nieminen, Saylor, Tesfai, Herman, & Lemasters, 1995)     
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14. Complex II in disease 
One of the most fundamental processes of life consists of mitochondrial function and 
oxidative phosphorylation via the respiratory chain. Deficiencies in mitochondrial 
function and in the activity of the many protein complexes of the respiratory chain have 
been associated with a wide variety of clinical conditions (Schapira, 2012). Complex II 
deficiencies with a defined genetic basis have been found in only a limited number of 
diseases, including the hereditary paraganglioma-pheochromocytoma tumor syndrome, a 
specific group of renal cell carcinomas, gastrointestinal stromal tumors (GIST) mainly 
associated with Carney-Stratakis syndrome, a subset of Leigh syndrome conditions, and 
recently in infantile leukoencephalopathy associated with mutations of the complex II-
specific assembly factor SDHAF1. 
Complex II of the respiratory chain, also known as succinate dehydrogenase (SDH), is 
located at the intersection of the tricarboxylic acid (TCA) cycle and mitochondrial 
oxidative phosphorylation. With the combination of these two functions, complex II is at 
the centre of the two essential energy production processes of the cell. Complex II is a 
heterotetramer and all four protein subunits, SDHA, -B, -C and –D, have been 
associated with disease. Three recently identified complex II assembly factors, SDHAF1 
SDHAF2, and prohibitin (PHB) are also involved in disease when mutated, specifically 
infantile leukoencephalopathy for SDHAF1, head and neck paraganglioma for SDHAF2, 
and sporadic breast cancer and breast cancer susceptibility for prohibitin (Schapira, 2012; 
Tang, Zhao, Nie, Wang, & Guan, 2013; Webster et al., 2013) and although clearly 
essential to the normal functioning of complex II, their exact functions are still poorly 
defined. Despite the fact that these proteins are all associated with the same protein 
complex, mutations lead to obvious differences in clinical phenotype. The molecular 
basis for this clinical divergence is still unknown. 
Biochemical analyses have shown that mutations in complex II-related genes often 
result in the reduction or loss of a functional enzyme complex, which may result in either 
the accumulation of succinate (King, Selak, & Gottlieb, 2006) or the generation of ROS, 
as detailed in previous sections, due to the perturbation of the electron transport chain 
(T. Ishii et al., 2005; Slane et al., 2006). The loss of SDH may also ultimately lead to a 
limited capacity to utilize oxidative phosphorylation for ATP production (Cervera et al., 
2008; Favier et al., 2009).   
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15. Differentiating apoptosis from programmed necrosis 
As detailed in beginning sections of the introduction, there are clear differences 
between apoptosis and necrosis. The termination of organ function is affected not only 
by the quantity of cells undergoing programmed cell death, but also by the mechanistic 
pathway leading up to cell death. There are essentially three main mechanistic pathways 
of interest: extrinsic or death receptor-mediated apoptosis (Cabal-Hierro & Lazo, 2012), 
intrinsic or mitochondrial mediated apoptosis (Munoz-Pinedo, 2012), and programmed 
necrosis, including necroptosis or regulated necrosis (Baines et al., 2005; Hitomi et al., 
2008). 
Apoptotic cell death can be a response to nonlethal developmental programming. 
These cells have been programmed to disassemble their organelles, DNA, and proteins, 
and dispose them with minimal damage, as detailed in the introduction. The biochemical 
pathway that mediates apoptosis is made up of a series of evolutionarily conserved 
caspase cysteine proteases. Caspases are indirectly activated via the effects of 
mitochondrial localised Bcl-2 family members that are activated by intrinsic 
transcriptional and/or post-translational signals (Youle & Strasser, 2008). Apoptosis is 
conserved throughout eukaryotes as a means of removing cells without engendering 
inflammation that is normally induced via the degeneration of dead cells and tissue; its 
execution is heavily constrained and highly organised. 
Compared to apoptosis, programmed necrosis is much more collateral and 
disorganised. There is no developmental function present for programmed necrosis, 
which is a response to external stimuli. The crucial mechanistic feature of programmed 
necrosis is the opening of the mitochondrial permeability transition pores, resulting in 
the disruption of mitochondrial respiratory function. Programmed cell necrosis occurs as 
a consequence of ATP deficiency, in contrast to apoptosis, which requires 
mitochondrial-derived ATP in order to fuel the multiple processes leading to cell 
disassembly. The metabolic shutdown present in programmed cell necrosis does not 
allow for the orderly removal of cell organelles, resulting in inflammation. The 
inflammation process occurs due to the presence of cell debris and disrupts the normal 
functioning of tissues and organs. 
In this thesis project, we look at three main inducers of complex II dissociation and 
ultimately cell death: arsenic trioxide, mitochondrial calcium influx, and cardiolipin 
dependency. The difference in cell death responses from each inducer is shown towards 
the end of the results section (fig. 44-1).  
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Fig. 50. Signal cascade involving Ca
2+
, cardiolipin, complex II, ROS and the PT pore for cell death. Upon influx of Ca
2+
 
into the matrix of mitochondria the ions bind CL (left panel), which leads to its dissociation from complex II that releases the 
enzymatically active SDHA and SDHB subunits. As a result ROS are generated that activate the PT pore for cell death (right 
panel).   
Future Directions  
Ongoing investigations are looking at whether or not cell death induction via the 
inhibition of downstream complexes to complex II is mediated by its dissociation. The 
connection between other complexes of the respiratory chain, ROS generation, and 
ultimately cell death induction via complex II dissociation will help to inform whether 
the signalling pathway involving mitochondrial calcium influx and binding to cardiolipin 
is exclusive to complex II or if it occurs in other components of the respiratory chain as 
well.  This can be addressed by inhibiting other complexes, namely complexes I, III, and 
IV, using rotenone, antimycin A, and sodium cyanide respectively, thereby inducing cell 
death, and looking for the possible inhibition of this induced cell death by incorporating 
inhibitors of complex II dissociation and ROS generation, prohibitin and 3NP 
respectively.     
Our results and discussions lay out a signalling pathway from mitochondrial Ca2+ influx 
that targets cardiolipin, to complex II disintegration, ROS formation, and PT-pore 
activation for cell death (fig. 50). Our findings will lead to more specific interference 
options in the numerous pathological scenarios that are connected with massive 
mitochondrial Ca2+ influx.
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Appendix 1: Verification of cardiolipin overexpression  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a) b) 
Fig. A1-1 Overexpression of CL with CLS1 upregulation. Images of HeLa cells were taken using a 
Leica SP5 confocal microscope following the transient 24-hour post-transfection of pcDNA3 empty vector 
or CLS1 using human CLS1 cDNA and immunofluorescence staining of CL expression with human CL 
primary antibody and goat anti-human Alexa Fluor® 488 secondary antibody. a) Image shows Alexa 
Fluor® 488 stain of pcDNA3 transfected HeLa cells. b) Image shows Alexa Fluor® 488 stain of CSL1 
transfected HeLa cells. 
Fig. A1-2 Overexpression of mitochondria localized CL with CLS1 upregulation. Images of 
HeLa cells were taken using a Leica SP5 confocal microscope following the transient 24-hour post-
transfection of pcDNA3 empty vector or CLS1 using human CLS1 cDNA and immunofluorescence 
staining of CL expression with human CL primary antibody and goat anti-human Alexa Fluor® 488 
secondary antibody in combination with TMRE stain. a) Image shows Alexa Fluor® 488 stain of 
pcDNA3 transfected HeLa cells. b) Image shows TMRE stain of pcDNA3 transfected HeLa cells c) 
overlay of panels a and b d) Image shows Alexa Fluor® 488 stain of CLS1 transfected HeLa cells. e) 
Image shows TMRE stain of CLS1 transfected HeLa cells f) overlay of panels d and e. 
a) b) c) 
d
) 
e) f) 
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Appendix 2: Verification of cytochrome c release 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. A2 Release of cytochrome c (CYCS) from the mitochondria upon As2O3 treatment of HeLa 
cells. Cells were treated with 1 M NaOH (As2O3 solvent) control or 10 µM of As2O3 for 20 hours prior to 
harvest and separation of a) cytosolic and b) cellular pellet fractions via resuspension in cell lysis buffer and 
high-speed centrifugation. GAPDH and COX IV were used as loading controls for the cytosolic and cellular 
pellet fractions respectively.   
   -                +                 
1 M NaOH 10 µM 
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b) 
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Appendix 3: FRET decrease correlated with [As2O3] 
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Fig. A3 Percent decrease in FRET efficiency ratio and complex II dissociation is correlated with As2O3 
concentration. HeLa cells were treated with NaOH, the solvent for the arsenic trioxide drug as a control, and 
compared with HeLa cells treated with 5 µM or 10 μM arsenic trioxide for 15 hours.  An initial calculation for 
FRET efficiency was made in triplicate for both sets prior to treatment and an end calculation for FRET 
efficiency was made in triplicate for both sets 15 hours post treatment.  The two sets of measurements were used 
to calculate the percent decrease in FRET efficiency ratio with a positive value representing a percent decrease and 
a negative value representing a percent increase. 
10 μM As2O3      -                 +  5 μM As2O3                 -                 +  
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Appendix 4: 3NP does not inhibit complex II dissociation 
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Fig. A4 Nitropropionic Acid (3NP) fails to inhibit the dissociation of complex II induced by treatment 
with the anti-cancer compound arsenic trioxide (As2O3). HeLa cells were treated with NaOH, the solvent 
for the As2O3 drug as a control, and compared with HeLa cells treated with 10 μM As2O3 for 15 hours with 
and without 1 mM 3NP treatment.  An initial calculation for FRET efficiency was made in triplicate for all four 
sets prior to treatment and an end calculation for FRET efficiency was made in triplicate for all four sets fifteen 
hours post treatment.  The two sets of measurements were used to calculate the percent decrease in FRET 
efficiency ratio with a positive value representing a percent decrease and a negative value representing a percent 
increase. 
10 μM As2O3                       -        -    +         +  
      1 mM 3NP              -                             +                   -                            +  
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Appendix 5: RR inhibits complex II dissociation 
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Fig. A5 Ruthenium red inhibits the dissociation of complex II induced by treatment with the anti-cancer 
compound arsenic trioxide (As2O3). HeLa cells were treated with NaOH, the solvent for the As2O3 drug as a 
control, and compared with HeLa cells treated with 10 μM As2O3 for 15 hours with and without 5 μM ruthenium 
red treatment.  An initial calculation for FRET efficiency was made in triplicate for all four sets prior to treatment 
and an end calculation for FRET efficiency was made in triplicate for all four sets fifteen hours post treatment.  The 
two sets of measurements were used to calculate the percent decrease in FRET efficiency ratio with a positive value 
representing a percent decrease and a negative value representing a percent increase. 
10 μM As2O3                                 -                        -                        +                      +  
5 μM Ruthenium Red                   -                     +                        -                       +  
** 
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Appendix 6: Validation of the designed FRET constructs 
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Fig. A6 Functionality of FRET constructs in HeLa cells. HeLa cells were co-transfected with both 
FRET constructs, treated as indicated, and monitored over a 13.6-hour period. The left plots show 
signals from the different channels, YFP (green, 514 nm), CFP (red, 458 nm), FRET (blue, resulting 
from excitation at the donor max and reading at the acceptor), and FRET efficiency (black, right panels) 
over time in sec x1,000. HeLa cells monitored without treatment (top panels), with addition of 1 M 
NaOH As2O3 solvent (middle panels), or with addition of 10 µM As2O3 (bottom). 
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Appendix 7: Calcein verification of PT-pore activation 
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Fig. A7 Calcein-based transition pore assay verifies activation of the PT-pore upon arsenic trioxide and 
ionomycin treatment in Hela cells. HeLa cells were treated with 1 M NaOH (untreated arsenic trioxide solvent) 
or DMSO (untreated ionomycin solvent) and 10 µM arsenic trioxide or 5 µM ionomycin for 20 hours. The cells 
were harvested following incubation and stained with 2 µM calcein AM and quenched with 80 mM CoCl2 for 
mitochondria localization, then quantified using flow cytometry analysis (FL1 channel). 
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Appendix 8: SDHA KD inhibits ionomycin and As2O3 
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Complex II inhibition via SDHA knockdown inhibits ionomycin-induced cell death. HeLa cells were treated for 
20 hours with DMSO (untreated ionomycin solvent) or 10 µM ionomycin following shRNA SCR (control) and shRNA 
SDHA knockdown for 24 hours. The cells were harvested following incubation and cell death was quantified using 
DioC6 and PI co-staining and flow cytometry analysis. 
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Fig. A8 Complex II inhibition via SDHA knockdown inhibits arsenic trioxide-induced cell death. HeLa cells 
were treated for 25 hours with 1 M NaOH (untreated arsenic trioxide solvent) or 10 µM arsenic trioxide following 
shRNA SCR (control) and shRNA SDHA knockdown for 24 hours. The cells were harvested following incubation and 
cell death was quantified using DioC6 and PI co-staining and flow cytometry analysis. 
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Appendix 9: Complex III inhibition inhibits As2O3 
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Fig. A9 Inhibition of respiratory chain complex III inhibits As2O3-induced cell death. HeLa 
cells were treated for 25 hours with 10 µM As2O3 in combination with either a complex III inhibitor, 
complex II inhibitor (Antimycin A, 3NP) or their respective carriers (100% ethanol, 100% ethanol). 
The cells were harvested following incubation and cell death was quantified using DioC6 and PI co-
staining and flow cytometry analysis. 
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Appendix 10: Inhibition of Ca2+ influx inhibits As2O3  
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Fig. A10 Inhibition of calcium influx inhibits As2O3-induced cell death. HeLa cells were treated for 25 
hours with 10 µM As2O3 in combination with either a calcium chelator, complex II inhibitor (BAPTA, 3NP) or 
their respective carriers (DMSO, 100% ethanol). The cells were harvested following incubation and cell death was 
quantified using DioC6 and PI co-staining and flow cytometry analysis. 
192 
 
Appendix 11: Cyclosporin A inhibits As2O3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0
5
10
15
20
25
30
35
40
45
50
UNT 10 µM As2O3 10 µM As2O3 10 µM As2O3 +
500 µM
Cyclosporin A
10 µM As2O3 10 µM As2O3 +
1 mM 3NP
%
 A
p
o
p
to
si
s 
Treatments 
** *** *** 
Fig. A11 Inhibition of the respiratory chain complex and the release of cytochrome C inhibits As2O3-
induced cell death. HeLa cells were treated for 25 hours with 10 µM As2O3 in combination with either a 
respiratory chain inhibitor (Cyclosporin A, 3NP) or the respective carrier (DMSO, 100% ethanol). The cells were 
harvested following incubation and cell death was quantified using DioC6 and PI co-staining and flow cytometry 
analysis. 
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Appendix 12: Complex IV inhibition inhibits As2O3 
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Fig. A12 Inhibition of the respiratory chain complex IV inhibits As2O3-induced cell death. HeLa 
cells were treated for 25 hours with 10 µM As2O3 in combination with either a respiratory chain inhibitor 
(NaCN, 3NP) or the respective carrier (H
2
O, 100% ethanol). The cells were harvested following 
incubation and cell death was quantified using DioC6 and PI co-staining and flow cytometry analysis. 
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Appendix 13: Uncoupling of the RC inhibits As2O3  
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Fig. A13 Inhibition of respiratory chain complexes inhibits As2O3-induced cell death. 
HeLa cells were treated for 25 hours with 10 µM As2O3 in combination with either a 
respiratory chain inhibitor (Cyclosporin A, FCCP, 3NP) or the respective carrier (DMSO, 95%, 
100% ethanol). The cells were harvested following incubation and cell death was quantified 
using DioC6 and PI co-staining and flow cytometry analysis. 
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Appendix 14: MCU upregulation verifies role of Ca2+   
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Fig. A14 3NP specifically inhibits MCU-induced cell death. HeLa cells were transfected 
with Caspase 2 as a negative control, and the mitochondrial calcium uniporter (MCU) and 
harvested after 48 hours for analysis using DIOC and PI staining. 3NP treatment was put onto 
the cells 24 hours prior to harvest for the inhibition effect. 
*** 
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Appendix 15: Western blot verification of constructs   
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GAPDH (37 kDa) 
Fig. A15-1 The verification of shRNA SDHA construct. 
HeLa cells were transfected with either shRNA SCR or 
shRNA CLS1 24 hours prior to harvest and probe for 
SDHA. GAPDH was used as a loading control. 
CLS1 (33 kDa) 
GAPDH (37 kDa) 
Fig. A15-2 The verification of CLS1 cDNA and shRNA 
CLS1 constructs. HeLa cells were transfected with either 
pcDNA3 empty vector or CLS1 cDNA and shRNA SCR or 
shRNA CLS1 24 hours prior to harvest and probe for CLS1. 
GAPDH was used as a loading control. 
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